

Temple University — Of The Commonwealth System of Higher Education

Consolidated Financial Statements and Supplemental Schedules as of and for the Years Ended June 30, 2023 and 2022, Independent Auditor's Reports in Accordance with *Government Auditing Standards*, Independent Auditor's Report on Compliance in accordance with Uniform Guidance, Schedule of Expenditures of Federal Awards for the Year Ended June 30, 2023, Independent Auditor's Report on compliance in accordance with *City of Philadelphia Subrecipient Audit Guide*, Schedule of Expenditures of City of Philadelphia Awards, and City of Philadelphia Statement of Program Expenditures and Program Revenue for the Year Ended June 30, 2023, Report on Schedule of Revenue for the Commonwealth of Pennsylvania Department of Health required by the *Pennsylvania Department of Health Audit Guidance*, and Schedule of Revenue for the Commonwealth of Pennsylvania Department of Health for the Year Ended June 30, 2023.

This Page is Intentionally Blank

**TEMPLE UNIVERSITY—
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
FOR THE YEAR ENDED JUNE 30, 2023**

TABLE OF CONTENTS

	<u>Page</u>
FINANCIAL STATEMENTS SECTION:	
INDEPENDENT AUDITOR'S REPORT	1-3
CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTAL SCHEDULES:	
Consolidated Balance Sheets as of June 30, 2023 and 2022	6
Consolidated Statements of Activities for the Years Ended June 30, 2023 and 2022	7-8
Consolidated Statements of Cash Flows for the Years Ended June 30, 2023 and 2022	9
Notes to Consolidated Financial Statements for the Years Ended June 30, 2023 and 2022	10-63
SUPPLEMENTAL SCHEDULES:	
Changes in Net Assets Without Donor Restrictions for the Years Ended June 30, 2023 and 2022	64-65
Subsidiary Organizations, June 30, 2023	66
FEDERAL AWARDS SECTION:	
INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF CONSOLIDATED FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH <i>GOVERNMENT AUDITING STANDARDS</i>	69-70
INDEPENDENT AUDITOR'S REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE	71-73
Summary of Schedule of Expenditures of Federal Awards for the Year Ended June 30, 2023	74
Schedule of Expenditures of Federal Awards for the Year Ended June 30, 2023	75-109
Notes to Schedule of Expenditures of Federal Awards for the Year Ended June 30, 2023	110-112
Schedule of Findings and Questioned Costs of Federal Awards for Year Ended June 30, 2023	113
Schedule of Prior Year Findings of Federal Awards for Year Ended June 30, 2023	114

**TEMPLE UNIVERSITY—
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
FOR THE YEAR ENDED JUNE 30, 2023**

TABLE OF CONTENTS

CITY OF PHILADELPHIA AWARDS SECTION:

INDEPENDENT AUDITOR'S REPORT ON COMPLIANCE FOR EACH MAJOR CITY OF PHILADELPHIA AWARDS; REPORT ON INTERNAL CONTROL OVER COMPLIANCE AND REPORT ON SCHEDULE OF EXPENDITURES OF CITY OF PHILADELPHIA AWARDS; SCHEDULE OF CITY OF PHILADELPHIA PROGRAM EXPENDITURES AND PROGRAM REVENUE REQUIRED BY THE <i>CITY OF PHILADELPHIA SUBRECIPIENT AUDIT GUIDE</i>	116-118
Schedule of Expenditures of City of Philadelphia Awards for the Year Ended June 30, 2023	119-120
Schedule of City of Philadelphia Program Expenditures and Program Revenue for the Year Ended June 30, 2023	121
Notes to Schedule of Expenditures of City of Philadelphia Awards for the Year Ended June 30, 2023	122
Schedule of Findings and Questioned Costs of City of Philadelphia Awards For the Year Ended June 30, 2023	123-125
Schedule of Prior Year Findings of City of Philadelphia Awards for the Year Ended June 30, 2023	126

PENNSYLVANIA DEPARTMENT OF HEALTH SECTION:

REPORT ON SCHEDULE OF REVENUE FOR THE COMMONWEALTH OF PENNSYLVANIA DEPARTMENT OF HEALTH REQUIRED BY THE <i>PENNSYLVANIA DEPARTMENT OF HEALTH AUDIT GUIDANCE</i>	128
Schedule of Revenue for the Commonwealth of Pennsylvania Department Health for the Year Ended June 30, 2023	129
Notes to Schedule of Revenue for the Commonwealth of Pennsylvania Department of Health for the Year Ended June 30, 2023	130

INDEPENDENT AUDITOR'S REPORT

To the Board of Trustees
Temple University – Of The Commonwealth System of Higher Education
Philadelphia, Pennsylvania

Opinion

We have audited the consolidated financial statements of Temple University – Of The Commonwealth System of Higher Education and subsidiaries (“Temple”), which comprise the consolidated balance sheets as of June 30, 2023, and 2022, and the related consolidated statements of activities, and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Temple as of June 30, 2023, and 2022, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Temple and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

The Financial Statements of Temple include various subsidiaries as outlined in Note 1 to the Financial Statements. The Financial Statements of Temple University – Of The Commonwealth System of Higher Education, includes subsidiaries of Temple University Health System Inc. (“TUHS”). The subsidiary of TUHS; TUHS Insurance Company, Ltd.; was audited by us; and the subsidiary of Temple; Temple Educational Support Services Ltd.; which was audited by other auditors were audited in accordance with generally accepted auditing standards but were not audited in accordance with *Government Auditing Standards* and, accordingly, are not covered by our reports in accordance with *Government Auditing Standards*.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Temple's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, and *Government Auditing Standards* we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Temple's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Temple's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Report on Supplemental Schedules

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The supplemental schedules on pages S-1 through S-3 are presented for the purpose of additional analysis of the financial statements rather than to present the financial position, results of operations, and cash flows of the individual companies, and are not a required part of the financial statements. These supplemental schedules are the responsibility of Temple's management and were

derived from and relate directly to the underlying accounting and other records used to prepare the financial statements. Such schedules have been subjected to the auditing procedures applied in our audits of the financial statements and certain additional procedures, including comparing and reconciling such schedules directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, such schedules are fairly stated in all material respects in relation to the financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated October 27, 2023 on our consideration of Temple's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Temple's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Temple's internal control over financial reporting and compliance.

Deloitte & Touche LLP

October 27, 2023



This Page is Intentionally Blank

TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES
Consolidated Balance Sheets
(in thousands)

	June 30, 2023	June 30, 2022
Assets		
Current assets:		
Cash and cash equivalents	\$ 506,047	\$ 772,010
Investments and self-insurance trust funds	1,403,204	1,285,285
Accounts, loans, and contributions receivable, net	583,167	519,007
Inventories and other assets	76,244	66,996
Deposits with trustees	19,873	20,328
Total current assets	2,588,535	2,663,626
Non-current assets:		
Accounts, loans, and contributions receivable, net	166,206	129,332
Endowment, investments, and self-insurance trust funds	1,137,694	1,073,947
Deposits with trustees	24,538	24,046
Other assets	130,600	92,925
Property, plant, and equipment, net	1,882,570	1,883,357
Operating lease right-of-use assets	87,307	94,429
Intangible assets, net	660	924
Funds held in trust by others	158,954	153,599
Total non-current assets	3,588,529	3,452,559
Total assets	\$ 6,177,064	\$ 6,116,185
Liabilities and Net Assets		
Current liabilities:		
Accounts payable and accrued expenses	\$ 496,864	\$ 552,992
Deferred revenue	105,337	91,605
Current portion of long-term debt, net	42,483	44,536
Current portion of accrued pensions and postretirement benefits	338	377
Total current liabilities	645,022	689,510
Non-current liabilities:		
Accrued expenses and other liabilities	461,534	413,725
Deferred revenue	16,594	13,814
Long-term debt, net	930,919	972,252
Operating lease liabilities	77,317	83,254
Refundable federal student loans	30,707	34,217
Accrued pensions and postretirement benefits	18,553	15,594
Total non-current liabilities	1,535,624	1,532,856
Total liabilities	2,180,646	2,222,366
Net assets:		
Without donor restrictions	3,202,917	3,166,444
With donor restrictions	793,501	727,375
Total net assets	3,996,418	3,893,819
Total liabilities and net assets	\$ 6,177,064	\$ 6,116,185

See accompanying notes to the consolidated financial statements.

**TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES**

Consolidated Statement of Activities

For the Year Ended June 30, 2023

(in thousands)

	Without Donor Restrictions	With Donor Restrictions	Total
Revenues:			
Tuition and fees, net of discounts of \$154,590	\$ 758,170	\$ —	\$ 758,170
Commonwealth of Pennsylvania appropriation (Note 17)	77,762	—	77,762
Grants and contracts (federal, state, local, and private)	237,963	—	237,963
Contributions for operations and endowments	25,858	39,296	65,154
Investment return, net of expenses	94,640	5,375	100,015
Sales of educational activities	14,158	—	14,158
Auxiliary enterprises	109,434	—	109,434
Patient care activities	2,484,330	—	2,484,330
Other sources	55,871	2	55,873
Net assets released from restrictions	9,801	(9,801)	—
Total revenues	3,867,987	34,872	3,902,859
Expenses:			
Educational and general:			
Academic and student services	794,155	—	794,155
Research and public service	275,293	—	275,293
Institutional support	202,231	—	202,231
Total educational and general	1,271,679	—	1,271,679
Auxiliary enterprises	131,715	—	131,715
Patient care activities	2,491,706	—	2,491,706
Total expenses	3,895,100	—	3,895,100
(Deficit) excess of revenues over expenses	(27,113)	34,872	7,759
Other changes in net assets:			
Investment return, net of expenses	30,833	26,108	56,941
Commonwealth grants for property, plant, and equipment (PP&E)	1,950	9,758	11,708
Contributions for PP&E	1	538	539
Loss on disposal of PP&E, net	(5,765)	—	(5,765)
Actuarial change in accrued pensions and postretirement benefits	2,873	—	2,873
Other components of net periodic postretirement benefit cost	16,294	—	16,294
Currency translation adjustment and foreign exchange realized gain, net	423	—	423
Other	11,827	—	11,827
Net assets released from restrictions for PP&E	5,150	(5,150)	—
Total other changes in net assets	63,586	31,254	94,840
Change in net assets	36,473	66,126	102,599
Net assets, beginning of year	3,166,444	727,375	3,893,819
Net assets, end of year	\$ 3,202,917	\$ 793,501	\$ 3,996,418

See accompanying notes to the consolidated financial statements.

**TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES**

Consolidated Statement of Activities

For the Year Ended June 30, 2022

(in thousands)

	Without Donor Restrictions	With Donor Restrictions	Total
Revenues:			
Tuition and fees, net of discounts of \$148,826	\$ 782,379	\$ —	\$ 782,379
Commonwealth of Pennsylvania appropriation (Note 17)	86,166	—	86,166
Grants and contracts (federal, state, local, and private)	314,649	—	314,649
Contributions for operations and endowments	23,030	33,529	56,559
Investment return, net of expenses	66,493	5,059	71,552
Sales of educational activities	12,897	—	12,897
Auxiliary enterprises	96,692	—	96,692
Patient care activities	2,421,724	—	2,421,724
Other sources	101,275	—	101,275
Net assets released from restrictions	10,208	(10,208)	—
Total revenues	3,915,513	28,380	3,943,893
Expenses:			
Educational and general:			
Academic and student services	839,528	—	839,528
Research and public service	259,484	—	259,484
Institutional support	166,973	—	166,973
Total educational and general	1,265,985	—	1,265,985
Auxiliary enterprises	132,780	—	132,780
Patient care activities	2,354,819	—	2,354,819
Total expenses	3,753,584	—	3,753,584
Excess of revenues over expenses	161,929	28,380	190,309
Other changes in net assets:			
Investment return, net of expenses	(191,128)	(77,872)	(269,000)
Commonwealth grants for property, plant, and equipment (PP&E)	—	6,234	6,234
Contributions for PP&E	3	(72)	(69)
Loss on extinguishment of debt	(9,650)	—	(9,650)
Loss on disposal of PP&E, net	(731)	—	(731)
Actuarial change in accrued pensions and postretirement benefits	31,471	—	31,471
Other components of net periodic postretirement benefit cost	12,691	—	12,691
Currency translation adjustment and foreign exchange realized gain, net	(196)	—	(196)
Gain on sale of equity method investment (Note 25)	234,591	—	234,591
Other	2,298	—	2,298
Net assets released from restrictions for PP&E	1,818	(1,818)	—
Total other changes in net assets	81,167	(73,528)	7,639
Change in net assets	243,096	(45,148)	197,948
Net assets, beginning of year	2,923,348	772,523	3,695,871
Net assets, end of year	\$ 3,166,444	\$ 727,375	\$ 3,893,819

See accompanying notes to the consolidated financial statements.

**TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES**

Consolidated Statements of Cash Flows
(in thousands)

	Year Ended June 30,	
	2023	2022
Cash flows from operating activities:		
Change in net assets	\$ 102,599	\$ 197,948
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Currency translation adjustment and foreign exchange realized (gain) loss, net	(423)	196
Provision for bad debts	15,439	3,108
Depreciation	164,009	155,066
Amortization and accretion	(2,297)	(1,423)
Impairment of intangibles	—	1,564
Realized and unrealized (gain) loss on investments, net	(90,518)	229,238
Actuarial change in accrued pensions and postretirement benefits	(2,873)	(31,471)
Loss on extinguishment of debt	—	9,650
Loss on disposal of property, plant, and equipment (PP&E) and assets held for sale, net	5,765	731
Gain on lease modification	—	(122)
Noncash contributions received	(13,564)	(2,747)
Proceeds from sale of noncash contributions	13,564	2,747
Contributions, grants, and investment income restricted for PP&E and long-term investment	(38,957)	(20,623)
Gain on insurance recovery	(11,827)	(6,943)
Gain on sale of equity method investment	—	(234,591)
Equity method investment loss	7,430	—
Changes in operating assets and liabilities:		
Accounts and contributions receivable	(85,079)	(3,290)
Inventories and other assets	(7,412)	(13,749)
Accounts payable and accrued expenses	(45,177)	(35,332)
Deferred revenue	16,695	(29,574)
Accrued pensions and postretirement benefits	(7,843)	(9,156)
Net change in operating lease right of use assets / liabilities	958	202
Net cash provided by operating activities	<u>20,489</u>	<u>211,429</u>
Cash flows from investing activities:		
Purchases of investments, deposits with trustees, and self-insurance trust funds	(1,147,993)	(1,263,157)
Sales and maturities of investments, deposits with trustees, and self-insurance trust funds	1,070,977	941,401
Net change in short-term investments	(18,963)	(18,835)
Proceeds from insurance recovery	10,258	8,502
Purchases of PP&E	(162,431)	(182,345)
Proceeds from sales of PP&E and assets held for sale	79	58
Proceeds from sale of equity method investment	—	301,600
Loans to students	(3,890)	(5,065)
Proceeds from collections on student loans	10,409	9,218
Purchase of equity method investment	(16,800)	—
Increase in receivable from equity method investment	(19,000)	—
Net cash used in investing activities	<u>(277,354)</u>	<u>(208,623)</u>
Cash flows from financing activities:		
investment	38,957	20,623
Refundable federal student loans	(3,511)	(6,060)
Change in split interest agreements	(38)	(1,237)
Proceeds from long-term debt, net of bond issuance cost of \$1,035	—	186,460
Repayment of long-term debt	(44,737)	(49,407)
Repurchase of bonds	—	(219,210)
Net cash used in financing activities	<u>(9,329)</u>	<u>(68,831)</u>
Effect of exchange rate changes on cash and cash equivalents	100	(741)
Net change in cash, cash equivalents, and restricted cash	<u>(266,094)</u>	<u>(66,766)</u>
Cash, cash equivalents, and restricted cash, beginning of the year	791,565	858,331
Cash, cash equivalents, and restricted cash, end of the year	<u>\$ 525,471</u>	<u>\$ 791,565</u>
Cash and cash equivalents	\$ 506,047	\$ 772,010
Restricted cash included in investments	19,424	19,555
Total cash, cash equivalents, and restricted cash	<u>\$ 525,471</u>	<u>\$ 791,565</u>
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$ 43,744	\$ 51,600
PP&E acquired through finance leases	4,945	1,023
Amounts accrued related to PP&E	16,881	14,219

See accompanying notes to the consolidated financial statements.

**TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES**

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

(dollars in thousands)

1. Description of Business and Operations

Founded in 1884, Temple University — Of The Commonwealth System of Higher Education (the “University”) is a comprehensive state-related research university with its headquarters and largest campus located in Philadelphia, Pennsylvania. The University provides education and training services to approximately 35,700 students at the undergraduate, graduate, and postdoctoral/professional levels, and performs research, training, and other services under grants, contracts, and similar agreements with sponsoring organizations, including federal, state, and local sponsors. The University offers more than 600 academic programs in 17 schools and colleges, including programs in art; business; education; engineering; law; liberal arts; media and communications; music and dance; science and technology; social work; sport, tourism, and hospitality management; theater, film, and media arts; and various health professions, including dentistry; medicine; pharmacy; podiatric medicine; and public health. The University has eight campuses; including six campuses across Pennsylvania and international campuses in Rome (Italy) and Tokyo (Japan), and offers study abroad programs in various locations. The University is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code.

As a state-related institution, the University receives annual operating and capital non-preferred appropriations from the Commonwealth of Pennsylvania (the “Commonwealth”). Non-preferred appropriations require a two-thirds vote of each chamber of the Commonwealth’s General Assembly for passage. The General Assembly is not obligated to appropriate funds to the University, and there is no guarantee that funding from the Commonwealth will continue consistent with historical levels or at levels requested by the University. The annual operating and capital appropriations from the Commonwealth were \$158,206 and \$99,000, respectively, in 2023 and \$158,206 and \$74,000, respectively, in 2022. In addition to the annual appropriations, the Commonwealth also provides funding for sponsored programs as well as patient care activities provided by the University’s health system (see Notes 17 and 18).

The University is the sole member of its subsidiary Temple University Health System, Inc. (“TUHS”). The University and TUHS are collectively referred to herein as “Temple”. See the accompanying supplemental schedule for a complete listing of Temple’s subsidiary organizations. A summary of Temple’s active and recently active subsidiaries and clinical faculty practice plan is as follows:

Temple’s Active Subsidiaries as of June 30, 2023

Temple University Health System, Inc. (“TUHS”)	A Pennsylvania nonprofit corporation dedicated to providing access to quality patient care and supporting excellence in medical education and research, of which the University is the sole member. TUHS was incorporated in August 1995 and serves principally to coordinate the activities and plans of its health care subsidiaries in Philadelphia and the surrounding area. TUHS’ subsidiaries and affiliates include a network of hospitals and outpatient centers, a comprehensive physician network of primary care and specialty practices, ambulatory services, various research entities, a foundation to support the health-care related activities of TUHS, and a captive insurance company established to reinsure the professional liability claims of certain subsidiaries of TUHS. See the accompanying supplemental schedules for a complete listing of TUHS’ subsidiaries.
Temple Educational Support Services, Ltd. (“TESS”)	A limited liability company organized and incorporated under the laws of Japan. TESS was established in December 1995 to operate the University’s Japan campus and is a wholly-owned subsidiary of the University.
Temple University School of Podiatric Medicine, Inc. (“TUSPM”)	A Pennsylvania nonprofit corporation that holds the real estate associated with the University’s School of Podiatric Medicine.

2. Summary of Significant Accounting Policies

Basis of Presentation and Consolidation — The consolidated financial statements have been prepared on the accrual basis of accounting, in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 958, *Not-for-Profit Entities*. The accompanying consolidated financial statements include the accounts of Temple and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Temple is required to classify its net assets into two categories based on the existence or absence of donor-imposed restrictions: net assets without donor-imposed restrictions and net assets with donor-imposed restrictions. Descriptions of the two net asset categories are as follows:

Net Assets without Donor Restrictions — Net assets not subject to donor-imposed restrictions. These net assets may be designated for specific purposes by action of the board of trustees or may otherwise be limited by contractual agreements with outside parties. Temple reports donor-restricted support whose restrictions are met in the same reporting period as support within *Net assets without donor restrictions*. All expenses from operations are reported as a reduction of *Net assets without donor restrictions*, since the use of restricted contributions in accordance with donors’ stipulations results in the release of the restriction.

Net Assets with Donor Restrictions — Net assets subject to donor-imposed restrictions, which are donor stipulations that specify a use for a contributed asset that is more specific than broad limits resulting from the following: a) the nature of the not-for-profit entity, b) the environment in which it operates and c) the purposes specified in its articles of incorporation or bylaws or comparable documents. Net assets subject to donor-imposed restrictions include contributions for which donor-imposed restrictions have not been met (primarily future capital projects), donor restricted endowment funds, charitable remainder unitrusts, pooled income funds, gift annuities, and pledges receivable. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, donor-restricted net assets are reclassified to *Net assets without donor restrictions* and reported in the consolidated statements of activities as *Net assets released from restrictions*.

Cash, Cash Equivalents, and Restricted Cash — Temple considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Temple maintains cash balances in financial institutions, which exceed federal depository insurance limits. Management believes that credit risks related to these deposits are minimal. Cash equivalents that are not traded on an active exchange are carried at cost, which approximates fair value.

Endowment and Investments — Endowment and investments (collectively referred to as “investments”) are comprised of the assets of Temple’s endowment, certain donor restricted funds, funds designated by the board of trustees to be invested as endowments, certain funds set aside to retire long-term debt, other plant-related funds, and other funds without donor restrictions held for operating purposes. These investments vary as to their level of liquidity, with differing requirements for notice prior to redemption or withdrawal. Investments established for donor and board-designated endowments, investments pledged as collateral, and certain investments set aside to retire long-term debt are classified as non-current assets. All other investments are classified as current assets (see Notes 3, 10, 11, and 14).

Temple reports investments including debt and equity securities at fair value. Temple also invests in various limited partnerships, hedge funds, and other investment funds whose fair value is measured at net asset value per share as determined by the respective fund managers and financial information provided by the

investment entities. This financial information includes assumptions and methods that are reviewed by Temple. Because these investments are not readily marketable, the estimated fair values are subject to uncertainty and, therefore, may differ from the value that would have been used had a ready market existed, and such differences could be material.

Temple has adopted, for endowments and funds designated by the board of trustees to be invested as endowments, a spending rule based on a percentage of the fair value of such investments, computed as a moving average over the prior twelve quarters. For these investments, the spending rule amount is reported as *Investment return* in revenues with the excess or shortfall of total return over the spending rule amount reported as *Investment return* in *Other changes in net assets* in the consolidated statements of activities. For all other investments, interest and dividend income is reported as *Investment return* in revenues and realized and unrealized gains or losses are reported as *Investment return* in *Other changes in net assets* in the consolidated statements of activities (see Notes 3 and 11).

Investment return, net of external and direct internal investment expenses, is reported as increases to net assets without donor restrictions or assets with donor restrictions based upon the existence or absence of donor-imposed restrictions.

Investments, in general, are exposed to various risks such as interest rate, credit, and overall market volatility. As such, it is reasonably possible that changes in the value of investments will occur in the near term and that such changes could materially affect the amounts reported in the consolidated financial statements.

Derivatives — The University enters into derivative financial instruments, principally futures contracts, to manage equity price risk. Futures contracts are recorded as contractual commitments on a trade-date basis and are carried at fair value based on closing exchange quotations. The fair value of derivative financial instruments at the reporting date generally reflects the amount the University would receive or pay to terminate the contract at the reporting date. Changes in fair value are recorded as *Investment return* in *Other changes in net assets*. The University does not designate any derivative instruments as hedging instruments (see Note 3).

Self-Insurance Trust Funds — Temple self-insures or maintains deductibles under its various insurance policies for property, casualty, automobile, general liability, medical malpractice, workers' compensation, certain health and welfare, and other claims. Self-insurance trust funds include assets that are designated for payments of workers' compensation risk retained by Temple. Provisions are made for estimated losses (claims made and claims incurred but not reported) generally based on actuarial methods, which include discounting of certain loss provisions (see Note 3).

Accounts, Loans, and Contributions Receivable — Accounts, loans, and contributions receivable are reported at their net realizable value. The allowance for doubtful accounts is based upon management's judgment including such factors as historical collection history, type of receivable, and periodic assessment of individual accounts. Temple writes-off receivables when they are determined to be uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts. Temple does not accrue interest on these amounts (see Note 4).

Inventories and Other Assets — Inventories are stated at the lower of cost or net realizable value, with cost being determined on the first-in, first-out, or average cost method. Inventories at June 30, 2023 and 2022, totaled \$44,115 and \$40,689, respectively, and are included in *Inventories and other assets* in the consolidated balance sheets. *Inventories and other assets* also include prepaid expenses, and advances. *Other assets, non-*

current include pension and postretirement plans that are in an over-funded position, which totaled \$80,101 and \$65,958 at June 30, 2023 and 2022, respectively (see Note 5).

Deposits with Trustees — Deposits with trustees include assets held in escrow by designated bond trustees for debt service payments and construction or enhancement of property, plant, and equipment (see Note 6).

Property, Plant, and Equipment — Property, plant, and equipment are recorded at cost less accumulated depreciation. Property, plant, and equipment gifted to Temple are recorded at the fair value at the date of acquisition. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three to forty years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the leasehold improvements or the lease term. Land is not depreciated. Depreciation for equipment commences once it is placed in service and depreciation for buildings and leasehold improvements commences once they are ready for their intended use (see Note 7).

Estimated useful lives of property, plant, and equipment are as follows:

	Useful Life
Land improvements	8 - 20 years
Buildings	20 - 40 years
Building improvements	15 - 40 years
Furniture, fixtures, and equipment	3 - 20 years
Library books	10 years

Cost of maintenance and repairs is charged to expense as incurred. Upon retirement or other disposition, the cost of the asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the consolidated statements of activities.

Long-Lived Assets — Temple reviews long-lived assets, such as property, plant, and equipment, for impairment whenever events or changes indicate that the carrying value of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to their expected undiscounted future cash flows. If such assets are considered to be impaired, the impairment is measured by the amount the carrying value exceeds the fair value of the assets. On September 1, 2021, a tornado that was a byproduct of Hurricane Ida (the “Storm”), struck the center of the University’s Ambler Campus; with remnants of the Storm also causing damage to the University’s boathouse located along the Schuylkill River. The Storm resulted in impairments to long-lived assets located at both locations totaling \$1,558. No impairment of long-lived assets occurred in 2023.

Goodwill and Other Intangibles — Goodwill and indefinite-lived intangible assets are not amortized, but are evaluated for impairment annually, or when indicators of a potential impairment are present. Temple’s annual impairment assessment date is June 30. The annual assessment for impairment of goodwill and indefinite-lived intangible assets is based on valuation models that incorporate assumptions and internal projections of expected future cash flows and operating plans. In 2022, based on the results of Temple’s assessment, impairments of indefinite-lived intangible assets totaled \$1,564. In 2023, there were no indicators of potential impairment of indefinite-lived intangible assets.

The cost of intangible assets with determinable useful lives is amortized to reflect the pattern of economic benefits consumed on a straight-line basis over the estimated periods benefited. Intangibles with contractual terms are generally amortized over their respective legal or contractual lives. When certain events or changes in operating conditions occur, an impairment assessment is performed and the lives of intangible assets with

determinable lives may be adjusted and impairment charges recorded. In 2023 and 2022, there were no indicators of potential impairment of intangible assets with determinable useful lives (see Note 23).

Leases — Temple determines if an arrangement is a lease at inception. A contract is or contains a lease if the contract conveys the right to control and obtain substantially all of the economic benefits from an identified asset, and provides Temple with the right to direct the use of the identified asset for a period of time in exchange for consideration. Operating leases are included in *Operating lease right-of-use assets*, *Operating lease liabilities (non-current)*, and *Accounts payable and accrued expenses (current)*. Operating lease right-of-use (“ROU”) assets represent Temple’s right to use an underlying asset for the lease term. Operating lease liabilities represent Temple’s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. If a lease agreement does not provide an implicit rate, based on the information available at the commencement date, Temple uses its incremental borrowing rate in determining the present value of lease payments. The rate implicit on Temple’s leases were not readily available and, as such, Temple used the incremental borrowing rate when measuring all leases. Temple determines its incremental borrowing rate based on the approximate rate at which Temple would borrow, on a collateralized basis over a similar term. The determination of the incremental borrowing rate includes numerous assumptions such as credit standing, lease term, amount of borrowing, and location of leased assets. Certain real estate leases include options to extend or terminate agreements. Options to extend or terminate the lease are considered in determining the lease term only when it is reasonably certain that the option will be exercised (see Note 9). Lease expense for lease payments is recognized on a straight-line basis over the lease term. Temple elected the practical expedient that allows lessees to choose not to separate lease and non-lease components and is applying this expedient to all real estate leases and all embedded equipment leases related to consumable purchase agreements. Certain lease agreements for real estate include payments based on actual common area maintenance and other expenses, such as insurance and taxes. These variable lease payments are recognized within operating expenses, but are not included in the calculation of right-of-use asset or liability balances. Additionally, Temple elected to not recognize lease assets and lease liabilities for all leases with a term of 12 months or less; such lease payments are recognized as expense on a straight-line basis over the lease term. Temple’s operating leases are primarily for facility space, automobiles, and office equipment. Temple’s finance leases are included in *Property, plant, and equipment, net*, and *Long-term debt* in the consolidated balance sheet (See Note 9).

Funds Held in Trust by Others — Temple is the irrevocable beneficiary of the income from certain perpetual trusts administered by third parties. Temple’s beneficial interest is reported at the fair value of the underlying trust assets. Because the trusts are perpetual and the original corpus cannot be used, these funds are reported as donor-restricted net assets. As Temple does not have the ability to redeem funds held in trust by others, these assets are categorized as Level 3 assets (see Note 10).

Asset Retirement Obligations — Temple recognizes the fair value of an asset retirement obligation in the period in which it is incurred if a reasonable estimate of fair value can be made. When the liability is initially recorded, Temple capitalizes the cost of the asset retirement obligation by increasing the carrying amount of the related long-lived asset. Changes in the obligation due to revised estimates of the amount or timing of cash flows required to settle the future liability are recognized by increasing or decreasing the carrying amount of the asset retirement obligation liability. Changes due solely to the passage of time (accretion of the discounted liability) are recognized as an increase in the carrying amount of the liability and as an operating expense in the statement of activities. The capitalized cost associated with the retirement obligation is depreciated over the useful life of the related asset. Upon settlement of the obligation, any difference between the cost to settle the asset retirement obligation and the liability recorded is recognized as a gain or loss in the consolidated statement of activities (see Note 8).

Defined Benefit Pension and Other Postretirement Plans — Temple recognizes the over-funded or under-funded status of its defined benefit pension and other postretirement plans as an asset or liability in its balance sheets and recognizes changes in the funded status of the plans that arise during the period, but are not recognized as components of net periodic benefit cost, as *Actuarial change in accrued pensions and postretirement benefits* in the consolidated statements of activities (see Note 5).

Fair Value Measurements — Temple categorizes its assets and liabilities measured at fair value into a three-level hierarchy, based on the priority of the inputs to the respective valuation techniques, with assets that are measured using the net asset value per share practical expedient being excluded from the fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). An asset's or liability's classification within the fair value hierarchy is based on the lowest level of significant input to its valuation. Temple's assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels (see Note 10).

The carrying values of short-term assets and liabilities, including cash equivalents (not traded on an active exchange), accounts receivable, and accounts payable, approximate their fair values. Investments, self-insurance trust funds, and deposits with trustees are carried at their estimated fair value (see Notes 3 and 10). The fair value of long-term debt is estimated based upon discounted cash flows at current market rates for instruments with similar remaining terms, which Temple considers Level 2 inputs (see Notes 9 and 10). Contribution receivables are recorded at the present value of expected future cash flows (see Note 4). Considerable judgment is necessary to interpret market data and develop estimated fair values. Accordingly, the estimates presented are not necessarily indicative of the amounts at which these instruments could be purchased, sold, or settled.

A reasonable estimate of the fair value of loans receivable from students under government loan programs and refundable federal student loans could not be made because the loans are not readily salable. These loans are recorded at cost, less an allowance for doubtful accounts (see Note 4).

Revenue Recognition — Temple's revenues primarily consist of tuition and fees, auxiliary enterprises, Commonwealth appropriations, grants and contracts, contributions, and patient care activities. Revenue recognition accounting policies for Temple's primary revenue sources are as follows (see Note 18 for additional revenue disclosures):

Tuition and Fees — Tuition and fees are recognized ratably on a daily straight-line basis over the academic period as the University satisfies its performance obligation (e.g., as instruction is provided to students). The University's transaction price is determined based on established fixed tuition rates based on student residency (in-state or out-of-state) and the school or college in which they enroll, net of financial assistance provided directly by the University. Such financial assistance is recorded as a tuition discount and represents the difference between the stated charge for tuition and fees and the amount that is billed to the student and/or third parties making payments on behalf of the student. Financial assistance provided to students was \$154,590 in 2023 and \$148,826 in 2022.

Auxiliary Enterprises — Auxiliary services exist to furnish goods or services to students, faculty, staff, or incidentally to the general public, and charges a fee directly related to, although not necessarily equal to, the cost of the goods or services. The distinguishing characteristic of auxiliary services is that they are managed as essentially self-supporting activities. Revenues from auxiliary enterprises include revenues from

contracts with customers to provide student housing and dining facilities, ticket sales for athletic and community events, other athletic department revenues, parking services, and other miscellaneous activities.

The University's transaction price for housing and meal plans is determined based on established fixed rates based on the dorms students chose to live in (e.g., residence halls and room type) and the meal plan type they elect. Payments for housing services are due approximately two weeks subsequent to the start of the academic term (consistent with tuition). Performance obligations for housing and dining services are delivered over the academic terms. Consequently, revenue from housing and dining services is recognized ratably as services are rendered. For ticket sales, revenue is recognized after the event occurs and for other auxiliary services (e.g., event parking, programs, merchandise, concessions) revenue is recognized at a point in time.

Commonwealth of Pennsylvania Appropriation — The University receives annual operating and capital appropriations from the Commonwealth. Operating appropriations are provided to support the general operations of the University, which, along with additional support provided by the University, allows for a reduction in tuition rates for Pennsylvania resident students. Funds are required to be spent in accordance with applicable laws and revenue is recognized ratably over the fiscal year as the funds are expended. Capital appropriations are provided to fund certain approved capital projects in support of the University's mission. Revenue from Commonwealth capital funding is recognized on an expense reimbursement basis and is classified as "with donor restrictions" until the capital project is completed and placed in service, at such time the net assets are released from restrictions.

Strategic Support Assessment — On an annual basis, the University charges TUHS a strategic support assessment ("SSA") in support of the Lewis Katz School of Medicine ("LKSOM") for its mission of research and education, and the associated benefit to TUHS and the patients it serves. The amount of the SSA and payment terms are determined annually as part of the annual budget process. The revenue, recorded by the University, and the equal expense, recorded by TUHS, are eliminated in consolidation. The SSA is comprised primarily of the share of appropriation used to support matching funds under the Commonwealth of PA Medical Assistance Program (see Note 17).

Grants, Contracts, and Contributions — Temple receives sponsored program funding from various governmental, corporate, and private sources. The funding may represent a reciprocal transaction in exchange for an equivalent benefit in return, or it may be a nonreciprocal transaction in which the resources provided are for the benefit of Temple, the funding organization's mission, or the public at large.

Revenues from exchange transactions are recognized as performance obligations are satisfied, which in some cases are as related costs are incurred. Revenues from non-exchange transactions (contributions) may be subject to conditions, in the form of both a barrier to entitlement and a refund of amounts paid (or a release from obligation to make future payments). Revenues from conditional non-exchange transactions are recognized when the barrier is satisfied. In addition, Temple has elected the simultaneous release option for conditional contributions that are also subject to purpose restrictions. Under this option, net assets without donor restrictions will include the donor-restricted contributions for which the purpose restrictions are met in the same reporting period as the revenue is recognized. Funds received in advance (for an exchange transaction prior to the performance obligation being satisfied; or for a contribution non-exchange transaction, prior to the condition being achieved) are recorded as *Deferred revenue* on the consolidated balance sheets.

In 2023 and 2022, sponsored programs revenue earned from federal, state, local, and private sources totaled \$237,963 and \$314,649, respectively. Federal funding includes student and institutional Coronavirus-19

(“COVID-19”) Higher Education Emergency Relief Funds (“HEERF”) of \$78,229 in 2022. No HEERF funds were recorded in 2023 (see Note 24). Indirect costs recovered on federally sponsored programs are generally based on predetermined reimbursement rates, which are stated as a percentage and distributed based on the modified total direct costs incurred. The University negotiates its federal indirect rate with its cognizant federal agency. Indirect costs recovered on all other grants and contracts are based on rates negotiated with the respective sponsors. Funds received from federal sources are subject to audit in accordance with compliance standards.

Patient Care Activities — Patient care activities provided by Temple are invoiced daily, from which revenue is recognized at a point in time as patient services are provided. *Patient care activities* include revenues from TUHS as well as clinical activities provided by the University.

Patient care activities revenue is recognized at the amount that reflects the consideration to which Temple expects to be entitled in exchange for providing patient care. These amounts are due from Medicare and Medicaid, managed care health plans, commercial payors, patients, and others. Reimbursement is primarily based on the payment terms of contractual arrangements, such as predetermined rates per visit or procedure, per diem rates, or discounted fee-for-service rates. Generally, Temple bills the patients and third-party payers several days after the services are performed and/or the patient is discharged. In addition, Temple receives medical assistance payments for the reimbursement of services for charity and uncompensated care services. The federal funding of such costs is subject to an upper payment limit and retrospective settlement.

Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided. Temple recognizes revenues for performance obligations satisfied over a period of time based on actual charges incurred in relation to total expected (or actual) charges. Temple believes that this method provides a reasonable representation of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in TUHS receiving inpatient acute care services. TUHS measures performance obligations from admission to the point where there are no further services required for the patient, which is generally the time of discharge. Temple recognizes revenues for performance obligations satisfied at a point in time, which generally relates to patients receiving outpatient services, when: (a) services are provided; and (b) Temple does not believe the patient requires additional services. The patient care activities provided by the University are for outpatient type services. The University recognizes revenues for performance obligations satisfied at a point in time, which generally relates to patients receiving outpatient services, when services are provided.

Temple estimates the transaction price for patients based on gross charges for services provided, reduced by explicit price concessions which include contractual adjustments provided to third-party payers and discounts provided to uninsured patients in accordance with Temple’s policy. Temple determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical collection experience. Revenues are also adjusted for implicit price concessions. Implicit price concessions are determined based on historical collection experience. The implicit price concessions included in estimating the transaction price represent the difference between amounts remaining to be paid and the amounts Temple generally expects to collect based on its historical experience. Subsequent changes to the estimate of transaction price are generally recorded as adjustments to patient service revenue in the period of change and are accrued on an estimated basis in the period the related services are rendered. Adjustments may also occur in future periods as final settlements are determined.

Because Temple’s patient service obligations generally relate to contracts with duration of less than one year, Temple has elected to apply the optional exemption and, therefore, is not required to disclose the

aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Generally, patients who are covered by third-party payors are responsible for related co-payments, coinsurance and deductibles, which vary in amount. Temple also provides services to uninsured patients and offers uninsured patients a discount from standard charges. Temple estimates the transaction price for patients with co-pays, co-insurance and deductibles and for those who are uninsured based on historical collection experience and current market conditions. Under Temple's uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual discount, which reduces net operating revenues at the time the self-pay accounts are recorded. The uninsured patient accounts, net of contractual discounts recorded, are further reduced to their net realizable value at the time they are recorded through implicit price concessions based on historical collection trends for self-pay accounts and other factors that affect the estimation process. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to *Patient care activities* revenue in the period of the change.

Consistent with Temple's mission, care is provided to patients regardless of their ability to pay. Temple provides care without charge, or at a standard rate discounted for uninsured patients that is not related to published charges, to patients who meet certain criteria under Temple's charity care policy. Some patients qualify for charity care based on federal poverty guidelines or their financial condition being such that requiring payment would impose a hardship on the patient. Because Temple does not pursue collection of amounts determined to qualify as charity care, they are not reported as *Patient care activities* revenue. Temple has determined that it has provided sufficient explicit price concessions for these accounts (see Notes 18, 21, and 22).

In assessing collectability, Temple uses a combination of contract specific adjustments (such as high dollar and long length-of-stay accounts) as well as a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. This portfolio approach is being used as Temple has a large volume of similar contracts with similar classes of customers. Temple reasonably expects that the effect of applying a portfolio approach would not differ materially from considering each contract separately. Management's judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. As a result, aggregating all of the contracts (which are at the patient level) by the particular payer or group of payers will result in the recognition of the same amount of revenue as applying the analysis at the individual patient level.

Amounts received under Medicare and Medicaid programs are subject to review and final determination by program intermediaries or their agents and the contracts Temple has with commercial payers typically provide for retroactive audit and review of claims. Revenue includes an estimate of variable consideration for retroactive revenue adjustments due to settlements of audits, reviews and investigations. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered or when known by Temple and adjusted in future periods as final settlements or changes in estimates are determined. Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates could change by a material amount in the near term.

Temple engages in various contracts with insurance companies where Temple is at risk for the total cost of care to an attributed patient population as well as contracts that provide for pay-for-performance incentives. The value of these agreements is estimated and included in net patient service revenue.

Advertising — Temple charges the costs of advertising to expense as incurred. Advertising expense was \$23,390 and \$20,925 in 2023 and 2022, respectively.

Other Changes in Net Assets — Temple considers all realized and unrealized gains and losses on investments, net of the endowment payout under Temple’s spending formula, as *Other changes in net assets*. *Other changes in net assets* also includes interest and dividends on endowments and funds designated by the board of trustees to be invested as endowments; activity related to property, plant, and equipment (including grants and contributions, gains (losses) on disposals, and net assets released from restrictions); gains (losses) on extinguishment of debt; actuarial changes in accrued pensions and postretirement benefits; other components of net periodic benefit cost (see Note 5); gains on insurance recoveries; and foreign currency adjustments.

Income Taxes — With the exception of TUHIC (Temple’s captive insurance company domiciled in Bermuda), TESS (operator of the University’s Japan campus), and certain inactive subsidiaries (see supplemental schedule), substantially all of the individual members of Temple are not-for-profit corporations as described in Section 501(c)(3) of the Internal Revenue Code and are exempt from federal income taxes on related income pursuant to Section 501(a) of the Internal Revenue Code. Temple files U.S. federal, state, and local information returns and no returns are currently under examination. The statute of limitations on Temple’s U.S. federal information returns remains open for three years following the year they are filed.

U.S. GAAP requires that a tax position be recognized or derecognized based on a “more likely than not” threshold. This applies to positions taken or expected to be taken in a tax return. Temple does not believe its consolidated financial statements include any uncertain tax positions that would require disclosure.

Functional Expense Allocation — Temple’s operation and maintenance of plant expenses (“O&M”) and depreciation expense (excluding depreciation related to auxiliary and library books) are allocated to the functional expense classifications based upon the proportionate share of expenses (excluding O&M and depreciation) reported in each functional classification in the statement of activities. Depreciation related to auxiliary fixed assets (e.g., dormitories, parking garages, and athletics) is fully allocated to *Auxiliary enterprises expense* and depreciation related to library books is fully allocated to academic support expense included in *Academic and student services* in the statement of activities (see Note 19).

Contributions from Related Parties — During the years ended June 30, 2023 and 2022, there were contributions from members of the Board of Trustees that did not have a material impact on the consolidated financial statements.

Use of Estimates — The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Temple’s critical estimates and assumptions include revenue recognition; adequacy of allowance for accounts, loans, and contribution receivable; the valuation of assets and liabilities recorded at fair value; valuation of claim based liabilities and conditional asset retirement obligations; useful lives for depreciation and amortization; impairment of intangible assets; incremental borrowing rate used in determining the present value of lease payments; estimated settlements with third-party payors; state Medicaid audit settlements; and accounting for pension and other postretirement benefits. Actual results could differ materially from these estimates.

Recently Issued Accounting Pronouncements — Recently issued accounting pronouncements that are applicable to Temple’s consolidated financial statements are as follows:

Standard	Description	Adoption
Standards that were adopted during fiscal years 2023 and 2022:		
<p>Leases</p> <p>ASU 2021-09 (Topic 842)</p>	<p>Provides lessees that are not public business entities with a practical expedient that allows them to elect, as an accounting policy, to use a risk-free rate as the discount rate for all leases. The standard allows lessees to make the risk-free rate election by class of underlying asset, rather than at the entity-wide level. An entity that makes the risk-free rate election is required to disclose which asset classes it has elected to apply a risk-free rate. The standard requires that when the rate implicit in the lease is readily determinable for any individual lease, the lessee use that rate (rather than a risk-free rate or an incremental borrowing rate), regardless of whether it has made the risk-free rate election. Temple did not elect the practical expedient allowed by ASU 2021-09.</p>	<p>Immediate (for entities that already adopted Topic 842)</p> <p>Retrospective or modified retrospective application (consistent with ASC 842 election).</p>
<p>Not-for-Profit Entities (Topic 958) Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets</p> <p>ASU 2020-07 (Topic 958)</p>	<p>Provides new presentation and disclosure requirements about contributed nonfinancial assets for not-for-profits, including additional disclosure rules for recognized contributed services. The amendments do not change the recognition and measurement requirements for those assets. Not-for-profits are required to present donated nonfinancial assets separately in the statement of activities from contributions of cash or other financial assets. A not-for-profit organization has to disclose more details about the donated nonfinancial asset it received by category in footnotes. Temple did not have significant contributions of nonfinancial assets. The new standard did not have a material impact on Temple’s combined financial statements.</p>	<p>July 1, 2021 (annual periods)</p> <p>July 1, 2022 (interim periods)</p> <p>Retrospective application</p>
<p>Compensation - Retirement Benefits - Defined Benefit Plans -General (Subtopic 715-20)</p> <p>ASU 2018-14 (Topic 715)</p>	<p>Improves the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. Specifically, the amendments remove disclosures that no longer are considered cost beneficial, clarify the specific requirements of disclosures, and add disclosure requirements identified as relevant.</p> <p>ASU 2018-14 adds requirements for an entity to disclose the following: (i) the weighted-average interest crediting rates used in the entity’s cash balance pension plans and other similar plans, (ii) a narrative description of the reasons for significant gains and losses affecting the benefit obligation for the period, and (iii) an explanation of any other significant changes in the benefit obligation or plan assets that are not otherwise apparent in the other disclosures required by ASC 715.</p> <p>The ASU removes guidance that currently requires the following disclosures: (i) amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year, (ii) information about benefits covered by related-party insurance and annuity contracts and significant transactions between the plan and related parties, and (iii) for nonpublic entities with Level 3 plan assets in the fair value hierarchy measured on a recurring basis, a reconciliation of the opening balances to the closing balances. (However, those entities would still need to disclose transfers of plan assets into and out of Level 3 and any purchases of Level 3 assets by the plan.)</p> <p>ASU 2018-14 also clarifies the guidance on defined benefit plans to require disclosure of (i) the projected benefit obligation (“PBO”) and fair value of plan assets for pension plans with PBOs in excess of plan assets (the same disclosure with reference to the accumulated postretirement benefit obligation rather than the PBO is required for other postretirement benefit plans) and (ii) the accumulated benefit obligation (“ABO”) and fair value of plan assets for pension plans with ABOs in excess of plan assets.</p> <p>The adoption of ASU 2018-14 did not have a material impact on Temple’s consolidated financial statements. The clarifications and changes required by the new standard are reflected in the accompanying pensions and postretirement benefits disclosures (see Note 5).</p>	<p>July 1, 2021 (annual periods)</p> <p>Retrospective application</p>

3. Endowment, Investments, and Self-Insurance Trust Funds

The carrying values of investments, including the endowment (see Note 11), at June 30, 2023 and 2022 are as follows:

	June 30, 2023	June 30, 2022
Investments (including endowment):		
Money market funds	\$ 77,546	\$ 67,879
Corporate bonds, notes, and other debt securities	382,002	383,847
U.S. government and agency securities	457,027	386,625
Municipal bonds	3,149	6,100
Fixed income funds	115,543	107,229
Equity funds and securities	1,002,069	904,675
Futures contracts	1,561	(5,798)
Commodity funds	15,989	13,744
Private equity funds	76,278	60,921
Real estate funds	104,031	121,452
Multi-strategy hedge funds	258,437	271,444
Opportunistic funds	30,879	25,946
Other	3,130	2,475
Total investments	\$ 2,527,641	\$ 2,346,539

The University utilizes an outsourced chief investment officer (“OCIO”) for its investment management responsibilities related to the University’s endowment, pension plans, and postretirement plan assets. The private equity asset allocation, which has a target allocation of 15% of the endowment assets and 10% of the postretirement plan assets, commenced funding in 2018 and is expected to take approximately five to seven years from inception to fully execute, resulting in an overweight position in U.S. equities at June 30, 2023 and 2022.

The carrying values of self-insurance trust funds at June 30, 2023 and 2022 are as follows:

	June 30, 2023	June 30, 2022
Self-insurance trust funds:		
Money market funds	\$ 1,602	\$ 1,495
U.S. government securities	11,655	11,198
Total self-insurance trust funds	\$ 13,257	\$ 12,693

Investment return reported in the statements of activities for the years ended June 30, 2023 and 2022 is as follows:

	Year Ended June 30,	
	2023	2022
Investment income:		
Interest and dividends	\$ 66,438	\$ 31,790
Realized gains, net	44,220	33,083
Change in unrealized gains (losses), net	46,298	(262,321)
Total investment income (loss)	\$ 156,956	\$ (197,448)

Derivatives:

Futures Contracts — A futures contract is a contractual agreement to make or take delivery of a standardized quantity of a type of commodity or financial instrument at a specified future date in accordance with the terms specified by a regulated futures exchange. The University uses equity index futures contracts to manage equity price risk. Losses in value may arise from changes in the value of the underlying instrument or if there is an illiquid secondary market for the futures contracts.

Upon entering into a futures contract, the University is required to deposit either cash or securities in an amount equal to a certain percentage of the nominal value of the contract (“initial margin”). Pursuant to the futures contract, the University agrees to receive from, or pay to, the broker an amount of cash equal to the daily fluctuation in the value of the futures contracts. Such receipts or payments are known as “variation margin” which are settled daily. Any variation margin unsettled at period-end is recorded as an unrealized gain (loss) in *Investment return in Other changes in net assets* in the statements of activities. The University recognizes a realized gain or loss when the contract is closed. Futures contracts expose the University to off-balance sheet market and liquidity risk. The University is exposed to market risk to the extent that adverse changes occur in the fair values of the underlying securities or indices. This market risk is in excess of the amount recognized in the statement of assets and liabilities. Liquidity risk represents the possibility that the University might not be able to rapidly adjust the size of its futures position in times of high volatility and financial stress at a reasonable price.

The University has credit risk associated with counterparty nonperformance. However, credit risk associated with exchange-traded contracts are typically perceived to be less because exchanges typically provide clearing house arrangements in which the collective credit of the managers of the exchange is pledged to support the financial integrity of the exchange. Margins, which may be subject to loss in the event of a default, are generally required in exchange trading and further mitigate credit risk. All of the futures contracts held by the University at June 30, 2023 and 2022 were exchange traded contracts.

At June 30, 2023 and 2022, the University had the following open futures subject to equity price risk, for which U.S. Treasury notes were pledged as collateral (see Note 14):

	Number of Contracts	Notional Amount	Variation Margin Unrealized Gain (Loss)
June 30, 2023			
Equity price futures contracts, not designated as hedging instruments, included in:			
Endowment	639	\$ 94,265	\$ 1,561
Postretirement benefits plan assets	113	14,758	209
Pension plans assets	48	5,421	(13)
June 30, 2022			
Equity price futures contracts, not designated as hedging instruments, included in:			
Endowment	716	\$ 89,191	\$ (5,798)
Postretirement benefits plan assets	150	17,928	(261)
Pension plans assets	45	5,346	(139)

4. Accounts, Loans, and Contributions Receivable

Accounts receivable, net of allowances are as follows:

	June 30, 2023	June 30, 2022
Students	\$ 48,749	\$ 49,895
Patients	334,761	268,130
Health care programs	71,480	55,535
Grants and contracts	82,380	94,150
Commonwealth construction	5,968	12,116
Recoveries from insurance providers	98,409	56,818
Other	48,672	32,239
Accounts receivable, gross	690,419	568,883
Less: Allowance for doubtful patient accounts	(1,248)	(2,150)
Less: Allowance for doubtful students, grants, contracts, and other accounts	(29,067)	(17,510)
Total accounts receivable, net	<u>\$ 660,104</u>	<u>\$ 549,223</u>

Loans to students are disbursed based on financial need and consist of loans granted by the University under federal government loan programs and loans granted from institutional resources. Upon the earlier of graduation or no longer having full-time student status, the students have a grace period, which varies by loan type, until repayment of loans is required.

The availability of funds for loans under federal government revolving loan programs is dependent on reimbursements to the pool from repayments on outstanding loans. At June 30, 2023 and 2022, funds advanced by the federal government totaled \$30,707 and \$34,217, respectively. Interest and fees collected are included in the revolving loan funds available for students. Federal loan funds are ultimately refundable to the government and are classified as liabilities in the consolidated balance sheets. Outstanding loans canceled under the program result in a reduction of the funds available for loan and a decrease in the liability to the government.

Loans to students are shown net of allowances as follows:

	June 30, 2023	June 30, 2022
Federal government loan programs:		
Perkins loan program*	\$ 11,566	\$ 18,659
Health professional and disadvantaged student loans	24,422	23,946
Nursing student loans	251	152
Federal government loan programs	36,239	42,757
Institutional loan programs	824	972
Student loans receivable, gross	37,063	43,729
Less: Allowance for doubtful federal government loan programs	(7,419)	(10,574)
Less: Allowance for doubtful institutional loan programs	(288)	(292)
Total student loans receivable, net	<u>\$ 29,356</u>	<u>\$ 32,863</u>

* On September 30, 2017, the Federal Perkins Loan program was not renewed in Congress, thus effectively ending the loan program. Previously loaned funds will continue to be collected, however, no new loans are being originated.

Student loans are considered past due when payment has not been received in over 30 days. Allowances for doubtful accounts are established based on prior collection experience and current economic factors which, in management's judgment, could influence the ability of loan recipients to repay the amounts per the loan terms. Further, the University does not evaluate the credit quality of the student loans receivable after the initial approval and calculation of the loans. Institutional loan balances are written off when they are deemed to be permanently uncollectible.

The aging of student loans receivable is as follows:

	June 30, 2023	June 30, 2022
30 days or less past due	\$ 27,047	\$ 29,893
31 through 89 days past due	947	1,328
90 days and greater past due	1,362	1,642
Total student loans receivable, net	<u>\$ 29,356</u>	<u>\$ 32,863</u>

Contributions receivable are unconditional promises to give, restricted by donors for scholarships, capital acquisitions, and other operating purposes. They are expected to be realized in the following periods:

	June 30, 2023	June 30, 2022
In one year or less	\$ 9,714	\$ 13,612
One to five years	20,186	22,050
Greater than five years	43,470	45,760
Contributions receivable, gross	<u>73,370</u>	<u>81,422</u>
Less: Allowance for doubtful contributions	(4,537)	(4,957)
Less: Present value discount	(8,920)	(10,212)
Total contributions receivable, net	<u>59,913</u>	<u>66,253</u>
Less: Current portion of contribution receivable, net	(7,256)	(11,800)
Non-current portion of contribution receivable, net	<u>\$ 52,657</u>	<u>\$ 54,453</u>

Changes to net contributions receivable during the years ended June 30, 2023 and 2022 are as follows:

	Year Ended June 30,	
	2023	2022
Balance, beginning of the year	\$ 66,253	\$ 74,903
New pledges	6,641	7,795
Collection of pledges	(12,919)	(15,886)
Pledges written off	(1,774)	(1,349)
Change in allowance	420	399
Change in discount to present value	1,292	391
Balance, end of the year	<u>\$ 59,913</u>	<u>\$ 66,253</u>

The discount rates used to calculate the present value discount are tied to U.S. Government treasury notes in effect at the time of contribution. Discount rates for durations between 1 and 30 years were between 3.81% and 5.40% for contributions made during the year ended June 30, 2023, and between 2.80% and 3.38% for contributions made during the year ended June 30, 2022.

Temple also receives bequest intentions and certain other conditional promises to give. These intentions and conditional promises to give are not included in the consolidated financial statements.

5. Pensions and Postretirement Benefits

Temple sponsors various postretirement programs, which include defined benefit pension plans (three plans sponsored by the University and, through June 29, 2022, six plans sponsored by TUHS, which were subsequently merged into a single defined benefit plan on June 30, 2022), three retiree health benefits pre-funding plans, referred to below as “postretirement benefits” (one plan sponsored by the University and two plans sponsored by TUHS), and defined contribution plans. Participation in these plans is based on prescribed eligibility requirements. Certain TUHS employees also participate in the University’s defined benefit plan. During 2022, TUHS offered participants in its defined benefit pension plan a lump sum payment option in settlement of its outstanding benefit obligations. The settlements offered resulted in an increase in benefit payments and settlement costs. No lump sum window or settlement charge occurred during the year ended June 30, 2023.

Temple makes contributions to its defined benefit pension plans that comply with the funding provisions of the Internal Revenue Code. Employees participating in the pension plans are eligible to begin receiving benefit payments upon retirement, provided age and service requirements have been met. In 2001, two of the University’s defined benefit pension plans were frozen, with no future accruals. The third pension plan sponsored by the University remains active for two collectively bargained groups of employees. In 2008, the remaining TUHS sponsored defined benefit plans were closed to new participants; only certain grandfathered employees are eligible to participate in the TUHS sponsored defined benefit pension plans.

The postretirement benefits plans are postretirement trusts established for the purpose of providing medical and prescription drug coverage to eligible retirees. Eligible active employees could elect to pre-pay a portion of their future medical costs. Contributions for a period of ten years were required in order to be eligible to retire and receive benefits on or after the age of 62. This plan had a series of sunset dates beginning in 1999 through June 30, 2003. No employees hired or rehired on or after the earlier of their respective sunset date or June 30, 2003 are eligible to participate in the postretirement benefits plan.

Defined contribution retirement plans are offered to all full-time faculty and staff, with the exception of the two collectively bargained groups that participate in the active defined benefit pension plan. Deposits to the defined contribution plans are provided through contributions made by Temple and its employees into participant managed accounts. Temple’s contributions to participants’ accounts are based on a defined percentage of the participants’ elected contributions, base wages, and length of service. Temple’s contributions to the defined contribution plans in 2023 and 2022 were \$86,066 and \$80,976, respectively.

Certain union employees are covered by multi-employer pension plans to which Temple contributes. A contributor to a multi-employer plan is liable, upon termination of the plan or its withdrawal from the plan, for its share of the plan’s unfunded vested liabilities. Until either event occurs, Temple’s share, if any, of the unfunded vested liabilities cannot be determined. At present, Temple has no plans to withdraw from the multi-employer pension plans. Pension expense for these plans was \$12,081 and \$10,969 in 2023 and 2022, respectively.

The activity of the defined benefit pension and postretirement benefit plans for the years ended June 30, 2023 and 2022 is as follows:

	Pensions		Postretirement Benefits	
	2023	2022	2023	2022
Change in benefit obligation:				
Benefit obligation, beginning of year	\$ 184,470	\$ 253,693	\$ 302,723	\$ 366,806
Service cost	2,778	2,800	8,716	11,479
Interest cost	7,800	5,411	13,496	9,097
Plan participant contributions	255	224	1,258	1,316
Actuarial gain	(6,271)	(42,604)	(15,536)	(70,059)
Benefits paid	(11,562)	(34,788)	(16,520)	(15,916)
Plan expenses	(2,534)	(3,339)	—	—
Settlement	—	3,073	—	—
Benefit obligation, end of year	<u>\$ 174,936</u>	<u>\$ 184,470</u>	<u>\$ 294,137</u>	<u>\$ 302,723</u>
Change in plan assets:				
Fair value of plan assets, beginning of year	\$ 175,783	\$ 247,265	\$ 361,397	\$ 389,954
Actual return on plan assets	1,430	(33,579)	17,225	(17,491)
Employer contributions	—	—	3,552	3,534
Plan participant contributions	255	224	1,258	1,316
Benefits paid	(11,562)	(34,788)	(16,520)	(15,916)
Plan expenses	(2,534)	(3,339)	—	—
Fair value of plan assets, end of year	<u>\$ 163,371</u>	<u>\$ 175,783</u>	<u>\$ 366,912</u>	<u>\$ 361,397</u>
Funded status:				
Funded status, end of year	<u>\$ (11,565)</u>	<u>\$ (8,687)</u>	<u>\$ 72,775</u>	<u>\$ 58,674</u>

The accumulated benefit obligation for the pension plans at June 30, 2023 and 2022 was \$173,737 and \$183,271, respectively.

	Pensions		Postretirement Benefits	
	2023	2022	2023	2022
The funded status recognized in the balance sheets:				
Assets, non-current	\$ 5,222	\$ 4,786	\$ 74,879	\$ 61,172
Liabilities, current	—	—	(338)	(377)
Liabilities, non-current	(16,787)	(13,473)	(1,766)	(2,121)
Net amount recognized, funded status	<u>\$ (11,565)</u>	<u>\$ (8,687)</u>	<u>\$ 72,775</u>	<u>\$ 58,674</u>
Accumulated amounts recognized in net assets without donor restrictions:				
Unrecognized net loss (gain)	\$ 62,064	\$ 64,330	\$ (88,353)	\$ (87,746)
Net amount recognized	<u>\$ 62,064</u>	<u>\$ 64,330</u>	<u>\$ (88,353)</u>	<u>\$ (87,746)</u>

	Pensions		Postretirement Benefits	
	2023	2022	2023	2022
Changes in plan assets and benefit obligations recognized in other changes in net assets:				
Actuarial (gain) loss	\$ (876)	\$ 5,968	\$ (10,699)	\$ (27,765)
Amortization of net actuarial (loss) gain	(1,390)	(4,281)	10,092	5,769
Recognition of settlement loss	—	(11,009)	—	—
Total recognized in other changes in net assets	\$ (2,266)	\$ (9,322)	\$ (607)	\$ (21,996)

The amortization of any prior service cost and unrecognized net loss is determined using a straight-line amortization of the cost over the average remaining service period of employees expected to receive benefits under the pension plans or the expected average future service to retirement under the postretirement benefit plan.

Temple uses the full yield curve (or spot rate) approach to estimate the service and interest costs related to Temple's pensions and postretirement benefits plans. Such approach estimates service and interest costs by applying specific spot rates along the yield curve to determine the benefit obligation of relevant projected cash outflows (as opposed to applying an average rate). The full yield curve approach (compared to an average rate approach) provides a more precise measurement of service and interest costs by aligning the timing of the plans' liability cash flows to the corresponding spot rate on the yield curve.

	Pensions		Postretirement Benefits	
	2023	2022	2023	2022
Components of net periodic cost:				
Operating expenses:				
Service cost	\$ 2,778	\$ 2,800	\$ 8,716	\$ 11,479
Other changes in net assets:				
Interest cost	7,800	5,411	13,496	9,097
Expected return on plan assets	(6,825)	(11,916)	(22,063)	(24,805)
Amortization of net actuarial loss (gain)	1,390	4,281	(10,083)	(5,768)
Settlement	—	11,009	(9)	—
Net periodic cost (including settlement expense)	\$ 5,143	\$ 11,585	\$ (9,943)	\$ (9,997)

	Pensions		Postretirement Benefits	
	2023	2022	2023	2022
Weighted-average assumptions used to determine the benefit obligations at end of year:				
Discount rate(s)	5.12%-5.15%	4.55%-4.80%	5.14%	4.76%
Expected long-term rate of return on plan assets	4.50%-5.40%	3.60%-3.75%	6.90%	6.25%
Rate of compensation increase	2.50%	2.50%	N/A	N/A
Assumed health care cost trend rates (pre-65 / post-65):				
Health care cost trend rate assumed for next year	N/A	N/A	7.17% / 7.56%	6.86% / 6.97%
Rate to which the cost trend rate is assumed to decline (the ultimate trend rate)	N/A	N/A	4.45% / 4.44%	4.45% / 4.44%
Year that ultimate rate is reached	N/A	N/A	2032 / 2032	2030 / 2030

	Pensions		Postretirement Benefits	
	2023	2022	2023	2022
Weighted-average assumptions used to determine net periodic cost at beginning of year:				
Discount rate(s) for benefit obligations	4.72%-4.80%	2.31%-3.04%	4.76%	2.85%
Discount rate(s) for service cost	4.96%	3.41%	4.98%	3.41%
Discount rate(s) for interest cost	4.37%-4.5%	1.58%-2.35%	4.47%	2.20%
Expected long-term rate of return on plan assets	3.60%-3.75%	3.75%-6.50%	6.25%	6.50%
Rate of compensation increase	2.5%	2.50%-3.00%	N/A	N/A
Assumed health care cost trend rates (pre-65 / post-65):				
Health care cost trend rate assumed for current year	N/A	N/A	7.40% / 7.93%	7.06% / 7.21%
Rate to which the cost trend rate is assumed to decline (the ultimate trend rate)	N/A	N/A	4.45% / 4.44%	4.45% / 4.44%
Year that ultimate rate is reached	N/A	N/A	2032 / 2032	2030 / 2030

Plan Assets and Expected Return — The long-term investment strategy for assets held in the pension and postretirement benefits plans is to meet present and future benefit obligations to all participants and beneficiaries; cover reasonable expenses incurred to provide such benefits; and provide a total return that maximizes the ratio of assets to liabilities by maximizing investment return at the appropriate level of risk. The expected return on plan assets equals a weighted-average of the individual expected returns for each asset category in the plans' portfolio. The target and actual asset allocation as of June 30, 2023 and 2022 is as follows (see Note 10 for plan asset fair value disclosures):

Asset class:	Pensions			Postretirement Benefits		
	Target*	2023	2022	Target*	2023	2022
Equity funds and securities	0%-25%	9 %	27 %	70%	65 %	69 %
Fixed income and cash	75%-100%	91 %	73 %	30%	35 %	31 %

* Target allocation are as of June 30, 2023 and exclude the impact of the portable alpha overlay strategies. At June 30, 2023, The University's pension plans have an asset allocation target of 25% equity and 75% fixed income and the TUHS pension plans have an asset allocation target of 100% fixed income. Effective June 30, 2022, the TUHS sponsored pension plans were merged into a single defined benefit plan; with its asset allocation being transitioned to fully fixed income securities.

Expected Cash Flows — The following table shows expected cash flows of the pension and postretirement benefits plans:

	Pensions		Postretirement Benefits	
Expected contributions for next fiscal year:				
Employer	\$	—	\$	338
Employee		N/A		1,300
Estimated future benefit payments reflecting expected future service for fiscal years ending June 30:				
2024	\$	13,313	\$	16,801
2025		12,492		17,415
2026		12,625		17,914
2027		12,798		18,667
2028		12,893		19,126
2029 through 2033		64,401		98,451

Other Plans — The actuarial present value of accumulated plan benefits related to a non-active group annuity pension plan has neither been determined nor included above because a guarantee of payment to the plan's beneficiaries has been made by The Equitable Life Assurance Society of America. This plan had total net assets available for benefits of \$821 and \$926 at June 30, 2023 and 2022, respectively.

6. Deposits with Trustees

Temple has on deposit with trustees amounts established for debt repayment. These deposits are primarily invested in U.S. Government securities and money market funds (see Note 9 for a description of debt issuances and Note 10 for fair value disclosures).

The fair values of deposits with trustees by debt issuance at June 30, 2023 and 2022 are as follows:

	June 30, 2023	June 30, 2022
Debt Repayment Funds:		
PAID, Second Series of 2016 (University)*	\$ 2	\$ —
PAID, First Series of 2015 (University)*	14	—
PHEFA, First Series of 2010B (University)*	10	1
THHEFAP, First Series of 2022 (TUHS)	4,023	1,790
THHEFAP, First Series of 2017 (TUHS)	40,362	42,583
Total deposits with trustees	<u>\$ 44,411</u>	<u>\$ 44,374</u>

* June 30, 2023 and 2022 amounts represent interest earned on deposits.

7. Property, Plant, and Equipment

Property, plant, and equipment at June 30, 2023 and 2022 is summarized as follows:

	June 30, 2023	June 30, 2022
Land and land improvements	\$ 141,408	\$ 136,410
Buildings and building improvements	2,696,332	2,647,491
Furniture, fixtures, equipment, and library books	1,368,536	1,340,811
Construction in progress	64,672	57,187
Property, plant, and equipment, gross	4,270,948	4,181,899
Less: Accumulated depreciation	(2,388,378)	(2,298,542)
Total property, plant, and equipment, net	<u>\$ 1,882,570</u>	<u>\$ 1,883,357</u>

Depreciation expense was \$164,009 and \$155,066 in 2023 and 2022, respectively.

Remainder of this Page is Intentionally Blank

8. Asset Retirement Obligations

Temple has recognized liabilities for conditional asset retirement obligations, primarily related to asbestos remediation in certain University facilities, which are included in *Accrued expenses and other liabilities* in Temple's consolidated balance sheets. Changes to the asset retirement obligation liability during the years ended June 30, 2023 and 2022 are as follows:

	2023	2022
Balance, beginning of the year	\$ 19,290	\$ 19,314
Liabilities incurred	88	—
Accretion expense	775	793
Revision of estimated cash flows	2,138	—
Liabilities settled	(2,443)	(734)
Foreign currency translation	(20)	(83)
Balance, end of the year	<u>\$ 19,828</u>	<u>\$ 19,290</u>

The fair value at June 30, 2023 and 2022 of \$19,828 and \$19,290, respectively, was calculated using the expected cash flow (expected present value) valuation method with the following Level 3 inputs: years to abatement ranging from 1 to 15 years and 1 to 16 years, respectively, an inflation factor of 2.00% to 4.50% (both years), a credit-adjusted risk free rate of 4.63% to 7.00% (both years), and a contractor market risk premium of 5.00% to 5.70% in 2023 and 5.00% in 2022.

9. Debt and Leases

Long-term debt consists of the following at June 30, 2023 and 2022:

	Maturity	Interest Rate†	Effective Rate	June 30,	
			2023	2023	2022
Long-term debt:					
University bond issuances:					
Revenue Bonds, First Series of 2020, issued at par	April 1, 2042	0.85%-3.18%	2.48%	\$ 164,210	\$ 171,295
PAID Revenue Bonds, First Series of 2016, including unamortized premium of \$3,527 and \$4,626, respectively	April 1, 2029	5.00%	3.62%	82,352	94,656
PAID Revenue Bonds, Second Series of 2016, including unamortized premium of \$8,617 and \$9,308, respectively	April 1, 2036	5.00%	3.73%	86,727	87,418
PAID Revenue Bonds, First Series of 2015, including unamortized premium of \$8,861 and \$9,477, respectively	April 1, 2045	5.00%	4.11%	114,191	116,592
PHEFA Revenue Bonds, First Series B of 2010, issued at par	April 1, 2040	5.37%-6.29%	4.07%	111,070	115,610
Total University bond issuances				<u>558,550</u>	<u>585,571</u>

	Maturity	Interest Rate†	Effective Rate 2023	June 30,	
				2023	2022
TUHS bond issuances:					
THHEFAP Hospital Revenue Bonds, Series 2022, including unamortized premium of \$21,161 and \$22,608, respectively	July 1, 2041	4.00%-5.00%	3.30%	187,051	188,498
THHEFAP Hospital Revenue Bonds, Series 2017, including unamortized premium of \$13,609 and \$15,832, respectively	July 1, 2034	5.00%	3.70%	218,129	233,447
Total TUHS bond issuances				405,180	421,945
Other long-term debt:					
PENNVEST (Pennsylvania Infrastructure Investment Authority)	May 1, 2039	1.00%-1.29%	1.00%	5,471	5,787
Loans payable (TESS)	Various	0.30%	0.30%	1,270	1,567
Equipment financing arrangements (TUHS)	December 31, 2024	2.86%		2,623	4,310
Finance leases				9,017	7,087
Deferred financing costs				(8,709)	(9,479)
Total long-term debt, net of deferred financing costs				973,402	1,016,788
Less: Current maturities of long-term debt				(42,483)	(44,536)
Non-current maturities of long-term debt, net of deferred financing costs				\$ 930,919	\$ 972,252

† Stated interest rate remaining through maturity. All bonds have an interest rate mode of fixed.

University Bond Issuances:

Revenue Bonds, First Series of 2020 — On June 25, 2020, the University issued \$176,690 of Temple University Federally Taxable Revenue Bonds, First Series of 2020 (“First Series of 2020 Bonds”) with stated interest rates ranging from 0.80% to 3.18%. The proceeds from the sale of the First Series of 2020 Bonds, together with other available funds, were used for the following items: (i) advance refund, on a taxable basis, a portion of the Pennsylvania Higher Educational Facilities Authority (“PHEFA”) Temple University First Series of 2012 previously issued on behalf of the University and (ii) paying costs of issuing the First Series of 2020 Bonds. The First Series of 2020 Bonds require annual principal payments of varying amounts beginning April 1, 2021 and ending on April 1, 2042. The First Series of 2020 Bonds are subject to redemption prior to their stated maturities at the option of the University, in whole or in part, on any date at the make-whole redemption price. The make-whole redemption price is the greater of (i) 100% of the principal amount of the bonds to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest to the maturity date of the bonds to be redeemed. The First Series of 2020 Bonds are secured by a pledge of gross revenues of the University, excluding all revenues of TUHS. Interest expense on the First Series of 2020 Bonds during the years ended June 30, 2023 and 2022 was \$4,181 and \$4,212, respectively.

PAID Revenue Bonds, First Series of 2016 — In fiscal 2016, the University, via the Philadelphia Authority for Industrial Development (“PAID”) issued \$134,080 of PAID Temple University Revenue Bonds, First Series of 2016 (“First Series of 2016 Bonds”) with a stated interest rate of 5.00%. The proceeds from the sale of the First Series of 2016 Bonds, together with other available funds, were used for the following items: (i) capital projects of the University, (ii) refunding a portion of the PHEFA Temple University Revenue Bonds,

First Series of 2006, and (iii) paying costs of issuing the First Series of 2016 Bonds. The First Series of 2016 Bonds require annual principal payments of varying amounts beginning April 1, 2016 and ending on April 1, 2029, with a first option call date of April 1, 2025. The First Series of 2016 Bonds are secured by a pledge of gross revenues of the University, excluding all revenues of TUHS. Interest expense on the First Series of 2016 Bonds during the years ended June 30, 2023 and 2022 was \$3,309 and \$3,736, respectively.

PAID Revenue Bonds, Second Series of 2016 — In fiscal 2016, the University, via PAID issued \$78,110 of PAID Temple University Revenue Bonds, Second Series of 2016 (“Second Series of 2016 Bonds”) with a stated interest rate of 5.00%. The proceeds from the sale of the Second Series of 2016 Bonds, together with other available funds, were used for the following items: (i) refunding the outstanding portion of PHEFA’s Temple University Revenue Bonds, First Series of 2006, and (ii) paying costs of issuing the Second Series of 2016 Bonds. The Second Series of 2016 Bonds require principal payments of varying amounts beginning April 1, 2030 and ending on April 1, 2036, with a first option call date of April 1, 2025. The Second Series of 2016 Bonds are secured by a pledge of gross revenues of the University, excluding all revenues of TUHS. Interest expense on the Second Series of 2016 Bonds during the years ended June 30, 2023 and 2022 was \$3,237 and \$3,264, respectively.

PAID Revenue Bonds, First Series of 2015 — In fiscal 2016, the University, via PAID issued \$130,440 of PAID Temple University Revenue Bonds, First Series of 2015 (“First Series of 2015 Bonds”) with stated interest rates ranging from 2.00% to 5.00%. The proceeds from the sale of the First Series of 2015 Bonds, together with other available funds, were used for the following items: (i) capital projects of the University, (ii) refunding a portion of PHEFA’s Temple University Revenue Bonds, First Series of 2006, and (iii) paying costs of issuing the First Series of 2015 Bonds. The First Series of 2015 Bonds require annual principal payments of varying amounts beginning April 1, 2016 and ending on April 1, 2045, with a first option call date of April 1, 2025. The First Series of 2015 Bonds are secured by a pledge of gross revenues of the University, excluding all revenues of TUHS. Interest expense on the First Series of 2015 Bonds during the years ended June 30, 2023 and 2022 was \$4,727 and \$4,839, respectively.

PHEFA Revenue Bonds, First Series of 2012 — In fiscal 2012, the University, via PHEFA issued \$200,000 of PHEFA Temple University Revenue Bonds, First Series of 2012 (“First Series of 2012 Bonds”) with stated interest rates ranging from 1.00% to 5.00%. The proceeds from the sale of the First Series of 2012 Bonds, together with other available funds, were used for the following items: (i) capital projects of the University and (ii) paying costs of issuing the First Series of 2012 Bonds. The First Series of 2020 Bonds provided for the advance refunding of \$160,175 aggregate principal amount of the First Series of 2012 Bonds, which had maturities ranging from April 2023 through April 2042. There were two non-refunded bond CUSIP numbers from the First Series of 2012 Bonds, one of which required a principal payment of \$4,395 on April 1, 2021, and the other requiring a principal payment of \$4,615 on April 1, 2022; after which the First Series of 2012 Bonds were fully satisfied. The First Series of 2012 Bonds were secured by a pledge of gross revenues of the University, excluding all revenues of TUHS. Interest expense on the First Series of 2012 Bonds during the years ended June 30, 2023 and 2022 was \$0 and \$28, respectively.

PHEFA Revenue Bonds, First Series B of 2010 — In fiscal 2010, the University, via PHEFA issued \$143,590 of PHEFA Temple University Revenue Bonds, Federally Taxable Build America Bonds, First Series B of 2010 (“First Series B of 2010 Bonds”) with stated interest rates ranging from 4.21% to 6.29%. The proceeds from the sale of the First Series B of 2010 Bonds, together with other available funds, were used for the following items: (i) capital projects of the University and (ii) paying costs of issuing the First Series B of 2010 Bonds. The First Series B of 2010 Bonds require annual principal payments of varying amounts beginning April 1, 2016 and ending on April 1, 2040, with an optional redemption at any time upon payment of the redemption price. The First Series A of 2010 Bonds are secured by a pledge of gross revenues of the

University, excluding all revenues of TUHS. Interest expense on the First Series B of 2010 Bonds during the years ended June 30, 2023 and 2022 was \$4,759 and \$4,935, respectively.

TUHS Bond Issuances:

THHEFAP Hospital Revenue Bonds, Series 2022 — In fiscal 2022, TUHS, via the Hospitals and Higher Education Facilities Authority of Philadelphia (“THHEFAP”) issued \$165,890 of THHEFAP Hospital Revenue Bonds, Series 2020. The proceeds of the Bonds were used to defease the Authority’s outstanding Revenue Bond Series A of 2012, which is recorded as a non-operating loss in other income.

THHEFAP Hospital Revenue Bonds, Series 2017 — In fiscal 2018, TUHS, via THHEFAP issued \$235,240 of THHEFAP Hospital Revenue Bonds, Series 2017. The proceeds of the Bonds were used to defease the Authority’s outstanding Revenue Bond Series A and B of 2007 and Revenue Bond Series B of 2012.

The TUHS bond issuances are generally collateralized by the assets and gross revenues of the TUHS Obligated Group. The TUHS Obligated Group includes TUHS, Temple University Hospital, Inc., Temple Physicians, Inc., Temple Health System Transport Team, Inc., American Oncologic Hospital, Institute for Cancer Research, Fox Chase Cancer Center Medical Group, Inc., and Fox Chase Network, Inc.

Interest expense on TUHS long-term debt during the years ended June 30, 2023 and 2022 was \$17,129 and \$23,465, respectively.

Temple has complied with all financial debt covenants during the years ended June 30, 2023 and 2022.

Other Long-term Debt:

PENNVEST Debt Obligation — In June 2017, the University and the Pennsylvania Infrastructure Investment Authority (“PENNVEST”) entered into an agreement for PENNVEST to provide financing totaling \$6,748 for the construction of certain storm water improvements, including a green roof assembly and green roof landscaping on the University’s library. Construction commenced in fiscal 2018 and the library project was completed and placed into service in the first quarter of fiscal year 2021. During the year ended June 30, 2020 and 2019, the University borrowed \$1,644 and \$5,104, respectively, against the obligation. The stated interest rate is 1.00% for years 1 through 5 and 1.29% for years 6 through maturity (May 1, 2039). Interest expense during the years ended June 30, 2023 and 2022 was \$56 and \$60, respectively.

Loans Payable (TESS) — In September 2019, TESS obtained two unsecured bank loans totaling \$2,792. The bank loans were in equal amounts of \$1,396 from Mizuho Bank, Ltd. (the “Mizuho Loan”) and Sumitomo Mitsui Banking Corporation (the “SMBC Loan”). Proceeds from the bank loans were used to fund TESS’ campus relocation in Tokyo, Japan. The Mizuho Loan matures in June 2029 and the SMBC Loan matures in September 2029; and both Loans accrue interest at 0.3 %. Interest expense on the two bank loans during the years ended June 30, 2023 and 2022 was \$4 and \$6, respectively.

Lines of Credit — TUHS has a \$100,000 line of credit (the “TUHS JPM Line of Credit”) with JPMorgan Chase Bank, N.A. (“JPM”) that expires in October 2023. Amounts borrowed accrue interest at the secured overnight financing rate (“SOFR”) plus 85 basis points. No amount was borrowed or outstanding at any time during 2023 or 2022.

From July 1, 2021, through April 27, 2022, the University had a \$100,000 revolving line of credit (the "JPM Line of Credit") and a \$7,500 unsecured line of credit (the "JPM Unsecured Line of Credit") from JPMorgan Chase Bank, N.A. ("JPM"). Both the JPM Line of Credit and the JPM Unsecured Line of Credit had a term of

one-year with an automatic renewal option. In April 2022, the JPM Line of Credit and the JPM Unsecured Line of Credit were renewed with a maturity date of April 27, 2023. The JPM Unsecured Line of Credit remained at \$7,500, however, the revolving line of the JPM Line of Credit was reduced to \$50,000; with an accordion feature added permitting certain increases to the revolving commitment up to an additional maximum principal amount of \$50,000. In April 2023, the JPM Line of Credit and JPM Unsecured Line of Credit were renewed (amounts unchanged) with a maturity date of April 26, 2024. Through April 27, 2022, amounts borrowed accrued interest at a rate equal to the one-month London Interbank Offered Rate (“LIBOR”) plus 45 basis points. With the transition from the LIBOR benchmark, effective April 28, 2022 through April 27, 2023, amounts borrowed accrued interest at the secured overnight financing rate (“SOFR”) plus 45 basis points; with an unused fee on the JPM Line of Credit of five basis points. Effective April 28, 2023 through April 26, 2024, amounts borrowed against the JPM Line of Credit accrue interest at SOFR plus 60 basis points; with an unused fee of 10 basis points. Amounts pledged against the JPM Unsecured Line of Credit accrue interest at 60 basis points, with no unused fee. The JPM Line of Credit is secured by a subordinated gross revenue pledge of the University and is cross-defaulted to the University's covenants in the various bond documents. The JPM Line of Credit can be used to fund seasonal working capital requirements, fund capital expenditure bridge financing, and fund general corporate purposes. During the years ended June 30, 2023 and 2022, no amount under the JPM Line of Credit or JPM Unsecured Line of Credit was outstanding, drawn, or pledged as collateral. Interest expense on the JPM Line of Credit (related to undrawn capacity) during the years ended June 30, 2023 and 2022 was \$34 and \$51, respectively.

Interest — Total interest expense incurred, net of capitalized interest, was \$37,438 and \$44,598 for the years ended June 30, 2023 and 2022, respectively. Temple capitalizes interest cost on qualifying assets. There was no capitalized interest at June 30, 2023 or 2022.

Fair Value and Maturity — As of June 30, 2023 and 2022, the fair value of Temple’s bond issuances (excluding net unamortized premium of \$55,775 and \$61,851, respectively, deferred financing costs of \$8,709 and \$9,479, respectively, and accrued interest of \$14,837 and \$13,472, respectively) with a principal value of \$907,955 and \$945,665, respectively, was approximately \$902,848 and \$1,039,111, respectively. The fair value was determined based upon discounted cash flows at current market rates for instruments with similar remaining terms. Temple considers these valuation inputs to be Level 2 inputs in the fair value hierarchy (see Note 10). The market prices utilized reflect the rate that Temple would have to pay to a credit-worthy third-party to assume its obligation and do not reflect an additional liability to Temple.

Long-term debt matures in varying amounts through 2045. The aggregate amounts of principal payments are as follows:

2024	\$	38,861
2025		41,876
2026		42,633
2027		44,343
2028		45,126
Thereafter		704,480
Total principal payments		<u>917,319</u>
Deferred financing costs		(8,709)
Unamortized premium and discount, net		55,775
Finance leases		9,017
Total long-term debt, net of deferred financing costs	\$	<u>973,402</u>

Leases:

Temple reports its leases in accordance with FASB ASC 842 – *Leases*, which defines a lease as a contract, or part of a contract, that conveys the right to control the use of identified property, plant, or equipment (the underlying asset) for a period of time in exchange for consideration. Both finance leases and operating leases create a right-of-use asset and a liability measured at the present value of the lease payments, with the corresponding right-of-use asset being adjusted for any prepaid (accrued) rent, lease incentives, and initial direct costs.

Temple leases certain facilities and equipment with initial terms in excess of one year. Leases with an initial term of 12-months or less are not recorded on the consolidated balance sheet; Temple recognizes lease expense for these leases on a straight-line basis over the lease term. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase/renewal option that is reasonably certain of exercise. There are no material restrictions or covenants imposed by Temple’s leases. See Note 2 for a summary of Temple’s lease accounting policy.

The right-of-use assets and lease liabilities under Temple’s finance and operating leases as of June 30, 2023 and 2022 are as follows:

Leases	June 30, 2023		June 30, 2022	
	Finance Leases	Operating Leases	Finance Leases	Operating Leases
Assets:				
Right-of-use assets	\$ 21,329	\$ 124,876	\$ 11,153	\$ 121,457
Accumulated amortization on finance leases and periodic reduction of ROU assets on operating leases	(12,174)	(37,569)	(4,269)	(27,028)
Right-of-use assets, net	<u>\$ 9,155</u>	<u>\$ 87,307</u>	<u>\$ 6,884</u>	<u>\$ 94,429</u>
Balance sheet classification (non-current)	PP&E	Operating lease right-of-use assets	PP&E	Operating lease right-of-use assets
Liabilities:				
Current portion of lease liability, balance	\$ 2,758	\$ 12,244	\$ 2,378	\$ 12,473
Non-current portion of lease liability, balance	6,259	77,316	4,709	83,254
Lease liabilities	<u>\$ 9,017</u>	<u>\$ 89,560</u>	<u>\$ 7,087</u>	<u>\$ 95,727</u>
Current portion of lease liabilities, classification	Long-term debt, current	AP and accrued expenses	Long-term debt, current	AP and accrued expenses
Non-current portion of lease liabilities, classification	Long-term debt, non-current	Operating lease liabilities	Long-term debt, non-current	Operating lease liabilities

A summary of the components of lease expense for the year ended June 30, 2023 and 2022 is as follows:

	Natural Expense Type	2023	2022
Operating lease cost:			
Fixed rent expense	Operating expenses	\$ 14,446	\$ 14,851
Finance lease cost:			
Amortization of ROU assets	Depreciation	2,545	2,739
Interest expense (on lease liability)	Interest	235	274
Short-term lease cost	Operating expenses	8,981	8,722
Variable lease cost	Operating expenses	4,015	4,518
Total lease cost		<u>\$ 30,222</u>	<u>\$ 31,104</u>

A maturity analysis of the future lease payments under finance and operating leases (with initial terms excess of one year) at June 30, 2023 is as follows:

Maturity of Lease Liabilities	Finance Leases	Operating Leases
2024	\$ 3,049	\$ 13,632
2025	2,512	13,121
2026	2,020	12,010
2027	1,194	11,564
2028	697	7,309
Thereafter	240	41,314
Obligation, gross	<u>9,712</u>	<u>98,950</u>
Liability accretion	(695)	(9,390)
Total obligation, net of liability accretion	<u>\$ 9,017</u>	<u>\$ 89,560</u>

Supplemental lease information as of June 30, 2023 and 2022 is as follows:

	June 30, 2023		June 30, 2022	
	Finance Leases	Operating Leases	Finance Leases	Operating Leases
Weighted average remaining lease-term (years)	3.99	12.36	3.58	13.17
Weighted average discount rates	3.77 %	1.72 %	3.30 %	1.50 %

Supplemental Cash Flow Information	June 30, 2023		June 30, 2022	
	Finance Leases	Operating Leases	Finance Leases	Operating Leases
Cash paid for amounts included in the measurement of lease liabilities:				
Operating cash flows [§]	\$ 235	\$ 13,248	\$ 274	\$ 14,447
Financing cash flows from finance leases [†]	3,016	N/A	3,447	N/A
Right-of-use assets obtained in exchange for new and modified finance and operating lease liabilities [‡]	4,944	7,387	1,023	29,528

[§] Payments arising from operating leases and the interest portion of finance leases are presented within operating activities in the combined statements of cash flows.

[†] Principal payments of lease liabilities arising from finance leases are included in Repayment of long-term debt and principal payments on finance leases in the financing section of the combined statements of cash flows.

[‡] 2022 balance includes extension of TUCC lease (see below).

As most of Temple's leases do not provide an implicit rate, the incremental borrowing rate, which is based on information available at the lease commencement date, is used to determine the present value of future lease payments. Temple's incremental borrowing rate applicable to the lease, is determined by estimating what it would cost Temple to borrow a collateralized amount equal to the total lease payments over the lease term based on the contractual terms of the lease and the location of the leased asset. The incremental borrowing rate on July 1, 2020 is used for operating leases that commenced prior to July 1, 2020 (the effective date of ASC 842).

Temple Japan — The University's Japan Campus leases facilities space with a lease term of 20 years (terminating on July 31, 2039). After the first ten years from commencement, the University may terminate the agreement, provided a three years notice is given to the lessor. At this time, the University has no intent to terminate the lease prior to July 31, 2039. At June 30, 2023 and 2022, the present value of lease payments related to this operating lease totaled \$28,406 and \$31,937, respectively.

Temple Rome — The University's Rome Campus leases facilities space with a lease term of 18 years (terminating on June 30, 2034). The University may terminate the lease, at any time, provided a six-month notice is given to the lessor. At June 30, 2023 and 2022, the present value of lease payments related to this operating lease totaled \$4,565 and \$4,930, respectively.

Temple University Center City — The University leases facilities space in Center-City Philadelphia, for its Temple University Center City ("TUCC") Campus. During 2022, the TUCC lease was renewed through 2027 and includes two separate three-year extension options, at the discretion of the University, that extend the lease through June 30, 2033. At June 30, 2023 and 2022, the present value of lease payments related to this operating lease totaled \$13,925 and \$17,880, respectively.

Related Party Lease Transactions — The University enters into various lease arrangements with TUHS, primarily for the use of facilities. During 2023 and 2022, lease payments to TUHS totaled \$68 and \$151, respectively, and lease payments collected from TUHS totaled \$1,151 and \$1,033, respectively.

TUHS has certain consumable agreements in which a vendor provides certain equipment at no additional cost in exchange for a commitment to purchase a minimum quantity of consumable products. These agreements

are considered embedded finance leases. At June 30, 2023 and 2022, ROU assets related to these agreements totaled \$1,529 and \$3,527, respectively, (included in *Property, plant, and equipment, net*), and lease liabilities totaled \$1,585 and \$3,587, respectively, (\$1,354 and \$2,029, respectively, included in *Accounts payable and accrued expenses, current* and \$231 and \$1,558, respectively, included in *Accrued expenses and other liabilities, non-current*). During the years ended June 30, 2023 and 2022, amortization of the leased assets totaled \$1,998 and \$2,130, respectively, interest on the lease liabilities totaled \$66 and \$117, respectively. During the year ended June 30, 2023, operating cash flows totaled \$66 and financing cash flows totaled \$2,029. A maturity analysis of future lease payments under these consumable agreements as of June 30, 2023 is as follows:

2024	\$	1,374
2025		233
2026		—
2027		—
2028		—
Thereafter		—
Obligation, gross		<u>1,607</u>
Liability accretion		<u>(22)</u>
Total obligation, net of liability accretion	\$	<u><u>1,585</u></u>

10. Fair Value Measurements

Temple applies the provisions of FASB ASC 820, *Fair Value Measurement*, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the consolidated financial statements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

A financial asset or liability classification is determined based on the lowest level input that is significant to the fair value measurement. The fair value hierarchy consists of the following three levels:

Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities that Temple can access at the measurement date. Active markets are those in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 assets primarily consist of money market funds, U.S. treasury securities, equity securities, exchange traded futures contracts, and equity and fixed income mutual funds.

Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 2 assets primarily consist of corporate bonds and notes, U.S. government agency securities, municipal bonds, and certain equity and fixed income funds.

Level 3 — Unobservable inputs based on management's own assumptions used to measure assets and liabilities at fair value or assets that management does not have the ability to redeem. Level 3 inputs include values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting Temple's own assumptions. Level 3 assets consist of perpetual trusts administered by third parties for which Temple does not have the ability to manage or redeem.

Investments for which fair value is measured using the net asset value per share practical expedient are not included within the fair value hierarchy.

The following tables provide the financial assets and liabilities carried at fair value measured on a recurring basis as of June 30, 2023 and 2022:

June 30, 2023	Level 1	Level 2	Level 3	Total
Investments (including endowment):				
Money market funds	\$ 76,595	\$ 951	\$ —	\$ 77,546
Corporate bonds, notes, and other debt securities	—	382,002	—	382,002
U.S. government and agency securities	364,190	92,837	—	457,027
Municipal bonds	—	3,149	—	3,149
Fixed income funds	74,511	—	—	74,511
Equity funds and securities	711,632	—	—	711,632
Futures contracts [§]	1,561	—	—	1,561
Real estate funds	—	320	—	320
Other	—	40	—	40
Total investments in fair value hierarchy	<u>\$ 1,228,489</u>	<u>\$ 479,299</u>	<u>\$ —</u>	1,707,788
Investments measured at NAV				816,763
Investments carried at equity				3,090
Total investments				<u>\$ 2,527,641</u>
Self-insurance trust funds:				
Money market funds	\$ 1,602	\$ —	\$ —	\$ 1,602
U.S. government securities	11,655	—	—	11,655
Total self-insurance trust funds	<u>\$ 13,257</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 13,257</u>
Deposits with trustees:				
Money market funds	\$ 25,558	\$ —	\$ —	\$ 25,558
U.S. government securities	5,443	13,410	—	18,853
Total deposits with trustees	<u>\$ 31,001</u>	<u>\$ 13,410</u>	<u>\$ —</u>	<u>\$ 44,411</u>
Funds held in trust by others:				
Funds held in trust by others	\$ —	\$ —	\$ 76,604	\$ 76,604
Beneficial interest in assets held by Episcopal Foundation	—	—	29,621	29,621
Beneficial interest in the Fox Chase Cancer Center Foundation	—	—	52,729	52,729
Total funds held in trust by others	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 158,954</u>	<u>\$ 158,954</u>

[§] Futures contracts are valued at the net unrealized appreciation (depreciation) on the instrument (see Note 3).

June 30, 2023	Level 1	Level 2	Level 3	Total
Pension plans:				
Money market funds	\$ 31,996	\$ —	\$ —	\$ 31,996
Corporate bonds and notes	—	20,207	—	20,207
U.S. government and agency securities	22,395	563	—	22,958
Municipal bonds	—	1,193	—	1,193
Collateralized mortgage obligations	—	1,059	—	1,059
Equity funds	167	—	—	167
Total pension plans in fair value hierarchy	<u>\$ 54,558</u>	<u>\$ 23,022</u>	<u>\$ —</u>	77,580
Pension plans measured at NAV				85,791
Total pension plans				<u>\$ 163,371</u>
Postretirement plans:				
Money market funds	\$ 14,394	\$ —	\$ —	\$ 14,394
U.S. government securities	75,767	—	—	75,767
Total postretirement plans in fair value hierarchy	<u>\$ 90,161</u>	<u>\$ —</u>	<u>\$ —</u>	90,161
Postretirement plans measured at NAV				276,751
Total postretirement plans				<u>\$ 366,912</u>

Remainder of this Page is Intentionally Blank

June 30, 2022	Level 1	Level 2	Level 3	Total
Investments (including endowment):				
Money market funds	\$ 66,885	\$ 994	\$ —	\$ 67,879
Corporate bonds, notes, and other debt securities	—	383,847	—	383,847
U.S. government and agency securities	312,006	74,619	—	386,625
Municipal bonds	—	6,100	—	6,100
Fixed income funds	67,435	—	—	67,435
Equity funds and securities	640,993	—	—	640,993
Futures contracts [§]	(5,798)	—	—	(5,798)
Real estate funds	—	320	—	320
Other	—	28	—	28
Total investments in fair value hierarchy	<u>\$ 1,081,521</u>	<u>\$ 465,908</u>	<u>\$ —</u>	<u>1,547,429</u>
Investments measured at NAV				796,663
Investments carried at equity				2,447
Total investments				<u>\$ 2,346,539</u>
Self-insurance trust funds:				
Money market funds	\$ 1,495	\$ —	\$ —	\$ 1,495
U.S. government securities	11,198	—	—	11,198
Total self-insurance trust funds	<u>\$ 12,693</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 12,693</u>
Deposits with trustees:				
Money market funds	\$ 25,730	\$ —	\$ —	\$ 25,730
U.S. government securities	5,247	13,397	—	18,644
Total deposits with trustees	<u>\$ 30,977</u>	<u>\$ 13,397</u>	<u>\$ —</u>	<u>\$ 44,374</u>
Funds held in trust by others:				
Funds held in trust by others	\$ —	\$ —	\$ 73,268	\$ 73,268
Beneficial interest in assets held by Episcopal Foundation	—	—	28,124	28,124
Beneficial interest in the Fox Chase Cancer Center Foundation	—	—	52,207	52,207
Total funds held in trust by others	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 153,599</u>	<u>\$ 153,599</u>

§ Futures contracts are valued at the net unrealized appreciation (depreciation) on the instrument (see Note 3).

June 30, 2022	Level 1	Level 2	Level 3	Total
Pension plans:				
Money market funds	\$ 5,898	\$ —	\$ —	\$ 5,898
Corporate bonds and notes	—	19,848	—	19,848
U.S. government and agency securities	22,740	—	—	22,740
Municipal bonds	—	1,358	—	1,358
Collateralized mortgage obligations	—	2,049	—	2,049
Equity funds	155	—	—	155
Total pension plans in fair value hierarchy	<u>\$ 28,793</u>	<u>\$ 23,255</u>	<u>\$ —</u>	52,048
Pension plans measured at NAV				123,735
Total pension plans				<u>\$ 175,783</u>
Postretirement plans:				
Money market funds	\$ 14,758	\$ —	\$ —	\$ 14,758
U.S. government securities	60,212	—	—	60,212
Equity funds and securities	5,575	—	—	5,575
Total postretirement plans in fair value hierarchy	<u>\$ 80,545</u>	<u>\$ —</u>	<u>\$ —</u>	80,545
Postretirement plans measured at NAV				280,852
Total postretirement plans				<u>\$ 361,397</u>

Temple assesses the valuation hierarchy for each asset or liability measured on an annual basis. From time to time, assets or liabilities will be transferred within the fair value hierarchy as a result of changes in, among other things, inputs used, liquidity, or valuation methodologies.

Except for \$135 of additional funds held in trusts by obtained during 2023, which are classified as Level 3 assets, during the years ended June 30, 2023 and 2022, there were no transfers into or out of Level 3, nor were there any purchases or sales of Level 3 assets.

Information for investments whose fair value is estimated using its net asset value (“NAV”) practical expedient (or its equivalent) at June 30, 2023 and 2022 is as follows:

June 30, 2023	Fair Values			Redemption	
	Investments / Endowment	Pensions	Post- retirement	Frequency	Notice Period
Commodity funds	\$ 15,989	\$ —	\$ 7,322	Daily	2 days
Multi-strategy hedge funds	258,437	6,959	73,544	Quarterly- Annual	45-90 days
Private equity	76,278	—	30,832	Illiquid	N/A
Real estate funds	103,711	—	13,979	Quarterly	45-90 days [^]
Fixed income funds	41,032	71,015	37,004	Daily- Quarterly	2-90 days
Equity funds	290,437	7,817	98,814	Daily- Monthly	1-90 days
Opportunistic funds	30,879	—	15,256	Quarterly- Illiquid	60 days- N/A
Total value	<u>\$ 816,763</u>	<u>\$ 85,791</u>	<u>\$ 276,751</u>		

June 30, 2022	Fair Values			Redemption	
	Investments / Endowment	Pensions	Post- retirement	Frequency	Notice Period
Commodity funds	\$ 13,744	\$ —	\$ 6,702	Daily	2 days
Multi-strategy hedge funds	271,444	9,249	83,322	Quarterly- Annual	45-90 days
Private equity	60,921	—	25,045	Illiquid	N/A
Real estate funds	121,132	—	16,842	Quarterly	45-90 days [^]
Fixed income funds	39,794	76,015	35,925	Daily- Quarterly	30-90 days
Equity funds	263,682	38,471	99,873	Daily- Monthly	1-30 days
Opportunistic funds	25,946	—	13,143	Quarterly- Illiquid	60 days- N/A
Total value	<u>\$ 796,663</u>	<u>\$ 123,735</u>	<u>\$ 280,852</u>		

[^] Subject to fund liquidity.

Unfunded commitments at June 30, 2023 and 2022 are as follows:

	June 30, 2023			June 30, 2022		
	Endowment	Post- retirement	Total	Endowment	Post- retirement	Total
Private equity	\$ 90,602	\$ 31,863	\$ 122,465	\$ 50,879	\$ 20,107	\$ 70,986
Real estate funds	51	2,648	2,699	51	—	51
Opportunistic funds	10,197	5,014	15,211	10,577	5,231	15,808
Unfunded commitments	<u>100,850</u>	<u>39,525</u>	<u>140,375</u>	<u>\$ 61,507</u>	<u>\$ 25,338</u>	<u>\$ 86,845</u>

Commodity funds include investments in both long and short commodity derivatives in a unitized fund structure.

Multi-strategy hedge funds include hedge fund-of-funds that invest in the commingled funds of hedge fund managers. Funds are allowed to take both long and short positions, use leverage and derivatives, and invest in many markets. Hedge funds may make equity, credit/fixed income, rate, and currency investments. Strategies employed may include long/short, event-driven, arbitrage, and macro.

Private equity investments include private partnerships, funds and/or other special purpose vehicles that invest in a range of strategies including, venture capital, growth equity, leveraged buyouts, credit-oriented opportunities, mezzanine and distressed debt, and special situations. Investments fund “start-up” companies or the buyout of existing companies or divisions within a company. Investments include domestic or international and encompass private and public securities. These funds can never be redeemed and these investments typically require capital lock-ups of 10 years or more.

Real estate funds include investments in public or private partnerships, funds and/or special purpose vehicles that make private real estate investments located within or outside the United States. Major sectors within this space include apartments, office properties, regional properties, industrial properties, and hotels, but may include land, medical facilities, self-storage and other real property investments. Investments may include

equity, debt, or both and may encompass “core”, “value-added”, or “opportunistic” opportunities. Investments are typically structured as partnerships.

Fixed income funds include investments made in commingled funds or fund-of-funds that invest in sovereign and government debt securities, corporate debt securities, U.S. Treasury Inflation-Protected securities. These funds generally seek long-term capital appreciation and provide a hedge against inflation.

Equity funds include investments made in commingled funds or fund-of-funds that invest in U.S., international, and global equity securities through a variety of active strategies. The funds generally seek long-term capital appreciation.

Opportunistic funds include investments with attractive risk/return characteristics based on a particular market environment. These investments include strategies such as private credit, distressed debt, and direct lending.

11. Endowment Funds

Temple’s endowment consists of a portfolio of actively managed individual funds established for a variety of purposes, including providing a funding source for (i) operations; (ii) scholarships and awards; (iii) academic leadership funds; and (iv) the master facility plan. The endowment includes both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments. As required by U.S. GAAP, net assets associated with endowment funds, including funds designated by the Board of Trustees to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

Board-Designated Endowment Funds — Board-designated endowment funds are quasi-endowment funds created by the Board of Trustees by designating a portion of Temple’s net assets without donor restrictions to be invested to provide income for an intended purpose. Board-designated endowment fund assets are recognized in net assets without donor restrictions.

Interpretation of Relevant Law — ASC 958, *Not-for-Profit Entities*, provides guidance on the net asset classification of donor-restricted endowment funds for not-for-profit organizations subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act (“UPMIFA”) and improves disclosure about an organization’s endowment funds regardless of whether the organization is subject to UPMIFA. The Commonwealth has not adopted UPMIFA, but rather has enacted Pennsylvania Act 141. The Board of Trustees has interpreted Commonwealth of Pennsylvania Act 141 as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, Temple classifies amounts in its donor-restricted endowment funds as net assets with donor restrictions because those net assets are time restricted until the Board of Trustees appropriates such amounts for expenditure. Most of those net assets also are subject to purpose restrictions that must be met before reclassifying those net assets to net assets without donor restrictions. The Board of Trustees of Temple has interpreted the relevant law as not requiring the maintenance of purchasing power of the original gift amount contributed to an endowment fund, unless a donor stipulates the contrary. As a result of this interpretation, when reviewing its donor-restricted endowment funds, Temple considers a fund to be underwater if the fair value of the fund is less than the sum of (a) the original value of initial and subsequent gift amounts donated to the fund and (b) any accumulations to the fund that are required to be maintained in perpetuity in accordance with the direction of the applicable donor gift instrument. Temple has interpreted the relevant law to permit spending from underwater funds in accordance with the prudent measures required under the law. Additionally, in accordance with the relevant law, Temple considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds: (i) the duration and preservation of the fund; (ii) the purposes of the organization

and the donor-restricted endowment fund; (iii) general economic conditions; (iv) the possible effect of inflation and deflation; (v) the expected total return from income and the appreciation of investments; (vi) other resources of the organization; and (vii) the investment policies of Temple.

Underwater Endowment — From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below their original value or the level that the donor requires Temple to retain as a fund of perpetual duration. When donor-restricted endowment deficiencies exist, they are classified as a reduction of donor-restricted net assets. These deficiencies resulted from unfavorable market fluctuations that occurred subsequent to the investment of contributions (often shortly after the investment of newly established endowments) and continued appropriation for certain programs that was deemed prudent by the Board of Trustees.

Underwater endowments at June 30, 2023 and 2022 are as follows:

	June 30, 2023	June 30, 2022
Underwater endowments:		
Number of underwater donor-restricted endowments	97	139
Original gift value	\$ 20,392	\$ 25,070
Fair value	19,144	22,959
Endowment deficiencies	<u>\$ (1,248)</u>	<u>\$ (2,111)</u>

Endowment Investment Policy — Temple has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets. Under this approach, as approved by the Board of Trustees, the endowment assets are invested in a manner that is intended to produce results that exceed the total of the amount drawn annually for operations plus the rate of inflation and investment management fees. Temple expects its endowment funds, over time, to provide an average real rate of return, net of investment management fees, of approximately 5.00% annually. Actual returns in any given year may vary from this amount. To satisfy its long-term rate-of-return objectives, Temple relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). Temple targets a diversified asset allocation that places a greater emphasis on equity-based investments to achieve its long-term return objectives within prudent risk constraints.

Endowment Spending Policy — Annually, the Board of Trustees approves a spending rule distribution percentage that is consistent with the long-term preservation of the real value of the assets, but in no event shall the percentage be less than 2.00% nor more than 7.00% per year. In 2023 and 2022, the spending rule limited the spending of endowment resources to 4.25% for the University and 4.50% for TUHS of the average fair value of endowment funds for the prior twelve fiscal quarters. To the extent that current yield is inadequate to meet the spending rule, a portion of cumulative realized net gains is available for current use. These endowment funds include scholarship funds, awards funds, academic leadership funds, and master facility funds. The draw to operations under the spending policy for the years ended June 30, 2023 and 2022 totaled \$36,876 and \$33,505, respectively.

Temple's endowment balances, including board-designated endowment funds, by net asset classification at June 30, 2023 and 2022 are as follows:

June 30, 2023	Without Donor Restrictions	With Donor Restrictions	Total
Board-designated endowment funds	\$ 311,619	\$ —	\$ 311,619
Donor-restricted endowment funds:*			
Original donor-restricted gift amount and amounts required to be maintained in perpetuity by donor	—	437,910	437,910
Accumulated investment gains	—	106,774	106,774
Term endowment funds	—	14,442	14,442
Total endowment funds	<u>\$ 311,619</u>	<u>\$ 559,126</u>	<u>\$ 870,745</u>

June 30, 2022	Without Donor Restrictions	With Donor Restrictions	Total
Board-designated endowment funds	\$ 299,074	\$ —	\$ 299,074
Donor-restricted endowment funds:*			
Original donor-restricted gift amount and amounts required to be maintained in perpetuity by donor	—	412,173	412,173
Accumulated investment gains	—	87,496	87,496
Term endowment funds	—	13,962	13,962
Total endowment funds	<u>\$ 299,074</u>	<u>\$ 513,631</u>	<u>\$ 812,705</u>

* Excludes donor restricted funds held in trust by others of \$76,604 at June 30, 2023 and \$73,268 at June 30, 2022 (see Notes 10 and 15).

Remainder of this Page is Intentionally Blank

The changes in Temple's endowment assets (excluding changes in funds held in trust by others, see Notes 10 and 15) for the years ended June 30, 2023 and 2022 are as follows:

June 30, 2023	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of the year	\$ 299,074	\$ 513,631	\$ 812,705
Investment return:			
Net investment income	17	8,191	8,208
Net realized gain	16,829	26,364	43,193
Net unrealized gain	7,246	11,352	18,598
Total investment return	24,092	45,907	69,999
Contributions and transfers:			
Donor contributions	466	23,795	24,261
Board-designated endowment	—	—	—
Other	190	466	656
Total contributions and transfers	656	24,261	24,917
Appropriation of endowment assets for expenditure (spending rule)	(12,203)	(24,673)	(36,876)
Endowment net assets, end of the year	<u>\$ 311,619</u>	<u>\$ 559,126</u>	<u>\$ 870,745</u>

June 30, 2022	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of the year	\$ 329,900	\$ 543,266	\$ 873,166
Investment return:			
Net investment (loss) income	(56)	475	419
Net realized gain	15,318	23,420	38,738
Net unrealized loss	(34,009)	(51,857)	(85,866)
Total investment return	(18,747)	(27,962)	(46,709)
Contributions and transfers:			
Donor contributions	261	19,559	19,820
Board-designated endowment	4	—	4
Other	37	(108)	(71)
Total contributions and transfers	302	19,451	19,753
Appropriation of endowment assets for expenditure (spending rule)	(12,381)	(21,124)	(33,505)
Endowment net assets, end of the year	<u>\$ 299,074</u>	<u>\$ 513,631</u>	<u>\$ 812,705</u>

Remainder of this Page is Intentionally Blank

12. Liquidity and Availability of Resources

Temple's financial assets and liquidity resources available within one year of the consolidated balance sheet date for general expenses (e.g., operating expenses and scheduled payments on debt) are as follows:

	June 30, 2023	June 30, 2022
Financial assets:		
Cash and cash equivalents	\$ 506,047	\$ 772,010
Investments (excluding purpose designated funds)	1,392,328	1,270,910
Accounts, loans, and contributions receivable, net (excluding donor restricted receivables)	564,395	500,406
Appropriation of board-designated endowment assets for general operating expenditures in the following year (estimate based on the fiscal year-end fair values and board approved spending rate for the subsequent year)	7,931	7,628
Total financial assets available within one year to fund general expenses	2,470,701	2,550,954
Liquidity resources (Note 9):		
Revolving line of credit (undrawn) (University)	50,000	50,000
Revolving line of credit (undrawn) (TUHS)	100,000	75,000
Unsecured line of credit (undrawn and unpledged) (University)	7,500	7,500
Total financial assets and liquidity resources available within one year	<u>\$ 2,628,201</u>	<u>\$ 2,683,454</u>

Temple's endowment funds consist of donor-restricted and board-designated endowment funds. Income from donor-restricted endowments is restricted for specific purposes and, therefore, is not available for general expenditure. As described in Note 11, for fiscal year 2023 and 2022 the Board of Trustees approved distribution of 4.25% to 4.50% of the average fair value for the prior 12 fiscal quarters, for a total spending rule appropriation of \$36,876 and \$33,505, respectively.

Temple's cash flows have seasonal variations during the year, primarily attributable to the collection of tuition, the timing of receipts of the Commonwealth appropriation, and the collection of donor contributions, which are typically more concentrated at calendar and fiscal year-end. As part of Temple's liquidity management, Temple structures its financial assets to be available as its general expenses, liabilities, and other obligations come due. In addition, Temple invests cash in excess of daily requirements in cash equivalents and short-term investments. To help manage unanticipated liquidity needs, at June 30, 2023 and 2022, Temple has committed lines of credit in excess of \$150,000 and \$130,000, respectively, available to be drawn. Additionally, at June 30, 2023 and 2022, Temple's board-designated endowment totaled \$311,619 and \$299,074, respectively, of which \$186,607 and \$179,489, respectively, has been board-designated to support general operations. Although Temple does not intend to spend from its board-designated endowment, other than amounts appropriated for general expenditure as part of its annual budget approval and appropriation process, amounts from its board-designated endowment could be made available if necessary. However, both the board-designated endowment and donor-restricted endowments contain investments with lock-up provisions that would reduce the total investments that could be made available. Temple also has unfunded commitments on alternative investments (see Note 9 for line of credit availability, Note 10 for investments, and Note 11 for endowments).

As discussed in Note 24, through June 30, 2022, Temple received federal provider relief funds and advanced payments from various Coronavirus relief acts totaling \$522,992 (of which \$86,927 was received in 2022, \$157,525 in 2021, and \$278,540 in 2020). These funds resulted in an increase in cash and cash equivalents at

June 30, 2022; all advanced amounts requiring repayment have been fully repaid as of June 30, 2023 (see Note 24).

13. Commitments and Contingencies

From time to time, claims are made against Temple based on a variety of theories of liability, including without limitation alleged negligence, acts of discrimination, medical malpractice, breach of contract, or disagreements arising from the interpretation of laws or regulations. In the opinion of management, after consultation with legal counsel, and subject to the disclosure below, the ultimate disposition of these matters is not expected to have a material adverse effect on Temple's future financial position or changes in its net assets.

On May 5, 2020, a putative class action complaint was filed against the University in the United States District Court for the Eastern District of Pennsylvania claiming that the decision to close campus and transition to distance education in response to the COVID-19 pandemic deprived students of the benefits of in-person instruction, access to campus facilities, student activities, and other benefits and services. The complaint alleges that plaintiffs have been deprived of certain opportunities and benefits during approximately 45% of the spring 2020 semester for which they paid and seeks disgorgement of a portion of tuition and a pro-rata amount of fees paid for the spring 2020 semester. The complaint is similar to many other lawsuits filed against colleges and universities in the United States since late March 2020. The University intends to vigorously defend this matter.

Under its hospital affiliation agreement with Chestnut Hill Hospital, TUHS has committed to making additional capital contributions any time a capital call is approved by the Chestnut Hill Hospital board of directors. See Note 21 for further discussion of the Chestnut Hill Hospital affiliation.

See Note 9 for commitments under finance and operating leases, Note 10 for unfunded investment commitments, and Note 14 for assets pledged as collateral.

14. Pledged Assets

At June 30, 2023 and 2022, TUHIC had restricted cash of \$617 and \$506, respectively, and non-current investments in fixed income securities of \$73,853 and \$73,815, respectively, held in trust in order to secure TUHIC's liabilities under certain reinsurance contracts.

At June 30, 2023 and 2022, the University had \$6,512 and \$5,103, respectively, of non-current investments in fixed income securities pledged as collateral under futures contracts (see Note 3). In addition, at June 30, 2023 and 2022, the University had \$304 and \$421, respectively, of postretirement benefits plan assets and \$58 and \$274, respectively, of pension plan assets in fixed income securities pledged as collateral under futures contracts (see Notes 3 and 5).

See Note 9 for amounts pledged as collateral under Temple's bond issuances, lines of credit, and letters and credit and Note 10 for unfunded investment commitments.

15. Net Assets

A summary of Temple's net assets is as follows:

	June 30, 2023	June 30, 2022
Net Assets:		
Without donor restrictions	\$ 3,202,917	\$ 3,166,444
With donor restrictions:		
Term endowments, life income funds, and accumulated endowment gains	121,216	101,458
Contributions for instruction, research, and support	50,536	43,433
Contributions for property, plant, and equipment	24,671	16,499
Corpus of contributions for endowments	437,910	412,173
Corpus of contributions for student loans	214	213
Funds held in trust by others	76,604	73,268
Beneficial interest in Episcopal Foundation	29,621	28,124
Beneficial interest in Fox Chase Cancer Center Foundation	52,729	52,207
Total net assets with donor restrictions	793,501	727,375
Total net assets	<u>\$ 3,996,418</u>	<u>\$ 3,893,819</u>

16. Accounts Payable and Other Accrued Expenses

Accounts payable and other accrued expenses at June 30, 2023 and 2022 consist of the following:

	June 30, 2023	June 30, 2022
Accounts payable	\$ 166,173	\$ 178,204
Accrued interest payable	14,837	13,472
Accrued payroll	49,222	46,605
Accrued vacation	46,238	42,977
Claim based liabilities, professional (Note 13), worker's compensation, general liability, and health and welfare benefits	391,187	372,131
Conditional asset retirement obligation (Note 8)	19,828	19,290
Student and other deposits	5,079	3,295
Payroll tax deferral (Note 24)	—	28,687
Employee retention credits (Note 24)	43,600	
Operating lease liabilities (current portion)	12,245	12,473
Estimated settlements with third-party payers (Note 24)	8,799	38,711
Other	201,190	210,872
Total accounts payable and other accrued expenses	958,398	966,717
Less: Current portion	(496,864)	(552,992)
Non-current, accounts payable and other accrued expenses	<u>\$ 461,534</u>	<u>\$ 413,725</u>

17. Commonwealth of Pennsylvania Grants and Other Support

Temple receives support from the Commonwealth primarily in the form of appropriations (operations and capital), grants and contracts, and medical assistance supplemental funding. Medical assistance supplemental funding is to provide access to health care services, including care for the uninsured and indigent population of Pennsylvania (see Note 18). Patient care supplemental funding provided by the Commonwealth is included in *Patient care activities* revenue in the consolidated statements of activities. There is no guarantee that funding from the Commonwealth will continue consistent with historical levels or at levels requested by Temple. Under certain circumstances, Temple could be required to repay certain of the support received from the Commonwealth.

Support received from the Commonwealth during 2023 and 2022 is as follows:

	Year Ended June 30,	
	2023	2022
Commonwealth of Pennsylvania support:		
Patient care related:		
Access to care and state and local hospital assessment programs, net	\$ 351,268	\$ 398,840
Academic Health Center funding	6,233	6,323
Total patient care support	357,501	405,163
Non-patient care related:		
Appropriation	158,206	158,206
Share of appropriation used to support matching funds under the Commonwealth of PA Medical Assistance Program*	(80,444)	(72,040)
Appropriation, net	77,762	86,166
Grants and contracts	22,555	17,695
Grants for property, plant, and equipment	11,708	6,234
Total non-patient care support	112,025	110,095
Total Commonwealth of Pennsylvania support	\$ 469,526	\$ 515,258

* Amount recorded in *Patient care activities* revenue by TUHS.

Academic Health Center funding from the Commonwealth is transferred from TUHS to the University to support allowable academic health center costs. Such funding is included in *Transfer from TUHS* in the consolidated statements of activities (and eliminated in consolidation).

18. Revenue

Tuition revenue is recognized in the fiscal year in which the academic programs are delivered. Undergraduate and graduate students who adjust their course load or withdraw completely within the “drop/add period”, typically the first two weeks of the academic term, are entitled to receive a full credit for all charges and a refund for any payments made in accordance with the University’s “drop/add” policy. Professional students do not have a formal “drop/add” period and all course load adjustments for professional students are at the discretion of the University. Payments for tuition are due approximately two weeks subsequent to the start of the academic term.

When students enroll or register for classes, a contract exists between the University and the student. For professional students, this typically occurs prior to fiscal year-end for the subsequent academic year. As professional students do not have discretion over the “drop/add” process, the University considers such

contract an indication of the professional student’s financial responsibility for the tuition and fees associated with those courses and a contractual agreement to the related payment terms. For non-professional students, the contract is considered cancellable until the “drop/add” period has ended, therefore, revenue and any deferred revenue contract obligation is recorded subsequent to the “drop/add” period (or if cash is received in advance of performance obligation).

The University offers two summer sessions. Summer I is provided in fiscal quarter four and Summer II spans fiscal years. Because the academic term for Summer II spans two reporting periods, a portion of the payments for Summer II (approximately 90%) are included in deferred revenue at June 30.

Temple’s revenues primarily consist of tuition and fees, auxiliary enterprises, Commonwealth appropriations, grants and contracts, contributions, and patient care activities. Revenue recognition by revenue source is as follows (see Note 2 for additional revenue disclosures):

Revenue Source	Revenue Recognition
Tuition and fees	Ratably over the academic term
Commonwealth operating appropriation	Ratably over the fiscal year
Commonwealth capital appropriation	Expense reimbursement
Grants and Contracts (exchange transaction)	As performance obligations are satisfied
Contributions (non-exchange transaction)	When the barrier (condition) is satisfied. If no barrier and no right of return/release exist, then recognized when received.
Patient care activities	As services are provided
Auxiliary enterprises:	
Housing	Ratably over the academic term
Meal Plans	Ratably over the academic term
Ticket sales	After event occurs
Parking passes	Ratably over the parking permit period
Other (e.g., event parking, programs, merchandise, concessions)	Point-of-sale

Deferred Revenue — Deferred revenue primarily includes payments received prior to the start of the academic term. The following table depicts activities for deferred revenue during the years ended June 30, 2023 and 2022.

	Tuition and Fees			Sponsored Contracts (Exchange)	Auxiliary Contract Liabilities	Deferred Rent	Other Deferred Revenues	Total
	Summer II (Undergrad/ Grad/ Professional)	Fall Semester (Undergrad/ Grad)	Fall Semester Professional Students					
Balance at June 30, 2021	\$ 17,313	\$ 3,231	\$ 17,869	\$ 33,032	\$ 14,322	\$ 2,564	\$ 47,314	\$135,645
Revenue Recognized in 2022	(14,371)	(3,231)	(17,869)	(33,032)	(3,490)	(730)	(47,315)	(120,038)
Cash received and contracts entered into in advance of performance	16,203	224	17,830	40,237	4,101	1	11,216	89,812
Balance at June 30, 2022	19,145	224	17,830	40,237	14,933	1,835	11,215	105,419
Revenue Recognized in 2023	(19,145)	(224)	(17,830)	(40,237)	(3,549)	(1,180)	(11,215)	(93,380)
Cash received and contracts entered into in advance of performance	17,288	272	18,888	55,921	6,228	1,424	9,871	109,892
Balance at June 30, 2023	\$ 17,288	\$ 272	\$ 18,888	\$ 55,921	\$ 17,612	\$ 2,079	\$ 9,871	\$121,931

The current portion of *Deferred revenue* of \$105,337 at June 30, 2023 will be recognized as revenue in fiscal 2024 in accordance with the revenue recognition policies described above and in Note 2.

Temple has elected the optional exemption to not disclose amounts where the performance obligation is part of a contract that has an original expected duration of one year or less. Temple expects to recognize substantially all revenue on these remaining performance obligations over the next twelve months.

Disaggregation of Revenue — In the fall semester of academic years 2023 and 2022, approximately 66% and 68%, respectively, of the University's students are residents of the Commonwealth, and approximately 34% and 32%, respectively, are from outside of Pennsylvania. The following tables provide the disaggregation of revenues at June 30, 2023 and 2022 for *Tuition and fees*, *Grants and contracts*, *Auxiliary enterprises*, and *Patient care activities*.

Revenues from *Tuition and fees*, during the years ended June 30, 2023 and 2022 were as follows:

	2023	2022
Tuition and fees revenues:		
Undergraduate students	\$ 566,915	\$ 581,422
Graduate students	119,267	126,459
Professional	146,714	148,273
Continuing education	6,822	5,637
Temple's Japan campus	27,950	23,539
Fees	45,092	45,875
Total tuition and fee revenues	912,760	931,205
Less: Discounts	(154,590)	(148,826)
Total tuition and fees revenues, net of discounts	<u>\$ 758,170</u>	<u>\$ 782,379</u>

Revenues from *Grants and contracts*, during the years ended June 30, 2023 and 2022 were as follows:

	2023	2022
Grants and contracts revenues:		
Federal [^]	\$ 133,681	\$ 221,815
Commonwealth of Pennsylvania	23,183	17,695
Local	4,470	5,272
Private	76,629	69,867
Total grants and contracts revenues	<u>\$ 237,963</u>	<u>\$ 314,649</u>

[^] Federal grants include *Higher Education Emergency Relief Funds* totaling \$0 and \$78,229, respectively (see Note 24).

Revenues from *Auxiliary enterprises*, during the years ended June 30, 2023 and 2022 were as follows:

	2023	2022
Auxiliary enterprises revenues:		
Housing	\$ 53,794	\$ 46,325
Meal plans	23,192	19,270
General activity fee	2,805	3,009
Athletics	11,735	10,840
Parking service	6,287	6,073
Liacouras Center	3,166	2,623
Other (primarily includes food services, bookstore, and TU Press)	8,455	8,552
Total auxiliary enterprises revenues	<u>\$ 109,434</u>	<u>\$ 96,692</u>

Revenues from *Patient care activities* recognized by major payor sources based on primary insurance designation during the years ended June 30, 2023 and 2022 were as follows:

	2023			2022		
	Inpatient	Outpatient	Total	Inpatient	Outpatient	Total
Patient care activities:						
Medicare	\$ 410,142	\$ 356,831	\$ 766,973	\$ 390,424	\$ 327,716	\$ 718,140
Medicaid	262,964	173,227	436,191	299,361	173,668	473,029
Commercial	196,818	392,997	589,815	205,216	391,374	596,590
Self-pay	645	8,687	9,332	1,125	6,545	7,670
Other	377,749	304,270	682,019	378,630	247,665	626,295
Total patient care activities*	\$ 1,248,318	\$ 1,236,012	\$ 2,484,330	\$ 1,274,756	\$ 1,146,968	\$ 2,421,724

* *Physician revenue is included in outpatient revenue in the above table.*

19. Expenses by Functional and Natural Classification

Expenses are presented by functional classification in alignment with the overall service mission of Temple. Temple's primary service missions are academic instruction, research, and patient care. Each functional classification displays all expenses related to the underlying operations by natural classification. Natural expenses attributable to more than one functional expense category are allocated using reasonable cost allocation techniques. Operation and maintenance of plant expenses ("O&M") and depreciation expense (excluding depreciation related to auxiliary and library books) are allocated to the functional expense classifications based upon the proportionate share of expenses (excluding O&M and depreciation) reported in each functional classification. Depreciation related to auxiliary fixed assets (e.g., dormitories, parking garages, and athletics) is fully allocated to *Auxiliary enterprises expense* and depreciation related to library books is fully allocated to *Academic support expense*. Interest expense on external debt is allocated to the functional categories which have benefited from the proceeds of the external debt.

Functional expense categories are as follows:

Academic and Student Services:

Instruction: Expenses for all activities that are part of the University's instruction program and include expenses for credit and noncredit courses; academic, vocational, and technical instruction; remedial and tutorial instruction; and regular, special, and extension sessions.

Academic Support: Expenses incurred to provide support services for the University's primary missions of instruction, research, and public service and includes expenses related to providing services that directly assist the academic functions of the University.

Student Services: Expenses incurred for activities with the primary purpose of contributing to students' emotional and physical well-being and intellectual, cultural, and social development outside the context of the formal instruction program. It includes expenses for student services administration; social and cultural development; counseling and career guidance; financial aid administration; student admissions; maintenance of student records; and student health services.

Student aid: Grants-in-aid, trainee stipends, tuition and fee waivers, and prizes to students.

Research and Public Service:

Research: Expenses for activities specifically organized to produce research, whether commissioned by an agency external to Temple or separately budgeted by an organizational unit within Temple.

Public Service: Expenses for activities established primarily to provide non-instructional services beneficial to individuals and groups external to the University. These activities include community service programs (excluding instructional activities) and cooperative extension services.

Institutional Support: Expenses for central, executive-level activities concerned with management and long-range planning for the entire University. Institutional support includes executive management, fiscal operations, general administration, and public relations/development.

Auxiliary Enterprises: Expenses relating to the operation of auxiliary enterprises. Auxiliary enterprises exist to furnish goods or services to students, faculty, staff, other institutional departments, or incidentally to the general public, and charges a fee directly related to, although not necessarily equal to, the cost of the goods or services. The distinguishing characteristic of an auxiliary enterprise is that it is managed as an essentially self-supporting activity. Auxiliary enterprises include residence halls, food services, intercollegiate athletics, University stores, faculty clubs, and parking.

Patient Care Activities: Primarily includes expenses associated with TUHS, as well as expenses from the University's medicine, podiatry and dental programs.

Expenses by functional and natural classification for the year ended June 30, 2023 and 2022 are as follows:

2023	Academic and Student Services	Research and Public Service	Institutional Support	Operations and Maintenance	Auxiliary Enterprises	Patient Care Activities	Total Expenses
Salaries and wages	\$ 442,218	\$ 123,389	\$ 82,419	\$ 33,500	\$ 26,518	\$ 1,145,496	\$ 1,853,540
Employee benefits	113,688	31,062	22,471	9,392	6,839	276,254	459,706
Operating expenses	121,340	84,389	79,804	56,371	62,832	923,919	1,328,655
Allocations and cost recoveries:							
Depreciation	58,942	17,235	13,719	163	24,169	49,781	164,009
Interest on indebtedness	7,645	1,151	776	(218)	11,357	16,727	37,438
Operations and maintenance	50,770	18,065	13,257	(78,677)	—	48,337	51,752
TUHS cost recovery	(448)	2	(10,215)	(20,531)	—	31,192	—
Total operating expenses	<u>\$ 794,155</u>	<u>\$ 275,293</u>	<u>\$ 202,231</u>	<u>\$ —</u>	<u>\$ 131,715</u>	<u>\$ 2,491,706</u>	<u>3,895,100</u>
Other components of net periodic postretirement benefit cost							(16,294)
Total							<u>\$ 3,878,806</u>

2022	Academic and Student Services	Research and Public Service	Institutional Support	Operations and Maintenance	Auxiliary Enterprises	Patient Care Activities	Total Expenses
Salaries and wages	\$ 443,245	\$ 118,404	\$ 76,552	\$ 32,776	\$ 31,222	\$ 1,079,492	\$ 1,781,691
Employee benefits	122,134	32,202	21,895	9,303	7,522	262,114	455,170
Operating expenses	157,911	75,286	56,758	47,678	57,993	876,396	1,272,022
Allocations and cost recoveries:							
Depreciation	59,101	16,041	11,286	134	24,209	44,722	155,493
Interest on indebtedness	7,921	1,676	830	(261)	11,834	20,325	42,325
Operations and maintenance	49,237	15,875	10,534	(73,204)	—	44,441	46,883
TUHS cost recovery	(21)	—	(10,882)	(16,426)	—	27,329	—
Total operating expenses	\$ 839,528	\$ 259,484	\$ 166,973	\$ —	\$ 132,780	\$ 2,354,819	3,753,584
Other components of net periodic postretirement benefit cost							(13,455)
Total							\$ 3,740,129

20. Professional Liability Insurance

Temple purchases primary commercial claims-made insurance coverage for professional liability claims from a commercial insurer, which in turn reinsures all of the risk with TUHIC, a wholly-owned captive insurance company domiciled in Bermuda. Temple is self-insured through its captive insurance company. In addition, Temple obtains \$500 (\$1,500 aggregate) coverage for its physicians from the Medical Care Availability and Reduction of Error fund (“Mcare”) and also purchases excess coverage from unaffiliated commercial insurers.

The Mcare Act was enacted by the Pennsylvania legislature in 2002. The Mcare Act created the Mcare Fund, which is the state-mandated funding mechanism for the payment of medical malpractice claims exceeding the primary layer of professional liability insurance carried by Temple’s physicians and other health care providers practicing in the state. The Mcare Fund is funded on a pay-as-you-go basis. The Mcare Fund levies health care provider surcharges, calculated as a percentage of the premiums established by the Joint Underwriting Association (also a Commonwealth of Pennsylvania agency) for basic coverage, to pay claims and administrative expenses on behalf of Mcare Fund participants. The Mcare Act legislation provides for the gradual phase-out of Mcare Fund coverage; however, this has been deferred by the Pennsylvania legislation and will be considered in the future.

Self-insured professional liabilities include amounts for reported claims, which, depending on occurrence and aggregate limits, are retained by Temple’s insurance captive or TUHS, and claims incurred but not reported, which are retained by TUHS. The gross carrying amount of accrued asserted and unasserted actuarially determined professional liability claims, includes self-insured professional liabilities plus amounts retained by Mcare and commercial insurers. Professional liabilities (discounted at 4.75% at June 30, 2023 and 2.75% at June 30, 2022) and related recoveries are as follows:

	June 30, 2023	June 30, 2022
Accrued professional liability claims retained, net	\$ 257,098	\$ 272,816
Plus: Accrued liabilities above retention limits (estimated insurance recoveries)	92,605	51,379
Accrued professional liability claims, gross	349,703	324,195
Less: Current portion of accrued professional liability claims, gross	(72,252)	(77,784)
Non-current, accrued professional liability claims, gross	\$ 277,451	\$ 246,411

Professional liability claims are included in *Accrued expenses* with the corresponding estimated insurance recoveries recorded in *Accounts, loans, and contributions receivable, net* in Temple's consolidated balance sheets.

21. Patient Care Activities

Temple provides health care services primarily to area residents through its inpatient and outpatient care facilities in the Greater Philadelphia Metropolitan Area. Temple serves a disproportionately high number of poor or indigent patients and accordingly, derives a substantial portion of its patient care revenues from the Federal Government (Medicare) and Commonwealth of Pennsylvania (Medical Assistance) programs. At June 30, 2023 and 2022, Temple had net accounts receivable from Medicare of \$53,090 and \$34,660, respectively, and from Medical Assistance of \$74,160 and \$71,115, respectively (see Note 4).

Patient accounts receivables are written off against the allowance for doubtful accounts when management determines that recovery is unlikely and Temple ceases collection efforts. Overall, the total of self-pay write-offs for the year ended June 30, 2023 has not changed significantly from the year ended June 30, 2022. Temple has not experienced significant changes in write-off trends nor has Temple changed its charity care policy (see Note 22).

As discussed in Note 2, *Patient care activities* revenue includes estimates of reimbursement from third-party payers. During the years ended June 30, 2023 and 2022, Patient care activities revenue increased (decreased) by \$40,779 and \$(7,756), respectively, as a result of settlements related to prior years and changes in estimates associated with Medicare cost reports and state Medicaid audits. Audits pertaining to fiscal years through 2016 have been closed.

Chestnut Hill Hospital — On August 8, 2022, TUHS formed an alliance with Redeemer Health ("Redeemer") and Philadelphia College of Osteopathic Medicine ("PCOM"), and collectively signed a definitive agreement to acquire Chestnut Hill Hospital and its associated physician practice plan, Chestnut Hill Clinic Company, LLC ("CHC") from Tower Health. The alliance completed the acquisition on January 1, 2023 for a purchase price of \$28,000. CHH Community Health, Inc. ("CHH") is a newly-formed Pennsylvania nonprofit corporation which owns and operates Chestnut Hill Hospital. CHC is a Pennsylvania limited liability company which employs the physicians and operates the physician practices that support Chestnut Hill Hospital, with CHH as its sole member.

TUHS is the majority equity-holder of CHH, with 60% ownership, and manages the 148-bed hospital, operating under the name Temple Health – Chestnut Hill Hospital. Redeemer and PCOM each have 20% ownership in CHH and have substantive participating rights. TUHS accounts for its investment in CHH under the equity method. TUHS' initial investment in CHH was \$16,800. For the year ended June 30, 2023, TUHS' share of CHH's net loss was \$(7,430), included in *Other sources revenue* in the consolidated statement of operations. At June 30, 2023, the value of TUHS' investment in CHH was \$9,370, included in noncurrent *Other assets* in the consolidated balance sheet. At June 30, 2023, TUHS also has a \$19,000 loan receivable from CHH, included in non-current *Other assets*, \$4,861 of other receivables due from CHH, included in current *Accounts, loans, and contributions receivable, net*, and \$996 of payables due to CHH, included in current *Accounts payable and accrued expenses* in the consolidated balance sheet.

Health Partners Plans — TUH and Episcopal Hospital were participants and governing members in a Medicaid, Medicare, and Children’s Health Insurance Program (“CHIP”) HMO known as Health Partners Plans (“HPP”). In November 2021, TUHS sold its equity interest in HPP for cash consideration totaling \$305,000, resulting in a gain of \$234,591, recognized in *Other income* in the 2022 consolidated statement of activities. TUHS received proceeds of \$301,600 at closing, with the remaining \$3,400 being held in escrow. During 2023, \$1,700 of the escrow was received; the remaining escrow is included in other receivables in the 2023 consolidated balance sheet. Prior to the sale, TUHS applied the equity method of accounting to its investment in HPP because it exercised significant influence over, but did not have a controlling interest in HPP. After the sale, TUH continues to participate in Medicaid contracts with HPP.

See Note 18 for a summary of Patient care activities revenues recognized by major payor sources based on primary insurance designation.

22. Charity Care

Temple maintains detailed records to identify and monitor the level of charity care it provides to its patients. Charity care costs are estimated by applying an overall cost to charge ratio to charity care charges. During the years ended June 30, 2023 and 2022, the estimated costs and expenses incurred to provide charity care, including the estimated unreimbursed cost of services in excess of specific payments for services rendered to Medical Assistance recipients, were \$235,224 and \$240,941, respectively (see Note 17).

23. Intangible Assets

At June 30, 2023 and 2022, intangible assets totaled \$660 and \$924, respectively. Intangible assets primarily relate to the affiliation with American Oncologic Hospital (“AOH”) and acquisitions of community-based primary care practices by Temple Physicians, Inc. There were no new intangible assets acquired during 2023 or 2022.

At June 30, 2023 and 2022, Temple does not hold any goodwill or other non-amortizing intangible assets. Details of amortizing intangible assets as of June 30, 2023 and 2022 are as follows:

June 30, 2023	Amortizing			
	Gross Carrying Amount*	Accumulated Amortization	Current Year Impairment	Net Book Value
Intellectual property	\$ 3,545	\$ (3,307)	\$ —	\$ 238
Contracts and agreements	1,860	(1,438)	—	422
Physician contracts	2,238	(2,238)	—	—
Other	619	(619)	—	—
Total intangible assets	<u>\$ 8,262</u>	<u>\$ (7,602)</u>	<u>\$ —</u>	<u>\$ 660</u>

June 30, 2022	Amortizing			
	Gross Carrying Amount*	Accumulated Amortization	Current Year Impairment	Net Book Value
Intellectual property	\$ 3,545	\$ (3,178)	\$ —	\$ 367
Contracts and agreements	1,860	(1,332)	—	528
Physician contracts	2,238	(2,238)	—	—
Other	619	(590)	—	29
Total intangible assets	<u>\$ 8,262</u>	<u>\$ (7,338)</u>	<u>\$ —</u>	<u>\$ 924</u>

* Net of impairments recorded in prior years.

Amortization expense for the years ended June 30, 2023 and 2022 was \$264 and \$280, respectively.

Amortization expense in future years is estimated as follows:

2024	\$	234
2025		214
2026		106
2027		106
2028		—
Thereafter		—
	<u>\$</u>	<u>660</u>

The changes in the carrying amount of intangible assets for the years ended June 30, 2023 and 2022 are as follows:

	Other Intangibles
Balance, June 30, 2021	\$ 2,768
Amortization	(280)
Impairment, indefinite live assets	<u>(1,564)</u>
Balance, June 30, 2022	924
Amortization	(264)
Balance, June 30, 2023	<u>\$ 660</u>

24. Coronavirus (COVID-19)

On March 27, 2020, the *Coronavirus Aid, Relief, and Economic Security Act* ("CARES Act") was signed into law. The CARES Act provided approximately \$14,000,000 in grants directly to institutions of higher education (Higher Education Emergency Relief Funds ("HEERF I")). The most significant portion of this funding allocation provided \$12,560,000 of grants using a formula based on student enrollment. Of the amount allocated to each institution under this formula, at least 50 percent was required to be used to provide students with emergency financial aid grants to help cover expenses related to the disruption of campus operations due to the coronavirus (including eligible expenses under a student's cost of attendance such as food, housing, course materials, technology, health care, and child care).

On December 27, 2020, the *Coronavirus Response and Relief Supplemental Appropriations Act* ("CRRSAA") Public Law 116-260 was signed into law. The CRRSAA authorized the *Higher Education Emergency Relief Fund II* ("HEERF II"), which provided \$22,700,000 in support for higher education institutions and students in order to prevent, prepare for, and respond to the coronavirus. Similar to CARES Act HEERF I, CRRSAA HEERF II included a student aid portion and an institutional portion. The minimum amount of the CRRSAA HEERF II allocation required to be spent on student aid, is equal to the amount of student aid that was required to be provided under the CARES Act HEERF I.

On March 11, 2021, the *American Rescue Plan Act of 2021 ("ARPA")* Public Law 116-20 was signed into law. The ARPA authorized the *Higher Education Emergency Relief Fund III ("HEERF III")*, which provides \$39,600,000 in support for higher education institutions and students in order to prevent, prepare for, and respond to the coronavirus. Similar to CARES Act HEERF I and CRRSAA HEERF II, ARPA HEERF III includes a student aid portion and an institutional portion. Of the amount allocated to each institution, at least 50 percent is required to be used to provide students with emergency financial aid grants to help cover expenses related to the disruption of campus operations due to the coronavirus (including eligible expenses under a student's cost of attendance such as food, housing, course materials, technology, health care, and child care).

As discussed above, HEERF grants to colleges and universities provide specific requirements on utilizing the funds, including a minimum amount to be used as emergency student financial aid and a maximum amount to be used for institutional purposes. The HEERF grants also provided limitations on the types of expenses and/or lost revenues that are allowable for the institutional share. HEERF grants are subject to Uniform Grant Guidance, with an implied right of return; and also include certain barriers to entitlement that must be achieved prior to revenue being recognized. Based on the terms of the CARES Act, CRRSAA, and ARPA, HEERF grants are considered conditional contributions under FASB ASU 2018-08, *Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made (ASC Topic 958)*.

The University was awarded \$28,740 under the CARES Act, of which a minimum of \$14,370 was required to be allocated to student aid and a maximum of \$14,370 could be allocated to the institutional portion. The University allocated \$14,728 to students for emergency financial aid grants and \$14,012 was allocated to institutional support for reimbursement of foregone revenue caused by campus closures due to the coronavirus and the necessary move to remote instruction. Foregone revenue related primarily to refunds made to students for housing, food, and other services that could no longer be provided as a result of the coronavirus closures. The institutional costs were incurred on or after March 13, 2020, the date of the proclamation of the national emergency. During 2020, \$28,664 was recognized as *Federal grants and contracts revenue* and \$14,652 was recorded as student aid in *Academic and student services expense*. The remaining \$76 of emergency financial aid was disbursed in 2021, at which time the federal grant revenue and corresponding student aid expense was recognized.

The University was awarded \$44,242 under CRRSAA, of which a minimum of \$14,370 was required to be allocated to student aid and a maximum of \$29,872 could be allocated to the institutional portion. During 2021, the University allocated \$14,724 to students for emergency financial aid grants and \$29,518 was allocated to institutional support for reimbursement of foregone revenue caused by campus closures due to the coronavirus and the necessary move to remote instruction. Foregone revenue related primarily to auxiliary enterprise services, such as housing, meal plans, and other services, that could no longer be provided as a result of the coronavirus closures. The institutional costs were incurred on or after March 13, 2020, the date of the proclamation of the national emergency. During 2021, \$44,242 was recognized as *Federal grants and contracts revenue* and \$14,724 was recorded as student aid in *Academic and student services expense*.

The University was awarded \$78,229 under the ARPA, of which a minimum of \$39,204 was required to be allocated to students for emergency financial aid grants and a maximum of \$39,025 could be allocated to institutional support for reimbursement of forgone revenue caused by campus closures due to the coronavirus and the necessary move to remote instruction. The University allocated \$39,388 to students for emergency financial aid grants and \$38,841 was allocated to institutional support. ARPA also required the institutional support to include amounts related to COVID-19 mitigation and student outreach around changes in financial aid. The institutional costs were incurred on or after March 13, 2020, the date of the proclamation of the national emergency. During 2022, \$78,229 was recognized as *Federal grants and contracts revenue* and \$39,388 was recorded as student aid in *Academic and student services expense*.

A summary of sources and uses of HEERF funds awarded to the University, under CARES, CRRSAA, and ARPA is as follows:

	CARES (HEERF I)	CRRSAA (HEERF II)	ARPA (HEERF III)	Total
Federal awards:				
Student aid (minimum)	\$ 14,370	\$ 14,370	\$ 39,204	\$ 67,944
Institutional portion (maximum)	14,370	29,872	39,025	83,267
Total	<u>\$ 28,740</u>	<u>\$ 44,242</u>	<u>\$ 78,229</u>	<u>\$ 151,211</u>
Amounts funded through June 30, 2022:				
Student aid	\$ 14,728	\$ 14,724	\$ 39,388	\$ 68,840
Institutional sources	14,012	29,518	38,841	82,371
Total	<u>\$ 28,740</u>	<u>\$ 44,242</u>	<u>\$ 78,229</u>	<u>\$ 151,211</u>
Recorded in federal grants and contracts in the statement of activities:				
2020	\$ 28,664	\$ —	\$ —	\$ 28,664
2021	76	44,242	—	44,318
2022	—	—	78,229	78,229
HEERF revenue recorded through June 30, 2022	<u>\$ 28,740</u>	<u>\$ 44,242</u>	<u>\$ 78,229</u>	<u>\$ 151,211</u>
HEERF revenue available in subsequent periods	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>

HEERF funds were fully recognized through June 30, 2022. No HEERF amounts were recorded in 2023.

In response to the COVID-19 pandemic, the federal government, through the Internal Revenue Service ("IRS"), offered Employee Retention Credits ("ERCs"); which are refundable tax credits for businesses that continued to pay employees while shut down due to the COVID-19 pandemic or had significant declines in gross receipts from March 13, 2020 to December 31, 2021. Eligible employers are able to claim the ERC on an original or adjusted employment tax return for a period within those dates. During calendar year 2022, the University submitted filings for ERCs related to the periods March 13, 2020 through June 30, 2021, totaling \$68,308. During the fourth quarter of 2023, ERCs totaling \$43,600, including accrued interest of \$1,522, were received by the University. ERCs totaling \$26,230 are in process of being reviewed by the IRS. The IRS has three years to audit the University's ERC filings. ERCs received during 2023 are included in *Other liabilities* in the June 30, 2023 combined balance sheet and are expected to be recognized as *Federal grants and contracts revenue* as additional IRS audit information is available.

The CARES Act also provided for deferred payment of the employer portion of social security taxes between March 27, 2020 and December 31, 2020 with 50% of the deferred amount due no later than December 31, 2021 and the remaining 50% due no later than December 31, 2022. Temple began deferring the employer portion of social security taxes in the fourth quarter of fiscal 2020, and continued deferring through December 31, 2020. At June 30, 2022, deferred employer social security taxes totaling \$28,687 were included in *Accounts payable and accrued expenses (current)*. At June 30, 2023, all deferred employer social security taxes that were deferred under the CARES Act have been paid.

The CARES Act authorized \$175,000,000 in funding to hospitals and other health care providers to be distributed through the Public Health and Social Services Emergency Fund (“Provider Relief Funds”). Payments from Provider Relief Funds are intended to compensate health care providers for lost revenues and qualified expenses incurred in response to the COVID-19 pandemic and are not required to be repaid; provided that the recipients attest to and comply with certain terms and conditions, including limitations on balance billing and not using Provider Relief Funds to reimburse expenses or losses that other sources are obligated to reimburse. Through June 30, 2023, TUHS received a total of \$213,188 in Provider Relief Fund payments (of which, \$8,698 was received in 2022, \$113,283 was received in 2021, and \$91,207 was received in 2020). The 2023 and 2022 consolidated statements of activities include \$8,698 and \$43,845, respectively, of Provider Relief Funds, which are included in revenues from *Other sources*. At June 30, 2022, Provider Relief Funds totaling \$8,698 were recorded as *Deferred revenue, current* in the consolidated balance sheets. At June 30, 2023, all Provider Relief Funds received by Temple have been earned.

In addition, during the fourth quarter of 2020, the CARES Act provided accelerated Medicare payments to TUHS totaling \$158,593. At June 30, 2022, \$29,321 was reported as estimated settlements with third-party payers included in *Accounts payable and accrued expenses* in the consolidated balance sheet. As of June 30, 2023, all advances have been repaid to or recouped by Medicare.

25. Subsequent Events

Temple has evaluated subsequent events through October 27, 2023, the date the consolidated financial statements were available to be issued. There were no events requiring adjustments to or disclosure in the consolidated financial statements.

* * * * *

Supplemental Schedules

The following schedules reflect the changes in net assets without donor restrictions for the University and its controlled entities. The columnar classification reflects the various budgetary categories and operations of Temple. Most patient care activities are provided by TUHS. Activities in the University’s *Clinical Practice Plan* include clinical activities performed by the LKSOM. The remaining *Patient care activities* provided by the University’s podiatry and dental programs are included in *Educational and General services*. *Other long-term* net assets include the net book value of property, plant, and equipment, net assets set aside to retire debt, University matching of federal loan programs, and the unfunded liability for pensions and postretirement benefits.

TEMPLE UNIVERSITY — OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES

Changes in Net Assets Without Donor Restrictions — For the Year Ended June 30, 2023 (in thousands)

	Net Assets Without Donor Restrictions										
	Temple University Health System	Temple Educational Support Services	University, Excluding Temple Educational Support Services							Consolidating Eliminations	Total
			Clinical Practice Plan	Educational and General	Quasi - Endowment	Externally Sponsored Activities	Unexpended Capital	Other Long-term	Total University		
Revenues:											
Tuition and fees, net of discounts of \$154,590	\$ —	\$ 32,540	\$ —	\$ 727,677	\$ —	\$ 3	\$ —	\$ —	\$ 727,680	\$ (2,050)	\$ 758,170
Commonwealth of Pennsylvania appropriation	—	—	—	77,762	—	—	—	—	77,762	—	77,762
Strategic support assessment (Note 19)	—	—	—	87,444	—	—	—	—	87,444	(87,444)	—
Grants and contracts	40,090	—	—	47,080	—	150,793	—	—	197,873	—	237,963
Contributions for operations and endowments	4,068	—	—	2,529	466	18,795	—	—	21,790	—	25,858
Investment return	27,610	—	—	38,847	—	26,350	—	1,833	67,030	—	94,640
Sales of educational activities	—	—	—	14,158	—	—	—	—	14,158	—	14,158
Auxiliary enterprises	—	—	—	108,182	—	—	226	1,026	109,434	—	109,434
Patient care activities	2,480,997	—	81	3,252	—	—	—	—	3,333	—	2,484,330
Other sources	39,788	—	—	8,471	—	3,577	3,912	123	16,083	—	55,871
Net assets released from restrictions	7,364	—	—	2,000	—	2,287	—	(1,850)	2,437	—	9,801
Total revenues	2,599,917	32,540	81	1,117,402	466	201,805	4,138	1,132	1,325,024	(89,494)	3,867,987
Expenses:											
Educational and general	57,752	28,232	—	912,078	—	170,964	8,032	96,671	1,187,745	(2,050)	1,271,679
Auxiliary enterprises	—	—	—	95,800	—	478	(89)	35,526	131,715	—	131,715
Patient care activities	2,573,184	—	181	5,726	—	—	—	59	5,966	(87,444)	2,491,706
Total expenses	2,630,936	28,232	181	1,013,604	—	171,442	7,943	132,256	1,325,426	(89,494)	3,895,100
Transfers:											
Property, plant, and equipment (PP&E) acquisitions	—	—	—	(13,749)	—	(4,594)	(63,914)	82,257	—	—	—
Retirement of indebtedness	—	—	—	(47,251)	—	—	(921)	48,172	—	—	—
Capital replacement and expansion	—	—	(2)	(48,333)	—	(610)	48,945	—	—	—	—
Transfer from TUP	—	—	—	—	—	—	—	—	—	—	—
Other transfers	—	—	—	19,961	190	(29,915)	10,318	(554)	—	—	—
Total transfers	—	—	(2)	(89,372)	190	(35,119)	(5,572)	129,875	—	—	—
Excess (deficit) of revenues over expenses and transfers	(31,019)	4,308	(102)	14,426	656	(4,756)	(9,377)	(1,249)	(402)	—	(27,113)
Other changes in net assets:											
Investment return	34,820	—	—	(13,678)	11,889	—	—	(2,198)	(3,987)	—	30,833
Commonwealth grants for PP&E	—	—	—	—	—	—	1,950	—	1,950	—	1,950
Contributions for PP&E	—	—	—	—	—	—	1	—	1	—	1
(Loss) gain on disposal of PP&E, net	(194)	(6)	—	—	—	—	—	(5,565)	(5,565)	—	(5,765)
Actuarial change in accrued pensions and postretirement	1,620	—	—	—	—	—	—	1,253	1,253	—	2,873
Other components of NPBC (Note 5)	3,368	—	—	12,926	—	—	—	—	12,926	—	16,294
Transfer from TUHS, net	(5,138)	—	—	415	—	—	4,723	—	5,138	—	—
Currency translation adjustment	—	440	—	(17)	—	—	—	—	(17)	—	423
Other	—	—	—	698	—	—	11,129	—	11,827	—	11,827
Net assets released from restrictions for PP&E	2,977	—	—	—	—	—	324	1,849	2,173	—	5,150
Total other changes in net assets	37,453	434	—	344	11,889	—	18,127	(4,661)	25,699	—	63,586
Change in net assets without donor restrictions	6,434	4,742	(102)	14,770	12,545	(4,756)	8,750	(5,910)	25,297	—	36,473
Net assets without donor restrictions, beginning of year	829,386	7,556	11,992	622,446	299,074	124,571	233,644	1,037,775	2,329,502	—	3,166,444
Net assets without donor restrictions, end of year	\$ 835,820	\$ 12,298	\$ 11,890	\$ 637,216	\$ 311,619	\$ 119,815	\$ 242,394	\$ 1,031,865	\$ 2,354,799	\$ —	\$ 3,202,917

TEMPLE UNIVERSITY — OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES

Changes in Net Assets Without Donor Restrictions — For the Year Ended June 30, 2022 (in thousands)

	Net Assets Without Donor Restrictions										
	Temple University Health System	Temple Educational Support Services	University, Excluding Temple Educational Support Services							Consolidating Eliminations	Total
			Clinical Practice Plan	Educational and General	Quasi - Endowment	Externally Sponsored Activities	Unexpended Capital	Other Long-term	Total University		
Revenues:											
Tuition and fees, net of discounts of \$148,826	\$ —	\$ 27,386	\$ —	\$ 756,793	\$ —	\$ —	\$ —	\$ —	\$ 756,793	\$ (1,800)	\$ 782,379
Commonwealth of Pennsylvania appropriation	—	—	—	86,166	—	—	—	—	86,166	—	86,166
Strategic support assessment (Note 19)	—	—	—	77,040	—	—	—	—	77,040	(77,040)	—
Grants and contracts	36,071	—	—	50,021	—	228,557	—	—	278,578	—	314,649
Contributions for operations and endowments	4,325	—	—	2,321	261	16,123	—	—	18,705	—	23,030
Investment return	24,251	—	—	17,394	—	23,559	—	1,289	42,242	—	66,493
Sales of educational activities	—	—	—	12,897	—	—	—	—	12,897	—	12,897
Auxiliary enterprises	—	—	—	95,681	—	—	91	920	96,692	—	96,692
Patient care activities	2,418,600	—	79	3,045	—	—	—	—	3,124	—	2,421,724
Other sources	89,691	—	—	8,973	—	1,859	695	57	11,584	—	101,275
Net assets released from restrictions	6,038	—	—	—	4	4,166	—	—	4,170	—	10,208
Total revenues	2,578,976	27,386	79	1,110,331	265	274,264	786	2,266	1,387,991	(78,840)	3,915,513
Expenses:											
Educational and general	52,368	26,736	—	921,912	—	167,926	4,967	93,876	1,188,681	(1,800)	1,265,985
Auxiliary enterprises	—	—	—	96,160	—	500	77	36,043	132,780	—	132,780
Patient care activities	2,426,914	—	215	4,667	—	—	—	63	4,945	(77,040)	2,354,819
Total expenses	2,479,282	26,736	215	1,022,739	—	168,426	5,044	129,982	1,326,406	(78,840)	3,753,584
Transfers:											
Property, plant, and equipment (PP&E) acquisitions	—	—	—	(17,245)	—	(3,535)	(76,046)	96,826	—	—	—
Retirement of indebtedness	—	—	—	(46,970)	—	—	(1,202)	48,172	—	—	—
Capital replacement and expansion	—	—	—	(47,091)	—	74	47,017	—	—	—	—
Other transfers	—	—	—	82,622	38	(101,505)	19,397	(552)	—	—	—
Total transfers	—	—	—	(28,684)	38	(104,966)	(10,834)	144,446	—	—	—
Excess (deficit) of revenues over expenses and transfers	99,694	650	(136)	58,908	303	872	(15,092)	16,730	61,585	—	161,929
Other changes in net assets:											
Investment return	(104,067)	—	—	(47,625)	(31,129)	—	—	(8,307)	(87,061)	—	(191,128)
Contributions for PP&E	—	—	—	—	—	—	3	—	3	—	3
Loss on extinguishment of debt	(9,650)	—	—	—	—	—	—	—	—	—	(9,650)
(Loss) gain on disposal of PP&E, net	(90)	(19)	—	—	—	—	—	(622)	(622)	—	(731)
Actuarial change in accrued pensions and postretirement	16,253	—	—	—	—	—	—	15,218	15,218	—	31,471
Other components of NPBC (Note 5)	(2,442)	—	—	15,133	—	—	—	—	15,133	—	12,691
Transfer from TUHS, net	(9,284)	—	—	5,950	—	—	3,334	—	9,284	—	—
Currency translation adjustment	—	(114)	—	(82)	—	—	—	—	(82)	—	(196)
Gain on sale of equity method investment	234,591	—	—	—	—	—	—	—	—	—	234,591
Other	122	—	83	3,660	—	—	(9)	(1,558)	2,176	—	2,298
Net assets released from restrictions for PP&E	1,020	—	—	—	—	—	798	—	798	—	1,818
Total other changes in net assets	126,453	(133)	83	(22,964)	(31,129)	—	4,126	4,731	(45,153)	—	81,167
Change in net assets without donor restrictions	226,147	517	(53)	35,944	(30,826)	872	(10,966)	21,461	16,432	—	243,096
Net assets without donor restrictions, beginning of year	603,239	7,039	12,045	586,502	329,900	123,699	244,610	1,016,314	2,313,070	—	2,923,348
Net assets without donor restrictions, end of year	\$ 829,386	\$ 7,556	\$ 11,992	\$ 622,446	\$ 299,074	\$ 124,571	\$ 233,644	\$ 1,037,775	\$ 2,329,502	\$ —	\$ 3,166,444

TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES
Subsidiary Organizations
June 30, 2023

The following is a summary of Temple's subsidiary organizations included in the consolidated financial statements and their tax-exempt status. Unless otherwise indicated, all exempt organizations are such under Internal Revenue Code Section 501(c)(3).

Temple University — Of The Commonwealth System of Higher Education ("Temple"), exempt
Temple Educational Support Services, Ltd. ("TESS"), non-exempt (Japan)
Temple University School of Podiatric Medicine, Inc. ("TUSPM"), exempt 501(c)(2)
Good Samaritan Insurance Co. Ltd. ("GSIC"), non-exempt (Bermuda) (inactive)
TUMP Offices, Inc. ("TUMP"), exempt 501(c)(2) (inactive)
Global Technology Management Corp. ("GTM"), non-exempt (inactive)
Temple University Health System, Inc. ("TUHS"), exempt [†]
Temple University Hospital, Inc. ("TUH"), exempt
Temple University Health System Foundation ("TUHSF"), exempt
TUH - Jeanes Campus Auxiliary ("Jeanes"), exempt
Temple Health Subsidiaries, Inc. ("THS"), non-exempt (inactive)
Temple Physicians, Inc. ("TPI"), exempt
Temple Faculty Practice Plan, Inc. ("TFPP"), exempt
Episcopal Hospital ("EH"), exempt
TUHS Insurance Co., Ltd. ("TUHIC"), non-exempt (Bermuda)
Temple Health System Transport Team, Inc. ("T3"), exempt
Temple Center for Population Health, LLC ("TCPH"), exempt
Temple Care, Inc. ("TC"), will be organized as a pass-through entity of TCPH for purposes of federal tax exemption.
The American Oncologic Hospital ("AOH"), exempt (doing business as, The Hospital of the Fox Chase Cancer Center), exempt
Fox Chase Limited ("FC"), non-exempt
The Institute for Cancer Research ("ICR"), exempt (doing business as, The Research Institute of Fox Chase Cancer Center), exempt
Fox Chase Cancer Center Medical Group, Inc. ("MGI"), exempt
Fox Chase Network, Inc. ("Network"), exempt
CHH Community Health, Inc. ("CHH"), (doing business as, Temple Health – Chestnut Hill Hospital and/or Chestnut Hill Health). CHH applied for federal tax exemption on May 1, 2023, which has not yet been approved. Ownership of CHH is as follows: TUHS 60%, Philadelphia College of Osteopathic Medicine, exempt, 20%, and Holy Redeemer Health System, exempt, 20%. CHH is the sole member of Chestnut Hill Clinic Company, LLC. (doing business as, Chestnut Hill Physicians).

This Page is Intentionally Blank

FEDERAL AWARDS SECTION:



Deloitte & Touche LLP
1700 Market Street
Philadelphia, PA 19103
USA

Tel: 215-246-2300
Fax: 215-448-2278
www.deloitte.com

INDEPENDENT AUDITOR’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF CONSOLIDATED FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

To the Board of Trustees
Temple University – Of The Commonwealth System of Higher Education
Philadelphia, Pennsylvania

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the consolidated financial statements of Temple University – Of The Commonwealth System of Higher Education and its subsidiaries (“Temple”), which comprise the consolidated balance sheet as of June 30, 2023, and the related consolidated statements of activities, and cash flows for the year then ended, and the related notes to the consolidated financial statements, which collectively comprise Temple’s consolidated financial statements and have issued our report thereon dated October 27, 2023 (collectively referred to as the “financial statements”).

The financial statements of Temple include various subsidiaries as outlined in Note 1 to the consolidated financial statements. The consolidated financial statements of Temple University – Of The Commonwealth System of Higher Education, includes subsidiaries of Temple University Health System Inc. (“TUHS”). The subsidiary of TUHS; TUHS Insurance Company, Ltd.; was audited by us; and the subsidiary of Temple; Temple Educational Support Services Ltd.; which was audited by other auditors were audited in accordance with generally accepted auditing standards, but were not audited in accordance with *Government Auditing Standards* and accordingly this report does not include reporting on internal control over financial reporting or instances of reportable noncompliance associated with these entities.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered Temple’s internal control over financial reporting (internal controls) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Temple’s internal control. Accordingly, we do not express an opinion on the effectiveness of Temple’s internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the Temple’s financial statements will not be prevented or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether Temple’s financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Temple’s internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Temple’s internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Deloitte & Touche LLP

October 27, 2023



Deloitte & Touche LLP
1700 Market Street
Philadelphia, PA 19103
USA
Tel: 215-246-2300
Fax: 215-448-2278
www.deloitte.com

INDEPENDENT AUDITOR’S REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE

To the Board of Trustees
Temple University – Of The Commonwealth System of Higher Education
Philadelphia, Pennsylvania

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Temple University – Of The Commonwealth System of Higher Education’s (“Temple”) compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of Temple’s major federal programs for the year ended June 30, 2023. Temple’s major federal programs are identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs.

In our opinion, Temple complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2023.

Our audit, described below, did not include the operations of Temple Educational Support Services, Ltd; Temple University School of Podiatric Medicine, Inc.; Good Samaritan Insurance Co. Ltd.; TUMP Offices, Inc.; Global Technology Management Corp.; Temple University Health System Foundation; TUH - Jeanes Campus Auxiliary; Temple Health Subsidiaries Inc.; Episcopal Hospital; TUHS Insurance Company, Ltd.; Temple Health System Transport Team, Inc.; Temple Care Inc.; Fox Chase Limited; Fox Chase Network, Inc.; because these subsidiaries did not receive federal awards subject to audit in accordance with the Uniform Guidance. Temple’s consolidated financial statements include the consolidated operations of Temple University Health System, Inc. and its subsidiaries; Institute for Cancer research d/b/a, The Research Institute of Fox Chase Cancer Center; Temple University Hospital, Inc.; Temple Center for Population Health LLC; American Oncologic Hospital d/b/a The Hospital of Fox Chase Cancer Center; Temple Faculty Practice Plan, Inc.; Temple Physicians, Inc.; and Fox Chase Cancer Center Medical Group, Inc.; (collectively referred to herein as “TUHS”), which expended federal awards which are not included in Temple’s accompanying Schedule of Expenditures of Federal Awards for the year ended June 30, 2023. Our audit, described below, does not include federal funding awarded to TUHS, because a separate audit in accordance with the Uniform Guidance was performed for TUHS for the year ended June 30, 2023.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost*

Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor’s Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of Temple and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of Temple’s compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to Temple’s federal programs.

Auditor’s Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on Temple’s compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Temple’s compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding Temple’s compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of Temple’s internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of Temple’s internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a

federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of Temple as of and for the year ended June 30, 2023, and have issued our report thereon dated October 27, 2023, which contained an unmodified opinion on those financial statements. Our audit was performed for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the financial statements as a whole.

Deloitte & Touche LLP

March 29, 2024

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023

Grantor/Pass-Through Grantor Program Title	CFDA Number	2023	
		Subrecipient Expenditures	Total Expenditures
Research and Development:			
Department of Health and Human Services:			
National Institutes of Health	93.R&D	\$ 8,359,877	\$ 73,843,632
Centers for Disease Control	93.CDC	443,686	1,109,764
Research on Health Care Costs, Quality and Outcomes	93.226	-	19,968
Adolescent Health Programs	93. 297	33,346	1,306,544
Health Resources and Services Administration	93.HRSA	-	139,544
Administration for Community Living	93.433 /464	90,361	1,779,262
Administration for Children and Families	93.632	-	617,873
DHHS Pass-Through Funds	Various	822,441	14,882,107
		9,749,711	93,698,694
National Science Foundation:			
NSF - Direct Awards	47.R&D	\$ 649,846	\$ 12,185,687
NSF - Pass-Through Funds	Various	-	850,971
		649,846	13,036,658
Other			
Other - Direct Awards	Various	\$ 706,261	\$ 12,409,691
Other - Pass-Through Funds	Various	98,488	8,491,650
		804,749	20,901,341
Total Research and Development		\$ 11,204,306	\$ 127,636,693
Student Financial Assistance:			
Department of Education:			
Federal Work Study	84.033	\$ -	\$ 2,424,353
Federal Supplemental Educational Opportunity Grant (FSEOG)	84.007	-	3,120,959
Pell	84.063	-	39,101,270
Perkins Loans	84.038	-	11,609,789
Perkins Loans Administrative Expenses	84.038	-	2,681,038
		-	58,937,409
Department of Health and Human Services:			
Health Professional Student Loans & Loans for Disadvantaged Students	93.342	\$ -	\$ 24,392,142
Health Professional Student Loans & Loans for Disadvantaged Students Admin. Exp.	93.342	-	228,524
Nursing Student Loans	93.364	-	248,084
Nursing Student Loans Administrative Expenses	93.364	-	5,175
		-	24,873,925
Federally Guaranteed Student Loans			
Direct Subsidized Loans	84.268	\$ -	\$ 48,631,794
Direct Unsubsidized Loans	84.268	-	151,665,278
Direct Parent Plus Loans	84.268	-	64,950,262
Direct Graduate Plus Loans	84.268	-	55,860,201
		-	321,107,535
Total Student Financial Assistance		\$ -	\$ 404,918,869
Other Programs:			
Coronavirus Response and Relief Supplemental Appropriations Act ("CRRSAA") and Coronavirus Aid, Relief, and Economic Security Act ("CARES Act")			
CARES Act Pass through funds	84.425U	\$ -	\$ 195,918
CARES Act Direct awards	84.425C	-	368,327
		-	564,245
Other - Direct Awards - NO NSF	Various	\$ 611,134	\$ 3,780,553
Other - Pass Through Funds	Various	114,620	13,803,579
COVID-19: Other - Pass Through Funds	Various	-	4,355,786
		725,754	21,939,918
Total Other Programs		\$ 725,754	\$ 22,504,163
Total Federal Awards		\$ 11,930,060	\$ 555,059,725

See notes to Schedule of Expenditures of Federal Awards

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			Y	\$30,541	\$46,066
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		-\$126
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$2,114
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$41,420
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$82,459
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$622,089
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$228,794
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$399,977
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$4,907
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$86,139
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			Y	\$11,068	\$184,940
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$82,168
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$12,918
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$118,824
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$27,010
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$465,482
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$469,005
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$242,762
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$102,032
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$37,800
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	Y			N		\$2,395
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		\$81
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		\$376,869
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			Y	\$430,403	\$818,607
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		\$3,286
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		\$24
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			Y	\$363,394	\$548,050
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		-\$3,112
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		-\$348
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			Y	\$16,252	\$636,060
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		\$46,811
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		\$535,024
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		\$225,201
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			Y	\$24,876	\$611,096
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		\$35,975
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			Y	\$203,325	\$203,325
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			Y	\$11,954	\$317,396
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			Y	\$1,963,883	\$3,650,193
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		\$61,429
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		\$57,276
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		\$9,287
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	Y			N		\$86,346
93	846		ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	Research and Development	\$1,004,634	\$127,636,693	Y			Y	\$3,161	\$3,757
93	846		ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	Research and Development	\$1,004,634	\$127,636,693	Y			N		\$303
93	846		ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	Research and Development	\$1,004,634	\$127,636,693	Y			N		-\$332
93	846		ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	Research and Development	\$1,004,634	\$127,636,693	Y			N		\$168,109
93	846		ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	Research and Development	\$1,004,634	\$127,636,693	Y			Y	\$7,920	\$527,075
93	846		ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	Research and Development	\$1,004,634	\$127,636,693	Y			N		\$76,806

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	846		ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	Research and Development	\$1,004,634	\$127,636,693	Y			N		\$4,031
93	213		RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	Research and Development	\$782,613	\$127,636,693	Y			N		-\$2,614
93	213		RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	Research and Development	\$782,613	\$127,636,693	Y			N		-\$42,708
93	213		RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	Research and Development	\$782,613	\$127,636,693	Y			N		\$31,857
93	213		RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	Research and Development	\$782,613	\$127,636,693	Y			N		\$488,606
93	213		RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	Research and Development	\$782,613	\$127,636,693	Y			N		\$160,957
93	213		RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	Research and Development	\$782,613	\$127,636,693	Y			N		\$118,106
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	Y			N		\$11,952
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	Y			Y	\$2,319	\$66,648
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	Y			N		-\$8,914
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	Y			N		\$126,910
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	Y			Y	\$6,929	\$74,205
93	395		CANCER TREATMENT RESEARCH	Research and Development	\$1,869,512	\$127,636,693	Y			Y	\$249,802	\$590,203
93	395		CANCER TREATMENT RESEARCH	Research and Development	\$1,869,512	\$127,636,693	Y			N		\$376,765
93	395		CANCER TREATMENT RESEARCH	Research and Development	\$1,869,512	\$127,636,693	Y			N		\$498,058
93	395		CANCER TREATMENT RESEARCH	Research and Development	\$1,869,512	\$127,636,693	Y			N		\$31,014
93	395		CANCER TREATMENT RESEARCH	Research and Development	\$1,869,512	\$127,636,693	Y			Y	\$138,465	\$315,040
93	396		CANCER BIOLOGY RESEARCH	Research and Development	\$1,592,976	\$127,636,693	Y			N		-\$796
93	396		CANCER BIOLOGY RESEARCH	Research and Development	\$1,592,976	\$127,636,693	Y			N		\$129,510
93	396		CANCER BIOLOGY RESEARCH	Research and Development	\$1,592,976	\$127,636,693	Y			N		\$341,059
93	396		CANCER BIOLOGY RESEARCH	Research and Development	\$1,592,976	\$127,636,693	Y			Y	\$19,689	\$491,285
93	396		CANCER BIOLOGY RESEARCH	Research and Development	\$1,592,976	\$127,636,693	Y			N		\$394,603
93	396		CANCER BIOLOGY RESEARCH	Research and Development	\$1,592,976	\$127,636,693	Y			N		\$31,873
93	397		CANCER CENTERS SUPPORT GRANTS	Research and Development	\$1,507,751	\$127,636,693	Y			Y	\$288,317	\$1,445,962
93	398		CANCER RESEARCH MANPOWER	Research and Development	\$412,305	\$127,636,693	Y			N		\$162,919
93	398		CANCER RESEARCH MANPOWER	Research and Development	\$412,305	\$127,636,693	Y			N		\$249,386
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$40,748
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$5,446
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$13,649
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$45
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$112,103
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$430,019
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$223,152
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		-\$26,296
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$379,019
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$379,610
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$44,562
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$399,819
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$7,606
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$312,613
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$96,847
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$398,463
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$961,434
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			Y	\$58,809	\$917,218
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$478,455
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$377,213
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$63,013

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$151,903
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$621,221
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$473,123
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			Y	\$122,187	\$374,522
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$639,919
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$1,253
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		-\$7,738
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$10,346
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		-\$12,884
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$138,736
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$3,108
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			Y	\$176,603	\$462,950
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			Y	\$17,718	\$468,243
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$48,509
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			Y	\$48,166	\$278,914
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$334,108
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$341,723
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		-\$13,639
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$14
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$1,493,774
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	Y			N		\$149,806
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	Y			N		-\$9,465
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	Y			N		\$30,964
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	Y			Y	\$121,711	\$246,265
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	Y			Y	\$113,236	\$441,194
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	Y			Y	\$154,853	\$229,101
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	Y			N		\$362,579
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	Y			N		\$390,474
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	Y			N		\$74,536
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	Y			N		\$120,526
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	Y			N		\$33,229
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	Y			N		\$599
93	121		ORAL DISEASES AND DISORDERS RESEARCH	Research and Development	\$1,289,351	\$127,636,693	Y			N		\$5,855
93	121		ORAL DISEASES AND DISORDERS RESEARCH	Research and Development	\$1,289,351	\$127,636,693	Y			N		\$52,744
93	121		ORAL DISEASES AND DISORDERS RESEARCH	Research and Development	\$1,289,351	\$127,636,693	Y			N		\$554
93	121		ORAL DISEASES AND DISORDERS RESEARCH	Research and Development	\$1,289,351	\$127,636,693	Y			N		-\$12,310
93	121		ORAL DISEASES AND DISORDERS RESEARCH	Research and Development	\$1,289,351	\$127,636,693	Y			N		\$394,739
93	121		ORAL DISEASES AND DISORDERS RESEARCH	Research and Development	\$1,289,351	\$127,636,693	Y			Y	\$15,757	\$200,657
93	121		ORAL DISEASES AND DISORDERS RESEARCH	Research and Development	\$1,289,351	\$127,636,693	Y			Y	\$20,098	\$160,532
93	121		ORAL DISEASES AND DISORDERS RESEARCH	Research and Development	\$1,289,351	\$127,636,693	Y			N		\$371,503
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			N		\$261

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			Y	\$35,156	\$87,669
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			N		\$13,178
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			N		\$623,254
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			N		\$19,930
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			N		\$86,200
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			N		\$1,455
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			N		\$1,245
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			Y	\$17,319	\$596,401
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			Y	\$130,139	\$502,728
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			Y	\$254,250	\$642,743
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			Y	\$166,042	\$727,328
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			N		\$427,840
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			N		\$345,829
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			N		\$181,976
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			N		\$70,357
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	Y			N		\$11,364
93	286		DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	Research and Development	\$120,501	\$127,636,693	Y			N		\$27,924
93	113		ENVIRONMENTAL HEALTH	Research and Development	\$562,047	\$127,636,693	Y			N		\$73,685
93	113		ENVIRONMENTAL HEALTH	Research and Development	\$562,047	\$127,636,693	Y			N		\$329,344
93	867		VISION RESEARCH	Research and Development	\$455,209	\$127,636,693	Y			N		\$757
93	867		VISION RESEARCH	Research and Development	\$455,209	\$127,636,693	Y			N		\$1
93	867		VISION RESEARCH	Research and Development	\$455,209	\$127,636,693	Y			N		-\$802
93	867		VISION RESEARCH	Research and Development	\$455,209	\$127,636,693	Y			N		\$136,994
93	867		VISION RESEARCH	Research and Development	\$455,209	\$127,636,693	Y			N		\$214,732
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$161,829
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		-\$150
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		-\$195
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$8,393
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		-\$66,795
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$254,610
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$127,453
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$199,723
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$608,544
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$458,570
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			Y	\$14,902	\$249,434
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			Y	\$31,038	\$44,096

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$457,621
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$319,226
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$278,396
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$345,978
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$457,552
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$232,334
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$361,788
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$165,931
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$49,308
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	Y			N		\$140,180
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			N		\$4,922
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			N		\$127,205
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			N		\$124,818
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			N		\$528,931
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			Y	\$2,027	\$567,216
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			N		\$6,408
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			Y	\$22,761	\$74,126
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			N		\$192,807
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			Y	\$115,017	\$385,628
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			N		\$210,132
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			N		\$301,223
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			N		\$62,155
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	Y			N		\$8,925
93	172		HUMAN GENOME RESEARCH	Research and Development	\$182,686	\$127,636,693	Y			N		\$182,686
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$3,590
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$1,482
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$897
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		-\$18,548
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$136,972
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$271,443
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			Y	\$19,490	\$198,154
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$202,052
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$182,153
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$35,140
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$161,425
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$119,262
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$69,993
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		-\$4,398
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			Y	\$388,565	\$666,470
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$321,984
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$412,323

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$303,774
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$330,680
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			Y	\$67,042	\$698,369
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$532,706
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			Y	\$6,523	\$454,593
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$150,714
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$323,855
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$77,817
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$4,220
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$2,636
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			Y	\$361,034	\$745,541
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$8,470
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$166,337
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$36,712
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$32,313
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$27,584
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$176,857
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$231,312
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$248,874
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$21,862
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$43,923
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$602
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		-\$2,065
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		-\$55,108
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$833,741
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$1,992,630
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	Y			N		\$336,151
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	Y			N		\$514,810
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	Y			N		\$376,395
93	839		BLOOD DISEASES AND RESOURCES RESEARCH	Research and Development	\$1,933,749	\$127,636,693	Y			N		\$5,398
93	839		BLOOD DISEASES AND RESOURCES RESEARCH	Research and Development	\$1,933,749	\$127,636,693	Y			N		\$11,615
93	839		BLOOD DISEASES AND RESOURCES RESEARCH	Research and Development	\$1,933,749	\$127,636,693	Y			Y	-\$6,719	\$147,258
93	839		BLOOD DISEASES AND RESOURCES RESEARCH	Research and Development	\$1,933,749	\$127,636,693	Y			Y	\$15,431	\$379,220
93	839		BLOOD DISEASES AND RESOURCES RESEARCH	Research and Development	\$1,933,749	\$127,636,693	Y			Y	\$33,262	\$285,843
93	839		BLOOD DISEASES AND RESOURCES RESEARCH	Research and Development	\$1,933,749	\$127,636,693	Y			N		\$892,058
93	839		BLOOD DISEASES AND RESOURCES RESEARCH	Research and Development	\$1,933,749	\$127,636,693	Y			N		\$82,218
93	839		BLOOD DISEASES AND RESOURCES RESEARCH	Research and Development	\$1,933,749	\$127,636,693	Y			Y	\$1,507	\$66,515
93	879		MEDICAL LIBRARY ASSISTANCE	Research and Development	\$386,419	\$127,636,693	Y			Y	\$45,515	\$232,500
93	879		MEDICAL LIBRARY ASSISTANCE	Research and Development	\$386,419	\$127,636,693	Y			N		\$153,919
93	307		MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	Research and Development	\$1,643,213	\$127,636,693	Y			N		-\$6,252
93	307		MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	Research and Development	\$1,643,213	\$127,636,693	Y			Y	\$218,627	\$475,612
93	307		MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	Research and Development	\$1,643,213	\$127,636,693	Y			N		\$234,795
93	307		MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	Research and Development	\$1,643,213	\$127,636,693	Y			N		\$163,585
93	307		MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	Research and Development	\$1,643,213	\$127,636,693	Y			Y	\$150,135	\$458,464
93	307		MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	Research and Development	\$1,643,213	\$127,636,693	Y			N		\$12,943
93	310		TRANS NIH RESEARCH SUPPORT	Research and Development	\$526,313	\$127,636,693	Y			Y	\$20,729	\$140,812
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$6,186
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$27,806

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$20,772
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$137,111
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			Y	\$1,716	\$259,990
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			Y	\$535	\$12,405
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$244,706
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			Y	-\$8,805	-\$7,948
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$9,378
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			Y	\$212,256	\$359,854
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			Y	\$449,956	\$720,400
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$427,311
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$4,220
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$83,958
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$91,975
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$525,885
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$45,440
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			Y	\$139,391	\$208,001
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$71,657
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$37,047
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$1,505
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			Y	\$53,757	\$155,544
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$108,280
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$27,122
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$18,945
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		-\$1,242
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$4,070
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$23,481
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$60,247
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$31,050
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			Y	\$462,837	\$1,377,868
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			Y	\$88,203	\$626,835
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	Y			N		\$27,696
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$275
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$13,809
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$80,095
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$172,426
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$187,485
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			Y	\$120,104	\$222,803
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$249,618
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$165,651
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			Y	\$15,755	\$648,904
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$1,125
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$329,289

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$386,491
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$19,309
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			Y	\$5,424	\$558,971
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$861,995
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			Y	\$14,245	\$296,418
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			Y	\$3,992	\$9,361
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$380,150
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$151,831
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$161,875
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$64,344
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			Y	\$54,215	\$216,309
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$327,025
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$261,066
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$30,593
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			Y	\$15,068	\$598,067
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$330,052
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$115,908
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$282,039
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$45,958
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$11,160
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	Y			N		\$6,254
93	273		ALCOHOL RESEARCH PROGRAMS	Research and Development	\$189,056	\$127,636,693	Y			N		\$11,638
93	273		ALCOHOL RESEARCH PROGRAMS	Research and Development	\$189,056	\$127,636,693	Y			N		\$24,569
93	136		INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	Research and Development	\$744,801	\$127,636,693	Y			Y	\$443,686	\$744,801
93	185		IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECT	Research and Development	\$364,963	\$127,636,693	Y			N		\$364,963
93	226		RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	Research and Development	\$22,991	\$127,636,693	Y			N		\$19,968
93	297		TEENAGER PREGANCY PREVENTION PROGRAM	Research and Development	\$1,306,544	\$127,636,693	Y			Y	\$33,346	\$1,306,544
93	011		NATIONAL ORGANIZATIONS OF STATE AND LOCAL OFFICIALS	Research and Development	\$139,544	\$127,636,693	Y			N		\$139,544

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	Y			Y	\$5,611	\$5,611
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	Y			N		\$14,822
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	Y			Y	\$16,500	\$667,842
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	Y			N		-\$13,018
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	Y			N		\$174,071
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	Y			N		\$200,379
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	Y			N		\$360,612
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	Y			Y	\$68,250	\$100,567
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	Y			N		\$61,197
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	Y			N		\$96,779
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	Y			N		\$78,703
93	464		ACL ASSISTIVE TECHNOLOGY	Research and Development	\$1,077,994	\$127,636,693	Y			N		\$31,697
93	632		UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	Research and Development	\$626,011	\$127,636,693	Y			N		\$50,662
93	632		UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	Research and Development	\$626,011	\$127,636,693	Y			N		\$566,806
93	632		UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	Research and Development	\$626,011	\$127,636,693	Y			N		\$405
93	043		SPECIAL PROGRAMS FOR THE AGING_TITLE III, PART D_DISEASE PREVENTION AND HEALTH PROMOTION SERVICES	Research and Development	\$151,742	\$127,636,693	N	New York City Department for the Aging	CT1 125 20201409590	N		\$150,270
93	070		ENVIRONMENTAL PUBLIC HEALTH AND EMERGENCY RESPONSE	Research and Development	\$45,594	\$127,636,693	N	RTI International	888-16-08-12 PO 65748L	N		\$45,594
93	072		LIFESPAN RESPITE CARE PROGRAM	Research and Development	\$31,388	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of High	RSG-19-113-01-CCG	N		\$31,388
93	103		FOOD AND DRUG ADMINISTRATION_RESEARCH	Research and Development	\$163,651	\$127,636,693	N	Oregon Health & Science University	1008581_TEMPLE_Fixed	N		\$12,141
93	103		FOOD AND DRUG ADMINISTRATION_RESEARCH	Research and Development	\$163,651	\$127,636,693	N	National Jewish Medical and Research Center	20128191	N		\$20,639

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	103		FOOD AND DRUG ADMINISTRATION RESEARCH	Research and Development	\$163,651	\$127,636,693	N	George Washington University	21-MC126	N		\$126,317
93	103		FOOD AND DRUG ADMINISTRATION RESEARCH	Research and Development	\$163,651	\$127,636,693	N	University Of Minnesota	N009958008	N		\$4,554
93	113		ENVIRONMENTAL HEALTH	Research and Development	\$562,047	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of High	CNVA00059250	N		\$98,213
93	113		ENVIRONMENTAL HEALTH	Research and Development	\$562,047	\$127,636,693	N	University of Texas Health Science Center at Houston	SA0002200	N		-\$3,269
93	113		ENVIRONMENTAL HEALTH	Research and Development	\$562,047	\$127,636,693	N	University of Texas Health Science Center at Houston	SA0002359	N		\$64,074
93	121		ORAL DISEASES AND DISORDERS RESEARCH	Research and Development	\$1,289,351	\$127,636,693	N	University of Pennsylvania	SUBAWARD 575712	N		-\$4,285
93	121		ORAL DISEASES AND DISORDERS RESEARCH	Research and Development	\$1,289,351	\$127,636,693	N	Boston University	4500003205	N		\$4,312
93	121		ORAL DISEASES AND DISORDERS RESEARCH	Research and Development	\$1,289,351	\$127,636,693	N	University of Pennsylvania	575712	N		\$65,997
93	121		ORAL DISEASES AND DISORDERS RESEARCH	Research and Development	\$1,289,351	\$127,636,693	N	University of Iowa	S03569-01	N		\$49,053
93	137		COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	Research and Development	\$126,498	\$127,636,693	N	Philadelphia Youth Sports Collaborative	3080-F21	N		\$29,390
93	137		COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	Research and Development	\$126,498	\$127,636,693	N	National Network of Public Health Institutes	G2336 AG-0963	N		\$40,940
93	137		COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	Research and Development	\$126,498	\$127,636,693	N	National Network of Public Health Institutes	G2447_AG-1077	N		\$56,168
93	145		HIV-RELATED TRAINING AND TECHINCAL ASSISTANCE	Research and Development	\$4,904	\$127,636,693	N	University of Illinois at Chicago	19507	N		\$4,904
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	N	Regents Univ Of California LA	2020-1248	N		\$58,967
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	N	Monell Chemical Senses Center	NIH049505MARGO	N		\$685
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	N	Boston University	4500003960	N		\$251,203
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	N	Northeastern University	500800-78050	N		\$142,566
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	N	Purdue University	11001185-006	N		\$123,975
93	173		RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	Research and Development	\$2,518,091	\$127,636,693	N	University of Arkansas for Medical Sciences	56477 - Temple	N		\$20,693
93	200		ADMINISTRATIVE ACTION	Research and Development	\$15,545	\$127,636,693	N	Cerner Corporation	75D30120C08752	N		\$15,545
93	213		RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	Research and Development	\$782,613	\$127,636,693	N	The Regents of the University of California, Berkeley	00011025	N		\$28,409
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	N	Drexel University	800002 / PO#U0213485	N		\$5,768
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	N	Administrators of the Tulane Edu Fund	TUL-HSC-555326-17/18	N		\$77,337
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	N	University of Nebraska Medical Center	34-5160-2114-001	N		-\$1,351
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	N	Washington University	WU-19-34/ WU-21-168-ST00000643	N		\$88,388
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	N	Yale University	GR113110 CON-80003057	N		\$388,335
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	N	University of Pennsylvania	1R01-MH-128155-02/4866528	N		\$180,470
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	N	Brown University	00001818	N		\$38,798
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	N	The Children's Hospital of Philadelphia	GRT-00001455	N		\$1,364

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	N	Drexel University	2R01MH110360-06/ PO# U0262456	N		\$306,712
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	N	Texas Biomedical Research Institute	22-05010-101	N		\$195,439
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	N	Research Foundation for Mental Hygiene, Inc.	P.O. 158236	N		\$68,880
93	242		MENTAL HEALTH RESEARCH GRANTS	Research and Development	\$7,131,290	\$127,636,693	N	Drexel University	900252	N		\$33,595
93	262		OCCUPATIONAL SAFETY AND HEALTH PROGRAM	Research and Development	\$11,565	\$127,636,693	N	Drexel University	1 R21OH011740-01-00	N		\$8,368
93	262		OCCUPATIONAL SAFETY AND HEALTH PROGRAM	Research and Development	\$11,565	\$127,636,693	N	University of Pittsburgh	AWD00004787 (136999-4)	N		\$3,197
93	273		ALCOHOL RESEARCH PROGRAMS	Research and Development	\$189,056	\$127,636,693	N	Yale University	GR101519 (CON-80001025)	N		\$1,280
93	273		ALCOHOL RESEARCH PROGRAMS	Research and Development	\$189,056	\$127,636,693	N	Regents of the University Of Michigan	3004628726	N		-\$3,842
93	273		ALCOHOL RESEARCH PROGRAMS	Research and Development	\$189,056	\$127,636,693	N	New York University	5P01AA027057-02/ PO # M2003623	N		\$17,206
93	273		ALCOHOL RESEARCH PROGRAMS	Research and Development	\$189,056	\$127,636,693	N	Sanford Research North	CY21-022-TU	N		\$43,118
93	273		ALCOHOL RESEARCH PROGRAMS	Research and Development	\$189,056	\$127,636,693	N	University Of Toledo	F-2023-16	N		\$95,087
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Regents of the University Of Michigan	SUBK00013673-005	Y	-\$203,400	-\$203,400
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Yale University	GR109734 (CON-80002396)	N		\$11,011
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Rand Corporation	SCON-00000312	N		-\$1,360
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	University of Pennsylvania	PO# 3327276	N		-\$4,611
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	University Of North Carolina at Greensboro	20150048.3	N		-\$14,378
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	University of Pennsylvania	PO3580189	N		-\$1,251
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Florida International University	800006849-01UG	N		\$420
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	University of South Carolina	Subaward No. 17-3378	N		\$120,733
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Fox Chase Chemical Diversity Center Inc.	R41DA047169 - TMPL	N		\$13,343
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	University of Kentucky	3200000570-19-151	N		\$18,856
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Rand Corporation	SUB# SCON-00000143	N		-\$105
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Regents of the University Of Michigan	SUBK00008373 PO# 3005195830	N		\$47,900
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Mebias Discovery LLC	1UG3DA047700-01	N		-\$12,565
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Seton Hall University	TU00010	N		\$1,085
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Brown University	00001461	N		\$475,132
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	University of Tennessee	Subaward A20-0184-S002	N		-\$1,786
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	George Mason University	E2051111	N		\$992
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	The Johns Hopkins University	2004827083	N		-\$6,501
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Brown University	00001670	N		\$69,661
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Fannin Partners	FTU001	N		\$74,913
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	San Diego State University	Research Foundation D8253-04 SA00 5A441A 7804	N		\$32,201
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Creative Bio-Peptides	2R44DA050349-02	N		\$80,562
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Washington University	WU-22-0215	N		\$66,958
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Praeventix, L.L.C.	A2020-221-002	N		\$76,634

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Joan&Sanford I. Weill Medical College of Cornell University	215225-1	N		\$76,963
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Brown University	00002168	N		\$12,916
93	279		DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	Research and Development	\$12,509,530	\$127,636,693	N	Praeventix, L.L.C.	1R44DA055443-01A1	N		\$2,568
93	286		DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	Research and Development	\$120,501	\$127,636,693	N	Regents of the University Of Michigan	SUBK00010811/ PO# 3006521301	N		\$60,958
93	286		DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	Research and Development	\$120,501	\$127,636,693	N	National Institutes of Health	A009800501	N		\$31,619
93	307		MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	Research and Development	\$1,643,213	\$127,636,693	N	Florida State University	R02116	Y	\$31,151	\$235,937
93	307		MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	Research and Development	\$1,643,213	\$127,636,693	N	Bentn Technologies, Inc	NIMHD-TUH-09-2021	N		\$21,479
93	307		MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	Research and Development	\$1,643,213	\$127,636,693	N	Trustees of the Univ of PA	584949	N		\$5,404
93	307		MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	Research and Development	\$1,643,213	\$127,636,693	N	Drexel University	900254	N		\$41,246
93	310		TRANS-NIH RESEARCH SUPPORT	Research and Development	\$526,313	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of Highe	10T2OD026554-01/0060736-130543	N		\$22,879
93	310		TRANS-NIH RESEARCH SUPPORT	Research and Development	\$526,313	\$127,636,693	N	National Alliance Against Disparities in Patient Health	RF00250-2022-0048 / 2021-AA-00	Y	\$2,258	\$101,359
93	310		TRANS-NIH RESEARCH SUPPORT	Research and Development	\$526,313	\$127,636,693	N	University of Pennsylvania	PO 4884998	N		\$237,259
93	310		TRANS-NIH RESEARCH SUPPORT	Research and Development	\$526,313	\$127,636,693	N	University of Arkansas for Medical Sciences	56493-TEMPLE	N		\$24,004
93	323		EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES (ELC)	Research and Development	\$637,018	\$127,636,693	N	City of Philadelphia	2220502	Y	\$590,837	\$637,018
93	350		NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	Research and Development	\$107,848	\$127,636,693	N	Duke University	WBSE	N		\$58,860
93	350		NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	Research and Development	\$107,848	\$127,636,693	N	University of Alabama at Birmingham	000518169-001	N		\$48,988
93	354		PUBLIC HEALTH EMERGENCY RESPONSE	Research and Development	\$168	\$127,636,693	N	Philadelphia Department of Public Health	CONTRACT NUMBER 2020623	N		\$168
93	361		NURSING RESEARCH	Research and Development	\$57,927	\$127,636,693	N	Washington University	WU-17-79 PO2928249C	N		\$6,205
93	361		NURSING RESEARCH	Research and Development	\$57,927	\$127,636,693	N	INDIANA UNIVERSITY	8573-TU	N		-\$319
93	361		NURSING RESEARCH	Research and Development	\$57,927	\$127,636,693	N	East Carolina University	AWD-21-0749-S002	N		\$52,041
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	N	Public Health Institute	AGREEMENT NO.01040	N		-\$458
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	N	Memorial Sloan Kettering Cancer Center	MSK#: 226808	N		\$2,860
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	N	Fox Chase Cancer Center	1515200	N		\$729,746
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	N	Fox Chase Cancer Center	1R01CA2380610115137-01	N		\$3,974
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	N	The Regents of the University of California	12051SC	N		\$19,680
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	N	University Of Minnesota	P007320701	N		-\$100
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of Highe	AWD00003953	N		\$187,907

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	N	Fox Chase Cancer Center	1R01CA262551-01A1	N		\$7,919
93	393		CANCER CAUSE AND PREVENTION RESEARCH	Research and Development	\$1,250,356	\$127,636,693	N	Ohio State University	SPC-1000006684 GR127426	N		\$28,027
93	394		CANCER DETECTION AND DIAGNOSIS RESEARCH	Research and Development	\$18,431	\$127,636,693	N	University Of Minnesota	P009745403	N		\$18,431
93	395		CANCER TREATMENT RESEARCH	Research and Development	\$1,869,512	\$127,636,693	N	University Of California Irvine	2020-JX-FX-0001	N		\$58,432
93	396		CANCER BIOLOGY RESEARCH	Research and Development	\$1,592,976	\$127,636,693	N	University of Pennsylvania	574290	N		\$41,065
93	396		CANCER BIOLOGY RESEARCH	Research and Development	\$1,592,976	\$127,636,693	N	University of Pennsylvania	579383	N		\$75,106
93	396		CANCER BIOLOGY RESEARCH	Research and Development	\$1,592,976	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of Highe	AWD00003405 (135524-1)	N		\$61,983
93	396		CANCER BIOLOGY RESEARCH	Research and Development	\$1,592,976	\$127,636,693	N	University of Pennsylvania	584574	N		\$27,288
93	397		CANCER CENTERS SUPPORT GRANTS	Research and Development	\$1,507,751	\$127,636,693	N	Fox Chase Cancer Center	FC00# 15134-03	N		\$40,242
93	397		CANCER CENTERS SUPPORT GRANTS	Research and Development	\$1,507,751	\$127,636,693	N	Fox Chase Cancer Center	7918000	N		\$21,547
93	421		STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATION'S HEALTH	Research and Development	\$295,653	\$127,636,693	N	The Task Force For Global Health	NU380T000316	N		\$3,362
93	421		STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATION'S HEALTH	Research and Development	\$295,653	\$127,636,693	N	The Task Force For Global Health	PO# 5280	N		\$30,925
93	421		STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATION'S HEALTH	Research and Development	\$295,653	\$127,636,693	N	National Association of County and City Health Officials	2022-121504	N		\$78,313
93	421		STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATION'S HEALTH	Research and Development	\$295,653	\$127,636,693	N	Association of State and Territorial Health Officials	Project 83-FE-2047-04-00	N		\$8,794
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	N	University Of Minnesota	A005198601	N		\$44,694
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	N	University Of Minnesota	A007250506	N		\$10,067
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	N	Live and Learn Society	265917-Temple	N		\$4,031
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	N	University of Illinois at Chicago	18246	N		\$7,662
93	433		ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	Research and Development	\$1,825,909	\$127,636,693	N	University Of South Florida	5820-1333-02-A	N		\$11,890
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	COPD Foundation, Inc.	UNKNOWN	N		\$2,149
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	New England Research Institutes, Inc.	U01HL107407	N		\$2,881
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	Massachusetts General Hospital	225710	N		\$198
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	Brigham & Women's Hospital	5U01HL130163-02	N		\$2,205

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	Regents of the University Of Michigan	SUBK000012342	Y	\$309,000	\$380,103
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	Trustees of Columbia University In The City of New York	15(GG015997-01)	N		\$1,036
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	Massachusetts General Hospital	224838	N		\$220,692
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	Massachusetts General Hospital	230744	N		\$34,637
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	Thomas Jefferson University	080-04000-S29201	N		-\$3,015
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	University of Iowa	S00210-01	N		\$10,249
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	The Johns Hopkins University	2003918282	N		\$3,335
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	Thomas Jefferson University	PO 2000112408/080-18007-S29001	N		-\$3,336
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	University Of Colorado	SUBAWARD # FY19.753.003	N		\$299,599
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	University of Pennsylvania	PO 5098672, 579313	N		\$454,325
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	Purdue University	11000983-028	N		\$118,986
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	University of Louisville	ULRF19-0985-02	N		\$20,534
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	Thomas Jefferson University	SUBAWARD 080-31050-R98703	N		\$8,751
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	Thomas Jefferson University	080-31050-S44801	N		\$14,252
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	Drexel University	900181	N		\$31,846
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	University of Pennsylvania	581905	N		\$12,580
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	University of Pittsburgh	AWD00004507 (136765-1)	N		\$41,915
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	University of South Carolina	23-5104 PO 2000066923	N		\$68,736
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	University of Pennsylvania	10081092	N		\$18,306
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	University of Alabama at Birmingham	000538895-SC001	N		\$6,191
93	837		CARDIOVASCULAR DISEASES RESEARCH	Research and Development	\$12,261,841	\$127,636,693	N	University of Alabama at Birmingham	00538896-SC001	N		\$29,192
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	National Jewish Health	20072309	N		\$48,087
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of Highe	9012549 (128373-11)	N		-\$99,766
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of Highe	9012549 (128373-12)	N		-\$6,079
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of Highe	9012549 (128373-14)	N		-\$3,077
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of Highe	CNVA00061271 (414279-2)	N		-\$190,704
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Regents of the University Of Michigan	SUBK00013404	N		\$35,945
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	New York University	OT2HL156812	N		\$464

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Joan&Sanford I. Weill Medical College of Cornell University	192243-6	N		\$49,610
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Alabama at Birmingham	2P01HL114470-06	N		\$87,056
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Pennsylvania	581435	N		\$1,652
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Board of the Leland Stanford Junior University	62346547-131009	N		\$11,857
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Koronis Biomedical Technologies Corp (KBT)	R44HL154932	N		\$6,905
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Joan&Sanford I. Weill Medical College of Cornell University	220367-8	N		-\$45,622
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Pittsburgh	AWD00005597 (418933-1)	N		\$41,519
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Joan&Sanford I. Weill Medical College of Cornell University	210581-15	N		\$4,186
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Joan&Sanford I. Weill Medical College of Cornell University	226628-15	N		\$6,984
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of California	10502sc	N		\$120,768
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Alabama at Birmingham	# 000513913 003	N		-\$131
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of Highe	AWD00005589 (418897-2)	N		\$33,606
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of North Carolina Chapel Hill	5125336	N		\$14,024
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Regents of the University Of Michigan	PO# 3007022630	N		\$249,885
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Thrombolex, Inc	5R44HL151032-02	N		\$135,951
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Board of the Leland Stanford Junior University	62346547-131009	N		-\$488
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Joan&Sanford I. Weill Medical College of Cornell University	192243-6	N		\$7,054
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Regents of the University Of Michigan	SUBK00014059	N		\$85,176
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Alabama at Birmingham	000530409-SC003	N		\$18,535
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Alabama at Birmingham	000531171-SC001	N		\$888
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Joan&Sanford I. Weill Medical College of Cornell University	225005-8	N		\$232,771
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Michigan	SUBK00015660	N		\$7,578
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Joan&Sanford I. Weill Medical College of Cornell University	214655-5	N		\$5,026
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Pittsburgh	AWD00007357420053	N		\$14,126
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Pennsylvania	585830	N		\$9,510

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	Verra Therapeutics, LLC	UNKNOWN	N		\$27,835
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	COPD Foundation, Inc.	2R44HL149580-02	N		\$2,226
93	838		LUNG DISEASES RESEARCH	Research and Development	\$1,835,939	\$127,636,693	N	University of Alabama at Birmingham	000530409-SC003	N		\$31,377
93	839		BLOOD DISEASES AND RESOURCES RESEARCH	Research and Development	\$1,933,749	\$127,636,693	N	Washington University	1UG3HL138325-01	N		\$5,974
93	839		BLOOD DISEASES AND RESOURCES RESEARCH	Research and Development	\$1,933,749	\$127,636,693	N	Coriell Institute For Medical Research	A22-0003-S001	N		\$18,138
93	839		BLOOD DISEASES AND RESOURCES RESEARCH	Research and Development	\$1,933,749	\$127,636,693	N	Case Western Reserve University	RES516976	N		\$20,782
93	839		Blood Diseases and Resources Research	Research and Development	\$1,933,749	\$127,636,693	N	Molecular Targeting Technologies	MTT1167303-01	N		\$18,730
93	840		TRANSLATION AND IMPLEMENTATION RESEARCH FOR HEART, LUNG, BLOOD DISEASES AND SLEEP DISORDERS	Research and Development	\$139,059	\$127,636,693	N	Vanderbilt University Medical Center	VUMC 92320	N		\$131,180
93	840		TRANSLATION AND IMPLEMENTATION RESEARCH FOR HEART, LUNG, BLOOD DISEASES AND SLEEP DISORDERS	Research and Development	\$139,059	\$127,636,693	N	University of Pennsylvania	1-R01-HL-153735-01	N		\$7,879
93	846		ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	Research and Development	\$1,004,634	\$127,636,693	N	University of California		N		\$3,800
93	846		ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	Research and Development	\$1,004,634	\$127,636,693	N	University of California, San Diego	S9002366 120233868	N		\$119,041
93	846		ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	Research and Development	\$1,004,634	\$127,636,693	N	ExesaLiberio Pharma, Inc.	UNKNOWN	N		\$1,564
93	846		ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	Research and Development	\$1,004,634	\$127,636,693	N	Praeventix, L.L.C.	1R43AR081768-01	N		\$72,537
93	846		ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	Research and Development	\$1,004,634	\$127,636,693	N	University of Queensland	RM2021002676	N		\$27,943
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	Regents of the University Of Michigan	3003453679	N		\$1,615
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	Regents of the University Of Michigan	SUBK00012108	N		\$21
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	Regents of the University Of Michigan	SUBK00012108	N		\$522
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	University of Michigan	3002818064	N		\$426
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	Regents of the University Of Michigan	3003773941	N		-\$1,174
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	Regents of the University Of Michigan	3004195236	N		\$686
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	McGill University	OB-16-09-21	N		\$54
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	University of Pennsylvania	SUBAWARD 576328	N		\$16,488
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	Emory University	A158740, PO A690559	N		\$126,746
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	Translational Genomics Research Institute (TGEN)	DISTEFANO-19-01	N		\$185,903
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	Drexel University	PO# U0202500	N		-\$1,378
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	Trustees of Columbia University In The City of New York	GG011642-04	N		\$9,996
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	University of Alabama at Birmingham	5R01DK108438-05 000509533-009	N		-\$22,504

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	University of Pennsylvania	582552	N		\$15,144
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	The Children's Hospital of Philadelphia	GRT-00000222/PO# 20265644	N		\$5,110
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	University of Pennsylvania	576045	N		\$5,322
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	University of Pennsylvania	576045	N		-\$11,194
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	Massachusetts General Hospital	228843	N		\$50,312
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	University of Louisville	ULRF_21-0699-02	N		\$11,673
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	The Pennsylvania State University	1R01DK132953-01	N		\$18,403
93	847		DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	Research and Development	\$4,762,619	\$127,636,693	N	University of Pennsylvania	586986	N		\$10,690
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	Regents of the University Of Michigan	3002112000-SHN	N		\$9,666
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	Regents of the University Of Michigan	3001413149-PNT	N		\$42,780
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	Regents of the University Of Michigan	SUBK00004100-ESETT	N		-\$41,042
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	The Johns Hopkins University	2002175090	N		\$433
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University Of Cincinnati	1U01NS095869-01	N		-\$13,657
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	Regents of the University Of Michigan	SUBK00008528	Y	\$82,095	\$82,095
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University of Cincinnati	Subaward No. 011266-135714	N		\$48,637
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University Of Cincinnati	Subaward No. 011337-135714	N		\$20,599
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University Of Cincinnati	012044-135714	N		\$1,556
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University Of Cincinnati	012340-135714	N		-\$223
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University Of Cincinnati	012043-135714	N		\$18,491
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University Of Cincinnati	014059-135714	N		-\$1,293
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University of Michigan	SUBK00017295	Y	\$10,500	\$16,255
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University Of Cincinnati	SUBAWARD NO. 011337-135714	N		\$21
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University Of Cincinnati	012765-135714	N		\$25,101
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University Of Cincinnati	013934-135714	N		\$11,111
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University Of Cincinnati	013888-135714	N		\$15,121
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	Northwestern University	60043694TU	N		-\$3,857
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	INDIANA UNIVERSITY	8092_TU; PO# 0084903	N		\$24,076

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	University Of Delaware	48140	N		-\$19,046
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	Thomas Jefferson University	080-19250-S09103 PO 2000110047	N		\$49,732
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	Dignity Health St. Joseph's Hospital and Medical Center	Temple33144	N		\$239,157
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	KannaLife Sciences, Inc.	KLS2-01	N		\$239,326
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	Northwestern University	60061958 TU	N		\$145,287
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	Regents of the University Of Michigan	SUBK00018268	N		\$8,276
93	853		EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	Research and Development	\$8,114,682	\$127,636,693	N	The Children's Hospital of Philadelphia	GRT-00002928 PO# 20463501	N		\$9,424
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	Institute for Clinical Research, Inc.	M16-TE-040-0705-1	N		\$33,920
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	Institute for Clinical Research, Inc.	M16-TE-040-0705-1	N		\$7,821
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	Emory University	SUBAWARD A554264	N		\$20,694
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	Benaroya Research Institute At Virginia Mason	FY22ITN547	N		\$1,771
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	Massachusetts General Hospital	227111	N		\$1,490
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	Pennsylvania State University	5674-TU-DHHS-4384	N		\$269,947
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	University Of New Mexico	3RDZ7	N		\$23,686
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	University of North Carolina Chapel Hill	5110850	N		\$105,310
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	Board of Trustees of Michigan State Univ	RC110226TU	N		\$40,902
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	Drexel University	940009	N		\$45,855
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	Yale University	CON-80003596/GR115963	N		\$68,586
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	The University of Texas Medical Branch at Galveston	22-85692-04	N		\$87,784
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	Seattle Children's Hospital	12854SUB	N		\$102,843
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	The Salk Institute for Biological Studies	A17-0059-S003	N		\$94,813
93	855		ALLERGY AND INFECTIOUS DISEASES RESEARCH	Research and Development	\$9,175,157	\$127,636,693	N	Vironika LLC	Z12-R43AI167400-TU	N		\$50,859
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	N	Wicked Device, LLC	265323	N		\$16,796
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	N	George Mason University	E2052931	N		\$3,568
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	N	The Pennsylvania State University	S001457-DHHS	N		\$121,759
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	N	Seattle Children's Hospital	12767SUB	N		\$37,781
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	N	Fox Chase Cancer Center	15168-01	N		\$111,825
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	N	CFD Research Corporation	0000002979	N		\$37,381

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	N	Rutgers The State University Of New Jersey	SUB00002457	N		\$88,841
93	859		BIOMEDICAL RESEARCH AND RESEARCH TRAINING	Research and Development	\$5,303,364	\$127,636,693	N	Texas A&M University	M2203808	N		\$31,587
93	860		EMERGING INFECTIONS SENTINEL NETWORKS	Research and Development	\$35,573	\$127,636,693	N	Olive View UCLA Edu & Res Inst	16-11	N		\$1,436
93	860		EMERGING INFECTIONS SENTINEL NETWORKS	Research and Development	\$35,573	\$127,636,693	N	Olive View UCLA Edu & Res Inst	16-26	N		\$9,455
93	860		EMERGING INFECTIONS SENTINEL NETWORKS	Research and Development	\$35,573	\$127,636,693	N	Olive View UCLA Edu & Res Inst	#20-39	N		\$21,891
93	860		EMERGING INFECTIONS SENTINEL NETWORKS	Research and Development	\$35,573	\$127,636,693	N	University of California at Los Angeles	1535 G LA045	N		\$2,791
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	N	University of North Carolina Chapel Hill	5109532	N		\$3,393
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	N	University of Pennsylvania	574940	N		\$106,226
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	N	Simbex LLC	R24HD0657303	N		\$3
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	N	Colorado State University	G-92849-02	N		\$143,299
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	N	RTI International	2-312-0216911-65664L	N		\$164,339
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	N	University Of Florida	SUB00002354	N		\$12,823
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	N	INDIANA UNIVERSITY	9272	N		\$36,403
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	N	Trustees of Columbia University In The City of New York	3(GG017754-01)	N		\$7,513
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	N	The Regents of the University of California	14152sc	N		\$190,573
93	865		CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	Research and Development	\$3,270,288	\$127,636,693	N	Trustees of Columbia University In The City of New York	2(GG018819-01)	N		\$11,220
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	N	The Johns Hopkins University	A2020-221-001	N		\$7,121
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	N	The Regents of the University of California, Santa Cruz	A18-0719-S001-P0687641	N		\$422,902
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	N	Regents of the University Of Michigan	PO # 3005707773	N		\$7,302
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	N	Ohio University	UT21864	N		\$39,288
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	N	Yale University	CON-80002777	N		\$142,041
93	866		AGING RESEARCH	Research and Development	\$3,884,321	\$127,636,693	N	XYKEN, LLC	1R44AG069564-3024V	N		\$6,492
93	867		VISION RESEARCH	Research and Development	\$455,209	\$127,636,693	N	University of Pennsylvania	581583	N		\$27,225
93	867		VISION RESEARCH	Research and Development	\$455,209	\$127,636,693	N	New York university, Grossman school of Medicine	22-A1-00-1007131	N		\$76,302
93	958		BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	Research and Development	\$1,974	\$127,636,693	N	State of Delaware, Department of Health and Social Services	35-06-22-003	N		\$1,974
93	RD2	HHSN268200736190C	NATIONAL INSTITUES OF HEALTH CONTRACT	Research and Development	-\$3,424	\$127,636,693	N	National Institutes of Health	HHSN268200736190C	N		-\$3,424
93	RD3	HHSN268200900049C	NATIONAL INSTITUES OF HEALTH CONTRACT	Research and Development	-\$3,494	\$127,636,693	N	Case Western Reserve University	RES508734 (OPTION 3)	N		-\$3,494

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	RD4	HHSN268200900049 C	NATIONAL INSTITUTES OF HEALTH CONTRACT	Research and Development	-\$6,681	\$127,636,693	N	Case Western Reserve University	RES510645 (OPTION 5)	N		-\$6,681
93	RD5	75N98022C0001	NATIONAL INSTITUTES OF HEALTH CONTRACT	Research and Development	\$256,712	\$127,636,693	N	Feinstein Institute for Medical Research	500884-TEMPLE/PO GRT2300002	N		\$256,712
93	RD6	75D30120C08465	CENTER FOR DISEASE CONTROL CONTRACT	Research and Development	\$258,774	\$127,636,693	N	McKing Consulting Corporation	TU-01-4198	N		\$258,774
93	RD7	UNKNOWN	NATIONAL INSTITUTES OF HEALTH CONTRACT	Research and Development	\$888	\$127,636,693	N	Trustees of Columbia University In The City of New York	OTA-20-011A	N		\$888
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		-\$444
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$8,378
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$28,290
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$69,871
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$106,540
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$60,116
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$66,492
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$6,876
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$35,256
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$59,533
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$75,864
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$130,671
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$382
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	Y			N		\$5,243
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$2,254
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$2,762
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$18,570
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			Y	\$13,989	\$16,420
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$2,946
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$93,083
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$8,101
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$18,720
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$134,365
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$119
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$54,499
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$40,363
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$62,917
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$66,610
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$62,626
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$206,353
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$1,006
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$142,723
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$23,871
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$45,071
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$81,421
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$39,101
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$84,541
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$95,568
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$133,019
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$23,359
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$33,918
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$81,893
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$51,733
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$18,693
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$95,816

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$238,551
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$47,399
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$120,706
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$121,134
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$86,545
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$169,751
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$153,299
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$76,283
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$104,992
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$175,233
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$80,483
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$3,011
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$307,093
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$18,493
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$35,968
47	049		NATIOAL SCIENCE FOUNDATION CONTRACT	Research and Development	\$3,551,686	\$127,636,693	Y			N		\$1,967
47	050		GEOSCIENCES	Research and Development	\$386,793	\$127,636,693	Y			N		\$326
47	050		GEOSCIENCES	Research and Development	\$386,793	\$127,636,693	Y			N		\$142,482
47	050		GEOSCIENCES	Research and Development	\$386,793	\$127,636,693	Y			N		\$43,081
47	050		GEOSCIENCES	Research and Development	\$386,793	\$127,636,693	Y			Y	\$3,588	\$125,939
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$1,018
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$8,190
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$59
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$1,525
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		-\$27,138
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$16,444
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$18,253
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$29,124
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$107,366
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$8,878
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$1,337
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$36,926
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$73,393
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$231
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$45,642
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$84,722
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$1,994

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			Y	\$24,558	\$63,521
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$36,498
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$17,542
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$79,396
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$89,265
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$51,831
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			Y	\$33,685	\$86,084
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$140,278
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$82,791
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			Y	\$78,665	\$1,111,727
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			Y	\$137,299	\$337,269
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$92,359
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$134,693
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$149,584
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$49,201
47	070		NATIOAL SCIENCE FOUNDATION CONTRACT	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$6,819
47	070		NATIOAL SCIENCE FOUNDATION CONTRACT	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$311,915
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$680
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$23,296
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	Y			N		\$7,910
47	074		BIOLOGICAL SCIENCES	Research and Development	\$1,171,680	\$127,636,693	Y			N		\$91,211
47	074		BIOLOGICAL SCIENCES	Research and Development	\$1,171,680	\$127,636,693	Y			N		\$2,820
47	074		BIOLOGICAL SCIENCES	Research and Development	\$1,171,680	\$127,636,693	Y			N		\$166,117
47	074		BIOLOGICAL SCIENCES	Research and Development	\$1,171,680	\$127,636,693	Y			N		\$38,945
47	074		BIOLOGICAL SCIENCES	Research and Development	\$1,171,680	\$127,636,693	Y			N		\$51,462
47	074		BIOLOGICAL SCIENCES	Research and Development	\$1,171,680	\$127,636,693	Y			N		\$342,093
47	074		BIOLOGICAL SCIENCES	Research and Development	\$1,171,680	\$127,636,693	Y			N		\$52,157
47	074		BIOLOGICAL SCIENCES	Research and Development	\$1,171,680	\$127,636,693	Y			N		\$286,691
47	074		BIOLOGICAL SCIENCES	Research and Development	\$1,171,680	\$127,636,693	Y			N		\$140,184
47	075		SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	Research and Development	\$795,762	\$127,636,693	Y			N		\$147,141
47	075		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$795,762	\$127,636,693	Y			N		\$51,554
47	075		SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	Research and Development	\$795,762	\$127,636,693	Y			N		\$34,804
47	075		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$795,762	\$127,636,693	Y			N		\$39,951
47	075		SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	Research and Development	\$795,762	\$127,636,693	Y			Y	\$33,224	\$247,290
47	075		SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	Research and Development	\$795,762	\$127,636,693	Y			N		\$15,255

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
47	075		SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	Research and Development	\$795,762	\$127,636,693	Y			N		\$115,341
47	075		SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	Research and Development	\$795,762	\$127,636,693	Y			N		\$32,485
47	075		SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	Research and Development	\$795,762	\$127,636,693	Y			N		\$86,790
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$12,522
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$21,095
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		-\$10,089
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$206,251
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$83,246
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$427,165
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$59,454
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$57,420
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$11,038
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$62,252
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$72,334
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$41,979
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			Y	\$21,600	\$135,608
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$173,289
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$6,047
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$311,695
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$5,744
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$29,361
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$28,595
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	Y			N		\$29,516
47	078		POLAR PROGRAMS	Research and Development	\$43,529	\$127,636,693	Y			N		\$32,921
47	078		POLAR PROGRAMS	Research and Development	\$43,529	\$127,636,693	Y			N		\$10,608
47	083		OFFICE OF INTEGRATIVE ACTIVITIES	Research and Development	\$706,477	\$127,636,693	Y			N		\$72,153
47	083		OFFICE OF INTEGRATIVE ACTIVITIES	Research and Development	\$706,477	\$127,636,693	Y			Y	\$303,238	\$387,993
47	083		OFFICE OF INTEGRATIVE ACTIVITIES	Research and Development	\$706,477	\$127,636,693	Y			N		\$172,011
47	083		OFFICE OF INTEGRATIVE ACTIVITIES	Research and Development	\$706,477	\$127,636,693	Y			N		\$74,320
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	N	American Society for Engineering Education	NO. 733	N		-\$3,411
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	N	Texas A&M Research Foundation	M2103385	N		\$47,002
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	N	Princeton University	SUB0000553	N		\$20,312
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	N	University Of South Florida	2121-1017-00-A	N		\$27,855
47	041		ENGINEERING GRANTS	Research and Development	\$895,936	\$127,636,693	N	Various Industries	IIP-0855881	N		\$151,110
47	049		MATHEMATICAL AND PHYSICAL SCIENCES	Research and Development	\$3,551,686	\$127,636,693	N	INDIANA UNIVERSITY	2221062	N		\$68,337
47	050		GEOSCIENCES	Research and Development	\$386,793	\$127,636,693	N	The Pennsylvania State University	5858-TU-NSF-8934	N		\$25,704
47	050		GEOSCIENCES	Research and Development	\$386,793	\$127,636,693	N	Oregon State University	S2089B-C	N		\$39,580
47	050		GEOSCIENCES	Research and Development	\$386,793	\$127,636,693	N	University Of Florida	SUB00001802	N		\$9,681
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	N	University of North Carolina at Charlotte	Subaward 20190333-01-TEM	N		\$103,713
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	N	INDIANA UNIVERSITY	9219_TU	N		\$8,547
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	N	Mississippi State University	060700.363656.01	N		\$68,387
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	N	University Of South Florida	2121-1013-00-A	N		\$13,130
47	070		COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	Research and Development	\$3,518,828	\$127,636,693	N	Various Industries	IIP-1439672	N		\$44,428
47	075		SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	Research and Development	\$795,762	\$127,636,693	N	American University	31588-01	N		\$25,151
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	N	Saint Josephs University	2018-11-TEU-01	N		\$14,532

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	N	State of Maryland	88060-Z3550204	N		\$32,188
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	N	Drexel University	920085	N		\$32,663
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	N	University Of California Irvine	2020-1371	N		\$90,497
47	076		STEM EDUCATION	Research and Development	\$1,960,356	\$127,636,693	N	Towson University	TOW000615	N		\$25,954
47	084		NSF Technology, Innovation, and Partnerships	Research and Development	\$5,611	\$127,636,693	N	University of Wisconsin-Madison	0000002617	N		\$5,611
10	025		PLANT AND ANIMAL DISEASE, PEST CONTROL, AND ANIMAL CARE	Research and Development	\$3,768	\$127,636,693	Y			N		\$3,768
10	310		AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	Research and Development	\$93,570	\$127,636,693	Y			N		\$83,620
10	699		PARTNERSHIP AGREEMENTS	Research and Development	\$27,728	\$127,636,693	Y			N		\$27,728
10	RD1	22-CS-11242308-056	US DEPARTMENT OF AGRICULTURE CONTRACT	Research and Development	\$20,870	\$127,636,693	Y			Y	\$9,888	\$20,870
10	RD2	18-JV-11111106-039	US DEPARTMENT OF AGRICULTURE CONTRACT	Research and Development	-\$57	\$127,636,693	Y			N		-\$57
11	307		ECONOMIC ADJUSTMENT ASSISTANCDE	Research and Development	\$608,193	\$127,636,693	Y			N		\$608,193
11	432		NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION	Research and Development	\$3,224	\$127,636,693	Y			N		\$3,224
12	300		BASIC AND APPLIED SCIENTIFIC RESEARCH	Research and Development	\$1,034,588	\$127,636,693	Y			N		-\$28,712
12	300		BASIC AND APPLIED SCIENTIFIC RESEARCH	Research and Development	\$1,034,588	\$127,636,693	Y			Y	\$38,185	\$479,267
12	300		BASIC AND APPLIED SCIENTIFIC RESEARCH	Research and Development	\$1,034,588	\$127,636,693	Y			N		\$141,012
12	300		BASIC AND APPLIED SCIENTIFIC RESEARCH	Research and Development	\$1,034,588	\$127,636,693	Y			N		\$261,067
12	300		BASIC AND APPLIED SCIENTIFIC RESEARCH	Research and Development	\$1,034,588	\$127,636,693	Y			N		\$130,656
12	300		BASIC AND APPLIED SCIENTIFIC RESEARCH	Research and Development	\$1,034,588	\$127,636,693	Y			N		\$50,038
12	351		SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION	Research and Development	\$954,395	\$127,636,693	Y			Y	\$79,881	\$756,790
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			N		-\$23,086
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			N		\$1,095
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			N		\$143,986
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			N		\$153,594
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			N		\$36,361
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			Y	\$10,443	\$207,382
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			Y	\$57,820	\$374,116
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			Y	\$2,837	\$150,684
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			N		\$51,224
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			N		\$395,119
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			N		\$168,987
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			N		\$103,993
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	Y			N		\$344,342
12	431		BASIC SCIENTIFIC RESEARCH	Research and Development	\$4,331,191	\$127,636,693	Y			N		\$25,134
12	431		BASIC SCIENTIFIC RESEARCH	Research and Development	\$4,331,191	\$127,636,693	Y			N		\$2,673,466
12	800		AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	Research and Development	\$355,626	\$127,636,693	Y			N		\$36,048
12	800		AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	Research and Development	\$355,626	\$127,636,693	Y			N		\$135,425
12	800		AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	Research and Development	\$355,626	\$127,636,693	Y			N		\$116,624
12	800		AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	Research and Development	\$355,626	\$127,636,693	Y			N		\$12,746
12	RD1	W81XWH21RJ204	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	\$19,839	\$127,636,693	Y			N		-\$723
12	RD2	0011857167-0002	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	\$122,298	\$127,636,693	Y			N		\$49,820
14	506		GENERAL RESEARCH AND TECHNOLOGY ACTIVITY	Research and Development	\$31,926	\$127,636,693	Y			N		\$31,926
15	926		AMERICAN BATTLEFIELD PROTECTION	Research and Development	\$875	\$127,636,693	Y			N		\$875
15	944		NATURAL RESOURCE STEWARDSHIP	Research and Development	-\$183	\$127,636,693	Y			N		-\$183
16	026		OVW Research and Evaluation Program	Research and Development	\$39,332	\$127,636,693	Y			N		\$39,332
16	560		NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	Research and Development	\$525,813	\$127,636,693	Y			N		\$86,221

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
16	560		NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	Research and Development	\$525,813	\$127,636,693	Y			N		\$193,542
16	601		TIME AND MATERIAL CONTRACTS	Research and Development	\$88,587	\$127,636,693	Y			N		\$24,975
21	009		VOLUNTEER INCOME TAX ASSISTANCE (VITA) MATCHING GRANT PROGRAM	Research and Development	\$2,251	\$127,636,693	Y			N		\$2,251
43	001		SCIENCE	Research and Development	\$262,592	\$127,636,693	Y			Y	\$17,660	\$17,660
43	001		SCIENCE	Research and Development	\$262,592	\$127,636,693	Y			Y	\$24,629	\$57,093
43	001		SCIENCE	Research and Development	\$262,592	\$127,636,693	Y			N		\$3,064
43	001		SCIENCE	Research and Development	\$262,592	\$127,636,693	Y			N		\$588
43	007		SPACE OPERATIONS	Research and Development	-\$101	\$127,636,693	Y			N		-\$101
64	RD1	36C77621P0200	US DEPARTMENT OF VETERAN'S AFFAIRS CONTRACT	Research and Development	\$14,628	\$127,636,693	Y			N		\$14,628
66	516		P3 AWARD NATIONAL STUDENT DESIGN COMPETITION FOR SUSTAINABILITY	Research and Development	\$15,383	\$127,636,693	Y			N		\$15,383
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$87,106
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$574
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$415,732
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$191,801
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$129,038
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$137,302
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$28,045
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$10,083
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$155,219
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$166,062
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$234,366
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$169,010
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$124,083
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	Y			N		\$11,334
84	220		CENTERS FOR INTERNATIONAL BUSINESS EDUCATION PROGRAM	Research and Development	\$199,323	\$127,636,693	Y			N		\$199,323
84	220A		CENTERS FOR INTERNATIONAL BUSINESS EDUCATION PROGRAM	Research and Development	\$221,301	\$127,636,693	Y			N		\$221,301
84	305		EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	Research and Development	\$912,464	\$127,636,693	Y			N		\$1,117
84	305		EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	Research and Development	\$912,464	\$127,636,693	Y			Y	\$158,357	\$215,680
84	305		EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	Research and Development	\$912,464	\$127,636,693	Y			N		-\$3,166
84	305		EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	Research and Development	\$912,464	\$127,636,693	Y			Y	\$160,365	\$390,296
84	324		PROGRAM ANNOUNCEMENT: SPECIAL TOPICS	Research and Development	\$147,148	\$127,636,693	Y			Y	\$146,196	\$147,019
84	336		TEACHER QUALITY PARTNERSHIP GRANTS	Research and Development	\$456,294	\$127,636,693	Y			N		\$456,294

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
84	365		SICKLE CELL TREATMENT DEMONSTRATION PROGRAM	Research and Development	\$263,189	\$127,636,693	Y			N		\$15,615
98	001		USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	Research and Development	\$1,103,206	\$127,636,693	Y			N		\$725,402
10	215		SUSTAINABLE AGRICULTURE RESEARCH AND EDUCATION	Research and Development	\$5,513	\$127,636,693	N	Clemson University	2440-215-2015298	N		\$5,513
10	253		CONSUMER DATA AND NUTRITIONAL RESEARCH	Research and Development	\$3,013	\$127,636,693	N	Administrators of the Tulane Edu Fund	TUL-HSC-559875-2223	N		\$3,013
10	309		MUSEUM GRANTS FOR AFRICAN AMERICAN HISTORY AND CULTURE	Research and Development	\$139,251	\$127,636,693	N	The Pennsylvania State University	2019-51181-30014	N		\$139,251
10	310		AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	Research and Development	\$93,570	\$127,636,693	N	Purdue University	F0013585302012	N		\$9,950
10	RD3	75F40119D10037	US DEPARTMENT OF AGRICULTURE CONTRACT	Research and Development	\$6,218	\$127,636,693	N	University of Pittsburgh	AWD00003449 2	N		\$6,218
11	011		OCEAN EXPLORATION	Research and Development	\$45,001	\$127,636,693	N	Smithsonian Institution	22-SUNC-440-0000472837	N		\$45,001
11	417		SEA GRANT SUPPORT	Research and Development	-\$11,507	\$127,636,693	N	Pennsylvania State University	5827-TU-NOAA-0074	N		-\$11,507
12	351		SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION	Research and Development	\$954,395	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of Highe	CNVA00048028 (412078-1)	N		\$1,809
12	351		SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION	Research and Development	\$954,395	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of Highe	AWD00004334 (417861-1)	N		\$195,796
12	401		NATIONAL GUARD MILITARY OPERATIONS AND MAINTENANCE (O&M) PROJECTS	Research and Development	\$734,950	\$127,636,693	N	Pennsylvania Department of Military and Veterans Affairs	4300599299	N		\$799
12	401		NATIONAL GUARD MILITARY OPERATIONS AND MAINTENANCE (O&M) PROJECTS	Research and Development	\$734,950	\$127,636,693	N	Pennsylvania Department of Military and Veterans Affairs	4300599763	N		\$35,138
12	401		NATIONAL GUARD MILITARY OPERATIONS AND MAINTENANCE (O&M) PROJECTS	Research and Development	\$734,950	\$127,636,693	N	Pennsylvania Department of Military and Veterans Affairs	4300599780	N		\$31,687
12	401		NATIONAL GUARD MILITARY OPERATIONS AND MAINTENANCE (O&M) PROJECTS	Research and Development	\$734,950	\$127,636,693	N	Pennsylvania Department of Military and Veterans Affairs	4300599688	N		\$12,493
12	401		NATIONAL GUARD MILITARY OPERATIONS AND MAINTENANCE (O&M) PROJECTS	Research and Development	\$734,950	\$127,636,693	N	Pennsylvania Department of Military and Veterans Affairs	4300599805	N		\$43,391
12	401		NATIONAL GUARD MILITARY OPERATIONS AND MAINTENANCE (O&M) PROJECTS	Research and Development	\$734,950	\$127,636,693	N	Pennsylvania Department of Military and Veterans Affairs	4300599299	N		\$186,770
12	401		NATIONAL GUARD MILITARY OPERATIONS AND MAINTENANCE (O&M) PROJECTS	Research and Development	\$734,950	\$127,636,693	N	Pennsylvania Department of Military and Veterans Affairs	4300599805	N		\$109,137
12	401		NATIONAL GUARD MILITARY OPERATIONS AND MAINTENANCE (O&M) PROJECTS	Research and Development	\$734,950	\$127,636,693	N	Pennsylvania Department of Military and Veterans Affairs	4300599763	N		\$88,921
12	401		NATIONAL GUARD MILITARY OPERATIONS AND MAINTENANCE (O&M) PROJECTS	Research and Development	\$734,950	\$127,636,693	N	Pennsylvania Department of Military and Veterans Affairs	4300599780	N		\$79,101
12	401		NATIONAL GUARD MILITARY OPERATIONS AND MAINTENANCE (O&M) PROJECTS	Research and Development	\$734,950	\$127,636,693	N	Pennsylvania Department of Military and Veterans Affairs	4300599688	N		\$23,403
12	401		NATIONAL GUARD MILITARY OPERATIONS AND MAINTENANCE (O&M) PROJECTS	Research and Development	\$734,950	\$127,636,693	N	Pennsylvania Department of Military and Veterans Affairs	4300599299	N		\$124,110
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	N	University of Alabama at Birmingham	000507860-012	N		\$15,061

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	N	State of Maryland	F302348-9	N		\$52,794
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	N	University of Alabama	000507860-001	N		-\$309
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	N	University of Alabama at Birmingham	000507860-012	N		\$182
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	N	Montclair State University	GR00506	N		\$55,137
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	N	State of Maryland	F302348-9	N		\$4,210
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	N	University of Pittsburgh of the Comlth Sys of Highe	AWD00004407 (417938-1)	N		\$26,268
12	420		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	Research and Development	\$2,274,947	\$127,636,693	N	Fox Chase Cancer Center	2404800 Yr 1 01	N		\$13,807
12	431		BASIC SCIENTIFIC RESEARCH	Research and Development	\$4,331,191	\$127,636,693	N	Drexel University	950042	N		\$176,671
12	431		BASIC SCIENTIFIC RESEARCH	Research and Development	\$4,331,191	\$127,636,693	N	Northeastern University	555080-78055	N		\$1,430,620
12	630		BASIC APPLIED AND ADVANCE RESEARCH IN SCIENCE AND ENGINEERING	Research and Development	\$263,188	\$127,636,693	N	Northeastern University	555089-78051	N		\$252,060
12	800		AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	Research and Development	\$355,626	\$127,636,693	N	University of Illinois	097110-17600	N		\$54,783
12	RD1	W912HQ-18-C-0037	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	\$19,839	\$127,636,693	N	APTIM	5012208	N		\$14,541
12	RD2	FA8650-18-C-1055	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	\$122,298	\$127,636,693	N	ALTAMIRA TECHNOLOGIES INC	FA8650-18-C-1055	N		\$58,551
12	RD3	W912HQ19C0056	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	\$93,575	\$127,636,693	N	Drexel University	SUBAWARD NO: 940006	N		\$93,575
12	RD4	W15QKN209C004	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	\$757,994	\$127,636,693	N	ThirdLaw, LLC	W15QKN209C004	N		\$757,994
12	RD5	W81XWH-20-1-0909	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	\$230,420	\$127,636,693	N	University of Queensland	RM2019002693	N		\$230,420
12	RD6	N00024-13-D-6400	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	\$84,613	\$127,636,693	N	Johns Hopkins University Applied Physics Laboratory	N00024-13-D-6400/ PO# 170744	N		\$84,613
12	RD7	202112-142136 (HQ0034-20-2-0007)	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	-\$57,309	\$127,636,693	N	Northeastern University	555074-78050	N		-\$57,309
12	RD8	W911SR-19-D-0006	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	\$28,138	\$127,636,693	N	SciTech Services Inc.	ScrTech 22-22-f-0037-02	N		\$28,138
12	RD9	202112-142136 (HQ0034-20-2-0007)	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	\$971,651	\$127,636,693	N	Northeastern University	555074-78050	N		\$971,651
12	RD1	W81XWH1910848	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	\$19,839	\$127,636,693	N	University of Maryland, Baltimore County	20532	N		\$6,021
12	RD2	FA9453-22-C-A127	US DEPARTMENT OF DEFENSE CONTRACT	Research and Development	\$122,298	\$127,636,693	N	Intelligent Fusion Technology, Inc	FA9453-22-C-A127	N		\$13,927
15	441		SAFETY AND ENVIRONMENTAL ENFORCEMENT RESEARCH AND DATA COLLECTION FOR OFFSHORE ENERGY AND MINERAL ACTIVITIES	Research and Development	\$26,012	\$127,636,693	N	TDI-Brooks International	M17PC00009	N		\$26,012
15	657		ENDANGERED SPECIES RECOVERY IMPLEMENTATION	Research and Development	\$48,228	\$127,636,693	N	National Fish and Wildlife Foundation	0406.19.066677	Y	\$5,113	\$48,228
16	560		NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	Research and Development	\$525,813	\$127,636,693	N	George Washington University	18-S37	N		\$77,806
16	560		NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	Research and Development	\$525,813	\$127,636,693	N	State of Maryland	Subaward 1903316	N		\$29,519
16	560		NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	Research and Development	\$525,813	\$127,636,693	N	National Opinion Reseach Center	G212.TU.01	N		\$56,838
16	560		NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	Research and Development	\$525,813	\$127,636,693	N	Rutgers The State University Of New Jersey	P.O. # 25090587	N		\$81,887
16	588		VIOLENCE AGAINST WOMEN FORMULA GRANTS	Research and Development	\$4,748	\$127,636,693	N	Rutgers The State University Of New Jersey	PO# 25122639	N		\$4,748

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
16	609		PROJECT SAFE NEIGHBORHOODS	Research and Development	\$6,428	\$127,636,693	N	Pennsylvania Commission On Crime And Delinquency	2019-GP-BX-0036	N		\$6,428
16	812		SECOND CHANCE ACT REENTRY INITIATIVE	Research and Development	\$26,445	\$127,636,693	N	Pennsylvania Department of Corrections	4400017651/4300654029	N		\$26,445
16	817		BRYNE CRIMINAL JUSTICE INNOVATION PROGRAM	Research and Development	\$27,872	\$127,636,693	N	The Village of Arts and Humanities	BJA-2014-3824	N		\$27,872
16	825		SMART PROSECUTION INITIATIVE	Research and Development	\$60	\$127,636,693	N	Pennsylvania Office of the attorney General	Contract Number 2020158	N		\$60
17	259		WIOA YOUTH ACTIVITIES	Research and Development	\$357,249	\$127,636,693	N	Intelligent Fusion Technology, Inc	IFT058-02	N		\$21,377
20	205		HIGHWAY PLANNING AND CONSTRUCTION	Research and Development	\$16,422	\$127,636,693	N	Pennsylvania Department of Transportation	4400017651 TEM WO 012	N		\$16,422
43	001		SCIENCE	Research and Development	\$262,592	\$127,636,693	N	California Inst of Technology	1632463	N		\$52,263
43	001		SCIENCE	Research and Development	\$262,592	\$127,636,693	N	American Museum Of Natural History	B78-2021-3	N		\$61,912
43	001		SCIENCE	Research and Development	\$262,592	\$127,636,693	N	University of Southern California	SCON-00004071	N		\$12,409
43	008		EDUCATION	Research and Development	\$15,124	\$127,636,693	N	The Pennsylvania State University	S000977-NASA	N		\$15,124
47	RD1	NSF-2236352	NATIOAL SCIENCE FOUNDATION CONTRACT	Research and Development	\$68,669	\$127,636,693	N	University of Arkansas	UA2023-368	N		\$68,669
59	037		SMALL BUSINESS DEVELOPMENT CENTERS	Research and Development	\$171,876	\$127,636,693	N	Kutztown University	SBA20230110	N		\$159,429
59	RD1	SBA20220511	US SMALL BUSINESS ADMINISTRATION CONTRCT	Research and Development	\$166,089	\$127,636,693	N	Kutztown University of Pennsylvania	SBA20220511	N		\$166,089
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	N	Central Michigan University	F63460	N		\$8,800
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	N	Mainstream Engineering Corporation	DE7037	N		\$78,656
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	N	Princeton University	SUB0000284	N		\$281,498
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	N	Northeastern University	503036-78053	N		-\$11,894
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	N	ThirdLaw, LLC	262886	N		-\$10
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	N	University Of Washington	UWSC11261	N		\$31,072
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	N	ThirdLaw, LLC	Subaward No. 265006	N		\$57,671
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	N	Brookhaven National Laboratory	368727	N		\$267
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	N	Fermi National Accelerator Laboratory	DE-AC02-07CH11359	N		\$220,833
81	049		OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	Research and Development	\$2,763,562	\$127,636,693	N	Central Michigan University	F64698	N		\$236,914
81	086		CONSERVATION RESERCH AND DEVELOPMENT	Research and Development	\$53,903	\$127,636,693	N	University of California - Berkeley	00010314	N		\$47,686
81	086		CONSERVATION RESERCH AND DEVELOPMENT	Research and Development	\$53,903	\$127,636,693	N	University Of Delaware	UDR0000276	N		\$6,217
81	087		RENEWABLE ENERGY RESEARCH AND DEVELOPMENT	Research and Development	\$7,916	\$127,636,693	N	Clemson University	2336-219-2024419	N		\$4,164
81	087		RENEWABLE ENERGY RESEARCH AND DEVELOPMENT	Research and Development	\$7,916	\$127,636,693	N	North Carolina State University	2020-3076-01	N		\$3,752
81	121		NUCLEAR ENERGY RESEARCH, DEVELOPMENTAND DEMONSTRATION	Research and Development	\$11,401	\$127,636,693	N	Utah State University	200658-694	N		\$11,401

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
81	135		ADVANCED RESEARCH PROJECTS AGENCY - ENERGY	Research and Development	\$11,058	\$127,636,693	N	Drexel University	950002	N		\$4,841
81	135		ADVANCED RESEARCH PROJECTS AGENCY - ENERGY	Research and Development	\$11,058	\$127,636,693	N	University Of Delaware	UDR0000252	N		\$6,217
81	RD1	W81XWH1920062	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$5,720	\$127,636,693	N	The Johns Hopkins Bloomberg School of Public Health	W81XWH1920062	N		\$1,540
81	RD2	DE-AC02-98CH10886	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$63,167	\$127,636,693	N	Brookhaven National Laboratory	223228	N		\$5,804
81	RD3	DE-AC02-06CH11357	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$61,858	\$127,636,693	N	Argonne National Laboratory	8F-30190	N		-\$32,204
81	RD4	1 DE-SC0019822	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$51,223	\$127,636,693	N	Mainstream Engineering Corporation	Subcontract No. DE-9822	N		\$17,583
81	RD5	DE-NA0003525	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$74,398	\$127,636,693	N	Sandia National Laboratories	PO-2149742	N		\$23,036
81	RD6	DE-AC07-051D14517	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$11,401	\$127,636,693	N	Battelle Energy Alliance, LLC	DE-AC07-051D14517	N		\$11,401
81	RD7	DE-AC02-06CH11357	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$643	\$127,636,693	N	Argonne National Laboratory	1F-60492	N		\$643
81	RD8	DE-SC0012704	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	-\$9,517	\$127,636,693	N	Brookhaven National Laboratory	400185	N		-\$9,517
81	RD9	DE-SC0012704	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$15,284	\$127,636,693	N	Brookhaven National Laboratory	396907	N		\$15,284
81	RD1	DOE-FOA-0002243	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$5,720	\$127,636,693	N	National Renewable Energy Laboratory	SUB-2021-10752	N		\$4,180
81	RD2	DE-AC36-08GO28308	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$63,167	\$127,636,693	N	Alliance For Sustainable Energy, LLC	SUB-2022-10070	N		\$57,363
81	RD3	DE-NA0003525	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$61,858	\$127,636,693	N	Sandia National Laboratories	PO# 2330239	N		\$94,062
81	RD4	DE-AC07-051D14517	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$51,223	\$127,636,693	N	Idaho National Laboratory	267310	N		\$33,640
81	RD5	DE-AC07-051D14517	US DEPARTMENT OF ENERGY CONTRACT	Research and Development	\$74,398	\$127,636,693	N	Idaho National Laboratory	267860	N		\$51,362
84	010		TITLE I GRANTS TO LOCAL EDUCATIONAL AGENCIES	Research and Development	-\$4,399	\$127,636,693	N	Philadelphia School District	OGC CONTRCAT # 784/F19	N		-\$4,399
84	126		REHABILITATION SERVICES_VOCATIONAL REHABILITATION GRANTS TO STATES	Research and Development	\$23,615	\$127,636,693	N	Pennsylvania Department of Labor And Industry	PO# 4300645937	N		\$23,615
84	287		TITLE IV, PART B OF ESEA	Research and Development	\$363,553	\$127,636,693	N	Pennsylvania Department Of Education	SAP FUND: 7051600000	Y	\$93,375	\$363,553
84	365		SICKLE CELL TREATMENT DEMONSTRATION PROGRAM	Research and Development	\$263,189	\$127,636,693	N	The Trustees of Columbia University in the City of New York	511238-02	N		\$27,523
84	407		TRANSITION PROGRAMS FOR STUDENTS WITH INTELLECTUAL DISABILITIES INTO HIGHER EDUCATION	Research and Development	\$41,176	\$127,636,693	N	Millersville University	PO# 4500635817	N		\$4,848
95	006		MODEL ACTS PROGRAM	Research and Development	-\$22,990	\$127,636,693	N	Legislative Analysis and Public Policy Association	G2199ONDCP03A	N		-\$22,990
97	061		CENTERS FOR HOMELAND SECURITY	Research and Development	\$83,859	\$127,636,693	N	The University of Central Florida Board of Trustees	GR107453	N		\$83,859
97	109		DISASTER HOUSING ASSISTANCE GRANT	Research and Development	-\$405	\$127,636,693	N	Education Northwest	REL 2021-TEM191	N		-\$405
97	RD1	70RSAT19CB0000002	US DEPARTMENT OF HOMELAND SECURITY	Research and Development	-\$24,475	\$127,636,693	N	The Johns Hopkins University	70RSAT19CB0000002	N		-\$24,475
97	RD2	20STTPC0001-03-01	US DEPARTMENT OF HOMELAND SECURITY	Research and Development	\$27,518	\$127,636,693	N	Kennesaw State University	20STTPC0001-03-01	N		\$27,518

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
98	001		USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	Research and Development	\$1,103,206	\$127,636,693	N	National Academy of Sciences	2000012797	N		\$19,716
98	001		USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	Research and Development	\$1,103,206	\$127,636,693	N	PACT	72012122CA00001	N		\$358,088
84	268		FEDERAL DIRECT STUDENT LOANS	ASSISTANCE	\$321,107,535	\$404,918,869	Y			N		\$48,631,794
84	268		FEDERAL DIRECT STUDENT LOANS	STUDENT FINANCIAL ASSISTANCE	\$321,107,535	\$404,918,869	Y			N		\$151,665,278
84	268		FEDERAL DIRECT STUDENT LOANS	STUDENT FINANCIAL ASSISTANCE	\$321,107,535	\$404,918,869	Y			N		\$64,950,262
84	268		FEDERAL DIRECT STUDENT LOANS	STUDENT FINANCIAL ASSISTANCE	\$321,107,535	\$404,918,869	Y			N		\$55,860,201
84	007		FEDERAL SUPPLEMENTAL EDUCATIONAL OPPORTUNITY GRANTS	STUDENT FINANCIAL ASSISTANCE	\$3,120,959	\$404,918,869	Y			N		\$3,120,959
84	033		FEDERAL WORK STUDY PROGRAM	STUDENT FINANCIAL ASSISTANCE	\$2,424,353	\$404,918,869	Y			N		\$2,424,353
84	038		FEDERAL PERKINS LOAN PROGRAM	STUDENT FINANCIAL ASSISTANCE	\$14,290,827	\$404,918,869	Y			N		\$11,609,789
84	038		FEDERAL PERKINS LOAN PROGRAM	STUDENT FINANCIAL ASSISTANCE	\$14,290,827	\$404,918,869	Y			N		\$2,681,038
84	063		FEDERAL PELL GRANT PROGRAM	STUDENT FINANCIAL ASSISTANCE	\$39,101,270	\$404,918,869	Y			N		\$39,101,270
93	342		HEALTH PROFESSIONS STUDENT LOANS	STUDENT FINANCIAL ASSISTANCE	\$24,620,666	\$404,918,869	Y			N		\$24,392,142
93	342		HEALTH PROFESSIONS STUDENT LOANS	STUDENT FINANCIAL ASSISTANCE	\$24,620,666	\$404,918,869	Y			N		\$228,524
93	364		NURSING STUDENT LOAN	STUDENT FINANCIAL ASSISTANCE	\$253,259	\$404,918,869	Y			N		\$248,084
93	364		NURSING STUDENT LOAN	STUDENT FINANCIAL ASSISTANCE	\$253,259	\$404,918,869	Y			N		\$5,175
84	425C	COVID 19	COVID 19 - EDUCATION STABILIZATION FUND UNDER THE CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY ACT	N/A	\$368,327	\$0	Y			N		\$368,327
12	300		BASIC AND APPLIED SCIENTIFIC RESEARCH	N/A	\$1,034,588	\$0	Y			N		\$1,260
12	431		MILITARY MEDICAL RESEARCH AND DEVELOPMENT	N/A	\$4,331,191	\$0	Y			N		\$25,300
12	U01	N6449820P5353	US DEPARTMENT OF DEFENSE CONTRACT	N/A	\$51,275	\$0	Y			N		\$51,275
12	U02	N6449822P5100	US DEPARTMENT OF DEFENSE CONTRACT	N/A	\$109,291	\$0	Y			N		\$109,291
15	954		NATIONAL PARK SERVICE CONSERVATION PROTECTION, OUTREACH AND EDUCATION	N/A	\$38,995	\$0	Y			N		\$38,995
16	601		CORRECTIONS TRAINING AND STAFF DEVELOPMENT	N/A	\$88,587	\$0	Y			N		-\$79
16	601		CORRECTIONS TRAINING AND STAFF DEVELOPMENT	N/A	\$88,587	\$0	Y			N		\$63,691
16	603		CORRECTIONS TECHNICAL ASSISTANCE/CLEARINGHOUSE	N/A	\$78,189	\$0	Y			N		\$78,189
16	839		STOP SCHOOL VIOLENCE	N/A	\$109,863	\$0	Y			N		\$109,863
21	008		LOW INCOME TAXPAYER CLINICS	N/A	\$101,542	\$0	Y			N		-\$28,640
21	008		LOW INCOME TAXPAYER CLINICS	N/A	\$101,542	\$0	Y			N		\$130,182
32	001		COMMUNICATIONS INFORMATION AND ASSISTANCE AND INVESTIGATION OF COMPLAINTS	N/A	-\$2,117	\$0	Y			N		-\$2,117
32	U03	CG Docket No. 10-210	FEDERAL COMMUNICATIONS COMMISSION	N/A	\$200,524	\$0	Y			N		\$200,524
32	U04	CG Docket No. 10-210	FEDERAL COMMUNICATIONS COMMISSION	N/A	-\$952	\$0	Y			N		-\$952
43	001		SCIENCE	N/A	\$262,592	\$0	Y			Y	\$41,008	\$57,603
84	022		ADULT EDUCATION - BASIC GRANTS TO STATES	N/A	\$37,758	\$0	Y			N		\$25,664

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
84	022		OVERSEAS PROGRAMS - DOCTORAL DISSERTATION RESEARCH ABROAD	N/A	\$37,758	\$0	Y			N		\$12,094
84	047		TRIO_UPWARD BOUND	N/A	\$688,733	\$0	Y			Y	\$109,158	\$166,657
84	047		TRIO_UPWARD BOUND	N/A	\$688,733	\$0	Y			Y	\$55,907	\$83,552
84	047		TRIO_UPWARD BOUND	N/A	\$688,733	\$0	Y			N		\$281,489
84	047		TRIO_UPWARD BOUND	N/A	\$688,733	\$0	Y			N		\$157,035
84	305		EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	N/A	\$912,464	\$0	Y			Y	\$25,646	\$308,537
84	325D		SPECIAL EDUCATION - PERSONAL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	N/A	\$346,290	\$0	Y			Y	\$179,801	\$346,290
84	335		CHILD CARE ACCESS MEANS PARENTS IN SCHOOL	N/A	\$32,086	\$0	Y			N		\$32,086
84	365		SICKLE CELL TREATMENT DEMONSTRATION PROGRAM	N/A	\$263,189	\$0	Y			N		\$220,051
93	059		TRAINING IN GENERAL, PEDIATRIC AND PUBLIC HEALTH DENTISTRY	N/A	\$6,626	\$0	Y			Y	\$6,162	\$6,626
93	464		ACL ASSISTIVE TECHNOLOGY	N/A	\$1,077,994	\$0	Y			N		\$6,394
93	464		ACL ASSISTIVE TECHNOLOGY	N/A	\$1,077,994	\$0	Y			Y	\$126,088	\$494,462
93	464		ACL ASSISTIVE TECHNOLOGY	N/A	\$1,077,994	\$0	Y			Y	\$67,364	\$545,441
93	632		UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	N/A	\$626,011	\$0	Y			N		\$965
93	632		UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	N/A	\$626,011	\$0	Y			N		-\$1,130
93	632		UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	N/A	\$626,011	\$0	Y			N		\$10,934
93	632		UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	N/A	\$626,011	\$0	Y			N		-\$2,631
93	747		ELDER ABUSE PREVENTION INTERVENTIONS PROGRAM	N/A	\$170,506	\$0	Y			N		\$136,756
93	924		RYAN WHITE HIV/AIDS DENTAL REIMBURSEMENT AND COMMUNITY BASED DENTAL PARTNERSHIP GRANTS	N/A	\$114,896	\$0	Y			N		\$114,896
12	630		BASIC APPLIED AND ADVANCE RESEARCH IN SCIENCE AND ENGINEERING	N/A	\$263,188	\$0	N	National Science Teachers Association	22-871-028	N		\$11,128
12	740		PAST CONFLICT ACCOUNTING	N/A	\$82,503	\$0	N	Ohio State University	SPC-1000004995 GRT00057086	N		\$82,503
14	889		TRIBAL HUD-VA SUPPORTIVE HOUSING PROGRAM	N/A	\$25,879	\$0	N	Office of Housing and Community Development	CONTRACT# 2020057	N		-\$198
14	889		TRIBAL HUD-VA SUPPORTIVE HOUSING PROGRAM	N/A	\$25,879	\$0	N	Philadelphia Housing Authority	005166	N		\$26,077
14	U05	UNKNOWN	U.S.DEPARTMENT OF HOUSING & URBAN DEVELOPMENT CONTRACT	N/A	\$566,402	\$0	N	Philadelphia Housing Authority	004970	Y	\$185,668	\$566,402
14	U06	UNKNOWN	U.S.DEPARTMENT OF HOUSING & URBAN DEVELOPMENT CONTRACT	N/A	\$40,749	\$0	N	Norris Community Resident Council	PA3A518CNG113	N		\$40,749
16	045		COMMUNITY-BASED VIOLENCE INTERVENTION AND PREVENTION INITIATIVE	N/A	\$64,395	\$0	N	New Kensington Community Development Corporation	TU - 1001	N		\$64,395
16	123		COMMUNITY_BASED VIOLENCE PREVENTION PROGRAM	N/A	\$243,582	\$0	N	Philadelphia Department of Behavioral Health	18-20438-01	N		\$87

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
16	123		COMMUNITY_BASED VIOLENCE PREVENTION PROGRAM	N/A	\$243,582	\$0	N	Philadelphia Department of Behavioral Health	2220224	N		\$243,495
16	575		CRIME VICTIM ASSISTANCE	N/A	\$466,072	\$0	N	Pennsylvania Commission On Crime And Delinquency	2017-VF-05-28222	N		\$785
16	575		CRIME VICTIM ASSISTANCE	N/A	\$466,072	\$0	N	Pennsylvania Commission On Crime And Delinquency	201820192020-VF-05-33217	N		\$465,287
16	738		EDWARD BRYNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	N/A	\$41,569	\$0	N	Pennsylvania Commission On Crime And Delinquency	2017-JG-LS-28510	N		-\$1,154
16	738		EDWARD BRYNE MEMORIAL JUSTICE ASSISTANCE GRANT PROGRAM	N/A	\$41,569	\$0	N	Pennsylvania Commission On Crime And Delinquency	2019-JG-LS-28510-2	N		\$42,723
17	259		WIOA YOUTH ACTIVITIES	N/A	\$357,249	\$0	N	Philadelphia Works	YO22-037	N		-\$422
17	259		WIOA YOUTH ACTIVITIES	N/A	\$357,249	\$0	N	Philadelphia Youth Network, Inc.	21226-CE010	N		\$1,795
17	259		WIOA YOUTH ACTIVITIES	N/A	\$357,249	\$0	N	Philadelphia Youth Network, Inc.	22087	N		\$2,956
17	259		WIOA YOUTH ACTIVITIES	N/A	\$357,249	\$0	N	Philadelphia Works	YO23-034	N		\$331,543
81	122		ELECTRICITY DELIVERY AND ENERGY RELIABILITY, RESEARCH, DEVELOPMENT AND ANALYSIS	N/A	-\$3,358	\$0	N	Texas A&M Research Foundation	M2000781	N		-\$3,358
84	002		ADULT EDUCATION - BASIC GRANTS TO STATES	N/A	\$456	\$0	N	Pennsylvania Department Of Education	GRANT# 064	N		\$1,866
84	002		ADULT EDUCATION: BASIC GRANTS TO STATES	N/A	\$456	\$0	N	The Pennsylvania State University	S002317-COP	N		-\$1,410
84	002A		ADULT EDUCATION: BASIC GRANTS TO STATES	N/A	\$477,064	\$0	N	Pennsylvania Department Of Education	FA-064-23-0030	N		\$477,064
84	048		CAREER AND TECHNICAL EDUCATION -- BASIC GRANTS TO STATES	N/A	\$877,213	\$0	N	Pennsylvania Department Of Education	PROJECT# FA-119-18-0001	N		\$432
84	048		CAREER AND TECHNICAL EDUCATION -- BASIC GRANTS TO STATES	N/A	\$877,213	\$0	N	Pennsylvania Department Of Education	FA-119-21-002	N		\$1,011
84	048		CAREER AND TECHNICAL EDUCATION -- BASIC GRANTS TO STATES	N/A	\$877,213	\$0	N	Pennsylvania Department Of Education	FA-119-22-0004	N		\$1,212
84	048		CAREER AND TECHNICAL EDUCATION -- BASIC GRANTS TO STATES	N/A	\$877,213	\$0	N	Pennsylvania Department Of Education	FA-119-23-0004	N		\$874,558
84	305A		EDUCATION RESEARCH, DEVELOPMENT AND DISSEMINATION	N/A	\$42,155	\$0	N	WestEd	S-00018320	N		\$42,155
84	324		RESEARCH IN SPECIAL EDUCATION	N/A	\$147,148	\$0	N	Lehigh University	543385-78001	N		\$129
84	367		SUPPORTING EFFECTIVE INSTRUCTION STATE GRANTS	N/A	\$17,825	\$0	N	Pennsylvania Department Of Education	524-23-0008	N		\$17,825
84	407		TRANSITION PROGRAMS FOR STUDENTS WITH INTELLECTUAL DISABILITIES INTO HIGHER EDUCATION	N/A	\$41,176	\$0	N	Millersville University	PO# 4500635820	N		\$36,328
93	043		SPECIAL PROGRAMS FOR THE AGING_TITLE III, PART D_DISEASE PREVENTION AND HEALTH PROMOTION SERVICES	N/A	\$151,742	\$0	N	New York City Department for the Aging	CONTRACT 125 20201408734	N		\$1,472

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	048		SPECIAL PROGRAMS FOR THE AGING, TITLE IV, TITLE II, DISCRETIONARY PROJECTS	N/A	\$176,630	\$0	N	Pennsylvania Department of Aging	4000020510	N		-\$269
93	048		SPECIAL PROGRAMS FOR THE AGING, TITLE IV, TITLE II, DISCRETIONARY PROJECTS	N/A	\$176,630	\$0	N	Pennsylvania Department of Aging	4100092915	N		\$39,081
93	048		SPECIAL PROGRAMS FOR THE AGING, TITLE IV, TITLE II, DISCRETIONARY PROJECTS	N/A	\$176,630	\$0	N	Pennsylvania Department of Aging	SAP VENDOR NUM 117671	N		\$137,818
93	079		COOPERATIVE AGREEMENTS TO PROMOTE ADOLESCENT HEALTH THROUGH SCHOOL BASED HIV/STD PREVENTION AND SCHOOL BASED SURVEILLANCE	N/A	\$154,131	\$0	N	Pennsylvania Department Of Education	4400011166	N		-\$590
93	079		COOPERATIVE AGREEMENTS TO PROMOTE ADOLESCENCE HEALTH THROUGH SCHOOL-BASED HIV/STD PREVENTION AND SCHOOL-BASED SURVEILLANCE	N/A	\$154,131	\$0	N	Pennsylvania Department Of Education	4100086633	N		\$154,721
93	110		MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	N/A	\$42,320	\$0	N	The Children's Hospital of Philadelphia	3204510621/ PO# 20213726	N		\$1,277
93	110		MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	N/A	\$42,320	\$0	N	The Children's Hospital of Philadelphia	3204510622 PO# 20286408	N		\$41,043
93	153		COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH	N/A	\$12,709	\$0	N	Access Matters	216306	N		\$12,709
93	217		FAMILY PLANNING SERVICES	N/A	\$244,114	\$0	N	Access Matters	210601-1	N		\$43,340
93	217		FAMILY PLANNING SERVICES	N/A	\$244,114	\$0	N	Access Matters	SL210601-1	N		-\$40,840
93	217		FAMILY PLANNING SERVICES	N/A	\$244,114	\$0	N	Access Matters	230601	N		\$241,614
93	226		RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	N/A	\$22,991	\$0	N	Veloxis Pharmaceuticals, Inc.	AHRQ R13HS028377	N		\$3,023
93	235		TITLE V STATE SEXUAL RISK AVOIDANCE EDUCATION (TITLE V STATE SRAE) PROGRAM	N/A	\$467,623	\$0	N	Pennsylvania Department of Health	SAP #4100069737	N		-\$1,410
93	235		AFFORDABLE CARE ACT (ACA) ABSTINENCE EDUCATION PROGRAM	N/A	\$467,623	\$0	N	Pennsylvania Department of Health	4100082233	N		\$469,033
93	243		SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES	N/A	\$390,664	\$0	N	Philadelphia Department of Behavioral Health	2220321	N		\$87,523
93	243		SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES	N/A	\$390,664	\$0	N	Philadelphia Department of Behavioral Health	2220321	N		\$303,141
93	268		IMMUNIZATION COOPERATIVE AGREEMENTS	N/A	-\$3,300	\$0	N	PMHCC	AWARD NO NH23IP922583	N		-\$3,300
93	391		ACTIVITIES TO SUPPORT STATE, TRIBAL, LOCAL AND TERRITORIAL (STLT) HEALTH DEPARTMENT RESPONSE TO PUBLIC HEALTH OR HEALTHCARE CRISES	N/A	\$2,003,243	\$0	N	Pennsylvania Department of Health	4100090589	Y	\$243,364	\$2,003,243
93	421		STATE RURAL HOSPITAL FLEXIBILITY PROGRAM	N/A	\$295,653	\$0	N	National Association of County and City Health Officials	2022- 031102	N		\$174,259
93	558		TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	N/A	\$321,088	\$0	N	Public Health Management Corporation	20647	N		\$2,239
93	558		TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	N/A	\$321,088	\$0	N	Public Health Management Corporation	UNKNOWN	N		\$2,209
93	558		TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	N/A	\$321,088	\$0	N	Philadelphia Works	CONTRACT# 090-20-336-1	Y	\$10,000	\$145,219
93	558		TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	N/A	\$321,088	\$0	N	Public Health Management Corporation	UNKNOWN	N		\$171,421
93	575		Child Care and Development Block Grant	N/A	\$2,554	\$0	N	Public Health Management Corporation	8690062337	N		\$2,554
93	630		DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	N/A	-\$2,773	\$0	N	Pennsylvania Department Of Developmental Disability	GRANT# 4100078039	N		-\$1,575

TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2023

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	630		DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	N/A	-\$2,773	\$0	N	Pennsylvania Department Of Developmental Disability	4100081444	N		-\$1,198
93	674		CHAFEE FOSTER CARE INDEPENDENCE PROGRAM	N/A	\$182,623	\$0	N	Valley Youth House	UNKNOWN	N		\$599
93	674		CHAFEE FOSTER CARE INDEPENDENCE PROGRAM	N/A	\$182,623	\$0	N	Valley Youth House	23-1365971	N		\$182,024
93	747		ELDER ABUSE PREVENTION INTERVENTIONS PROGRAM	N/A	\$170,506	\$0	N	Pennsylvania Department of Aging	PO# 4300730856	N		\$33,750
93	778		MEDICAL ASSISTANCE PROGRAM	N/A	\$1,403,288	\$0	N	Pennsylvania Department Of Public Welfare	4300591464	N		\$302,109
93	778		MEDICAL ASSISTANCE PROGRAM	N/A	\$1,403,288	\$0	N	Pennsylvania Department of Health	4100083406	N		\$155,819
93	778		MEDICAL ASSISTANCE PROGRAM	N/A	\$1,403,288	\$0	N	Pennsylvania Department Of Public Welfare	4300621036	N		\$92,834
93	778		MEDICAL ASSISTANCE PROGRAM	N/A	\$1,403,288	\$0	N	Pennsylvania Department of Human Services	4400017651	N		\$46,774
93	778		MEDICAL ASSISTANCE PROGRAM	N/A	\$1,403,288	\$0	N	Office of Developmental Programs/PA Dept of Human Services	PO# 4300731672	Y	\$20,000	\$805,752
93	788		OPIOID STR	N/A	\$169,596	\$0	N	Philadelphia Department of Behavioral Health	2120007-01	N		-\$21
93	788		OPIOID STR	N/A	\$169,596	\$0	N	Philadelphia Department of Behavioral Health	2120007	N		\$169,617
93	898		CANCER PREVENTION AND CONTROL PROGRAMS FOR STATE, TERRITORIAL and TRIBAL ORGANIZATIONS	N/A	-\$9,850	\$0	N	Se Ahec -Pa Department Of Health	4400017651	N		-\$9,850
93	914		HIV EMERGENCY RELIEF PROJECT GRANTS	N/A	\$560,607	\$0	N	AIDS Activities Coordinating Office	RS0648	N		-\$40
93	914		HIV EMERGENCY RELIEF PROJECT GRANTS	N/A	\$560,607	\$0	N	AIDS Activities Coordinating Office	RS2648	N		\$84,316
93	914		HIV EMERGENCY RELIEF PROJECT GRANTS	N/A	\$560,607	\$0	N	AIDS Activities Coordinating Office	RW2701	N		\$151,313
93	914		HIV EMERGENCY RELIEF PROJECT GRANTS	N/A	\$560,607	\$0	N	AIDS Activities Coordinating Office	RW2700	N		\$271,762
93	914		HIV EMERGENCY RELIEF PROJECT GRANTS	N/A	\$560,607	\$0	N	AIDS Activities Coordinating Office	RM2222	N		\$31,780
93	914		HIV EMERGENCY RELIEF PROJECT GRANTS	N/A	\$560,607	\$0	N	AIDS Activities Coordinating Office	RW2419	N		\$21,476
93	918		GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	N/A	\$65,847	\$0	N	Philadelphia Department of Public Health	2220191	N		\$65,847
93	940		HIV PREVENTION ACTIVITIES HEALTH DEPARTMENT BASED	N/A	\$194,019	\$0	N	AIDS Activities Coordinating Office	2120558	N		\$87,291
93	940		HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED	N/A	\$194,019	\$0	N	AIDS Activities Coordinating Office	EC1002	N		-\$26,926
93	940		HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED	N/A	\$194,019	\$0	N	AIDS Activities Coordinating Office	CP0027	N		-\$49,918
93	940		HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED	N/A	\$194,019	\$0	N	AIDS Activities Coordinating Office	EC2002	N		\$71,730
93	940		HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED	N/A	\$194,019	\$0	N	AIDS Activities Coordinating Office	CP2027	N		\$111,842
93	U07	10T2OD034479-01	NATIONAL INSTITUES OF HEALTH CONTRACT	N/A	\$18,096	\$0	N	George Mason University	E2060461	N		\$18,096
94	006		AMERICORPS STATE AND NATIONAL	N/A	\$186,419	\$0	N	Jumpstart National	610200 JS-SITE #61	N		-\$69
94	006		AMERICORPS STATE AND NATIONAL	N/A	\$186,419	\$0	N	Jumpstart National	610200-JS-SITE #61	N		-\$123
94	006		AMERICORPS STATE AND NATIONAL	N/A	\$186,419	\$0	N	Jumpstart National	2920200	N		-\$302
94	006		AMERICORPS STATE AND NATIONAL	N/A	\$186,419	\$0	N	Jumpstart National	2920200	N		\$36,761
94	006		AMERICORPS STATE AND NATIONAL	N/A	\$186,419	\$0	N	Jumpstart National	2920230	N		\$150,152

**TEMPLE UNIVERSITY -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Passthrough Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
97	036		DISASTER GRANTS - PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED DISASTERS)	N/A	\$3,685,464	\$0	N	Pennsylvania Emergency Management Agency	PEMA-DAP-9	N		\$3,927,099
97	036		DISASTER GRANTS - PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED DISASTERS)	N/A	\$3,685,464	\$0	N	Philadelphia Department of Public Health	NH23IP922583	Y	-\$344,412	-\$233,791
97	036		DISASTER GRANTS - PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED DISASTERS)	N/A	\$3,685,464	\$0	N	Pmhcc	NU50CK000521	N		-\$7,844
21	027	COVID 19	COVID 19 - CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	N/A	\$4,343,339	\$0	N	OVPR Laurel Harvest Labs	A2021-195	N		\$6,719
21	027	COVID 19	COVID 19 - CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	N/A	\$4,343,339	\$0	N	Pennsylvania Department Of Education	FA-SRS-22-0003	N		\$4,321,372
21	027	COVID 19	COVID 19 - CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	N/A	\$4,343,339	\$0	N	Pennsylvania Commission On Crime And Delinquency	2022-CV-VI-39769	N		\$8,361
21	027	COVID 19	COVID 19 - CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	N/A	\$4,343,339	\$0	N	Pennsylvania Department Of Education	GRANT# 064	N		\$6,887
59	037	COVID 19	COVID-19: SMALL BUSINESS DEVELOPMENT CENTERS	N/A	\$171,876	\$0	N	Kutztown University	SBAHQ20C0042	N		\$12,447
84	425U	COVID 19	COVID 19 - EDUCATION STABILIZATION FUND UNDER THE CORONAVIRUS AID, RELIEF, & ECONOMIC SECURITY ACT	N/A	\$195,918	\$0	N	Philadelphia School District	2240	N		\$41,009
84	425U	COVID 19	COVID 19 - EDUCATION STABILIZATION FUND UNDER THE CORONAVIRUS AID, RELIEF, & ECONOMIC SECURITY ACT	N/A	\$195,918	\$0	N	Philadelphia School District	2719	N		\$21,517
84	425U	COVID 19	COVID 19 - EDUCATION STABILIZATION FUND UNDER THE CORONAVIRUS AID, RELIEF, & ECONOMIC SECURITY ACT	N/A	\$195,918	\$0	N	School District of Phila	3750	N		\$133,392

TOTAL EXPENDITURES OF FEDERAL AWARDS \$11,930,060 \$55,059,725

**TEMPLE UNIVERSITY –
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION**

**NOTES TO SCHEDULE OF EXPENDITURES – FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

(1) BASIS OF PRESENTATION

The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) summarizes the expenditures of Temple University – Of The Commonwealth System of Higher Education (“Temple”) under programs of the federal government for the year ended June 30, 2023. The information in the Schedule is presented in accordance with the requirements of *Title 2 U.S. Code of Federal Regulations (“2 CFR”) Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (“Uniform Guidance”). The Schedule does not include the federal funding awarded to Temple University Health System, Inc. and its subsidiaries (“TUHS”). A separate audit in accordance with the U.S. Office of Management and Budget (“OMB”) *Compliance Supplement* was performed for TUHS for the year ended June 30, 2023.

Because the Schedule presents only a selected portion of the operations of Temple University, it is not intended to, and does not, present the financial position, revenues, expenses, and changes in net assets of Temple. For the purposes of the Schedule, federal awards include all grants, contracts, and similar agreements entered into directly between Temple and agencies or departments of the federal government and all subawards to Temple by nonfederal organizations pursuant to federal grants, contracts, and similar agreements.

Temple’s consolidated financial statements include the consolidated operations of Temple University Health System, Inc. and its subsidiaries, which received federal awards, which are not included in Temple’s Schedule of Expenditures of Federal Awards for the year ended June 30, 2023.

Federally guaranteed loans issued to students of Temple directly by Temple are also included in the Schedule.

Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. Pass-through entity identifying numbers are presented where available.

Assistance Listing Numbers (“ALN”) numbers are from those published by the Office of Management and Budget and the General Services Administration. As provided for in 2 CFR §200.42(b); Programs without an ALN number are presented with only the federal agency’s two-digit prefix followed by the abbreviation “RD” for those programs in the research and development cluster or “U” (i.e. unknown) and sequentially numbered by federal agency in place of a ALN number. The federal agency two-digit prefixes are as follows:

Prefix	Federal Agency
10	Department of Agriculture
11	Department of Commerce
12	Department of Defense
14	Department of Housing and Urban Development
15	Department of the Interior
16	Department of Justice
17	Department of Labor
20	Department of Transportation
21	Department of the Treasury
32	Federal Communication Commission
43	National Aeronautics & Space Administration
45	National Foundation on the Arts and the Humanities
47	National Science Foundation
59	Small Business Administration
64	Department of Veterans Affairs
81	Department of Energy
84	Department of Education
93	Department of Health and Human Services
94	Corporation for National and Community Service
95	Executive Office of the President
97	Department of Homeland Security
98	Agency for International Development

The Schedule is presented using the accrual basis of accounting. Expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Pass-through entity identifying numbers are presented where available.

The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America for not-for-profit organization.

(2) INDIRECT COSTS

Temple does not elect to use the de minimis indirect cost rate allowed under the Uniform Guidance.

(3) FEDERAL STUDENT LOAN PROGRAMS

Federally-guaranteed loans (including subsidized and unsubsidized loans) issued to students of Temple directly by Temple during the year ended June 30, 2023, are summarized below:

	<u>ALN Number</u>	<u>Amount Authorized</u>
Direct Parent Plus Loans	84.268	\$ 64,950,262
Direct Graduate Plus Loans	84.268	55,860,201
Direct Subsidized Loans	84.268	48,631,794
Direct Unsubsidized Loans	84.268	151,665,278
		<u>\$ 321,107,535</u>

Temple is responsible only for the performance of certain administrative duties with respect to the federally guaranteed student loan programs; therefore, the net assets and transactions for those programs are not included in the Temple's consolidated financial statements.

Temple also participated in and administers the following student loan programs:

	ALN <u>Number</u>	Loans Outstanding as of <u>June 30, 2023</u>	Loans Made During Year Ended <u>June 30, 2023</u>
Perkins Loans	84.038	\$ 11,609,789	\$ -
Health Professionals Student Loans and Loans for Disadvantaged Students	93.342	\$ 24,392,142	\$ 3,834,562
Nursing Student Loans	93.364	<u>\$ 248,084</u>	<u>\$ 151,066</u>
		<u>\$ 36,250,015</u>	<u>\$ 3,985,628</u>

Temple accounts for such loan programs in separate revolving loan funds. As such, the balances and transactions of these loan programs are recorded in Temple's consolidated financial statements. The amounts on the Schedule for these loan programs also include expenditures for the administrative costs of the respective programs.

(4) SUBRECIPIENTS

Uniform Guidance defines a subrecipient as a nonfederal entity that receives a subaward from a pass-through entity to carry out part of a federal program but does not include an individual who is a beneficiary of such program or payments to a contractor. A contractor is an entity that receives a contract by which a nonfederal entity purchases property or services needed to carry out the project or program under a federal award. A nonfederal entity may concurrently receive federal funds as a recipient, subrecipient, and contractor, depending on the substance of its agreements with federal awarding agencies and pass-through entities. Therefore, Temple must make case-by-case determinations whether each agreement it makes for the disbursement of federal program funds casts the party receiving the funds as a subrecipient or a contractor based on the Uniform Guidance definitions and management's judgement. The total amount identified as provided to subrecipients during the year ended June 30, 2023 was \$11,930,060.

TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

**SCHEDULE OF FINDINGS AND QUESTIONED COSTS – FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

SECTION I—SUMMARY OF AUDITOR’S RESULTS		
<i>Financial Statements</i>		
Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP: UNMODIFIED		
Internal control over financial reporting:		
• Material weakness (es) identified?	___yes	<u>X</u> no
• Significant deficiency (ies) identified?	___yes	<u>X</u> none reported
Noncompliance material to financial statements noted?	___yes	<u>X</u> no
<i>Federal Awards</i>		
Internal control over major federal programs:		
• Material weakness (es) identified?	___yes	<u>X</u> no
• Significant deficiency (ies) identified?	___yes	<u>X</u> none reported
Type of auditor’s report issued on compliance for major federal programs: UNMODIFIED		
Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?	___Yes	<u>X</u> no
Identification of major federal programs: Student Financial Assistance Cluster (See Schedule of Federal Expenditures for various ALN #) Coronavirus State and Local Fiscal Recovery Funds (ALN # 21.027) Medical Assistance Program (ALN # 93.778)		
Dollar threshold used to distinguish between type A and type B programs:	\$ 3,000,000	
Auditee qualified as low-risk auditee?	<u>X</u> yes	___ no

SECTION II—FINANCIAL STATEMENT FINDINGS

The audit disclosed no items required to be disclosed in this section.

SECTION III—FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

The audit disclosed no items required to be disclosed in this section.

**TEMPLE UNIVERSITY –
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION**

**SCHEDULE OF PRIOR YEAR FINDINGS – FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Prior year audit Schedule of Findings and Questioned Costs did not contain any findings; therefore, no items required to be reported in this section.

CITY OF PHILADELPHIA AWARDS SECTION:



Deloitte & Touche LLP
1700 Market Street
Philadelphia, PA 19103
USA
Tel: 215-246-2300
Fax: 215-448-2278
www.deloitte.com

INDEPENDENT AUDITOR’S REPORT ON COMPLIANCE FOR EACH MAJOR CITY OF PHILADELPHIA AWARDS; REPORT ON INTERNAL CONTROL OVER COMPLIANCE AND REPORT ON SCHEDULE OF EXPENDITURES OF CITY OF PHILADELPHIA AWARDS; SCHEDULE OF CITY OF PHILADELPHIA PROGRAM EXPENDITURES AND PROGRAM REVENUE REQUIRED BY THE *CITY OF PHILADELPHIA SUBRECIPIENT AUDIT GUIDE*

To the Board of Trustees
Temple University – Of The Commonwealth System of Higher Education
Philadelphia, Pennsylvania

Report on Compliance for Each Major City of Philadelphia Award

Opinion on Each Major City of Philadelphia Award

We have audited Temple University – Of The Commonwealth System of Higher Education’s (“Temple”) compliance with the types of compliance requirements identified as subject to audit in the *City of Philadelphia Subrecipient Audit Guide* that could have a direct and material effect on each of Temple’s major City of Philadelphia awards for the year ended June 30, 2023. Temple’s major City of Philadelphia awards are identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs - City of Philadelphia awards.

In our opinion, Temple complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major City of Philadelphia awards for the year ended June 30, 2023.

Our audit, described below, did not include the operations of Temple Educational Support Services, Ltd; Temple University School of Podiatric Medicine, Inc.; Good Samaritan Insurance Co. Ltd.; TUMP Offices, Inc.; Global Technology Management Corp.; Temple University Health System Foundation; TUH - Jeanes Campus Auxiliary; Temple Health Subsidiaries, Inc.; Temple Physicians, Inc.; Temple Faculty Practice Plan, Inc.; Episcopal Hospital; TUHS Insurance Company, Ltd.; Temple Health System Transport Team, Inc.; Temple Center for Population Health, LLC; Temple Care Inc.; American Oncologic Hospital d/b/a The Hospital of Fox Chase Cancer Center; Fox Chase Limited; Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center; Fox Chase Cancer Center Medical Group, Inc.; Fox Chase Network, Inc.; because these subsidiaries did not receive City of Philadelphia awards subject to audit in accordance with the *City of Philadelphia Subrecipient Audit Guide*. As discussed in Note 1, Temple’s consolidated financial statements include the consolidated operations of Temple University Temple, Inc. and its subsidiary, Temple University Hospital Inc.; (collectively referred to herein as “TUHS”), which expended City of Philadelphia awards which are not included in Temple’s accompanying Schedule of Expenditures of City of Philadelphia Awards for the year ended June 30, 2023. Our audit, described below, does not include City of Philadelphia awards to TUHS, because a separate audit in accordance with the *City of Philadelphia Subrecipient Audit Guide* was performed for TUHS for the year ended June 30, 2023.

Basis for Opinion on Each City of Philadelphia awards

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of *City of Philadelphia Subrecipient Audit Guide*. Our responsibilities under those Standards and the *City of Philadelphia Subrecipient Audit Guide* are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of Temple and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major City of Philadelphia awards. Our audit does not provide a legal determination of Temple's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to Temple's City of Philadelphia awards.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on Temple's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the *City of Philadelphia Subrecipient Audit Guide* will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Temple's compliance with the requirements of each major City of Philadelphia awards as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the *City of Philadelphia Subrecipient Audit Guide*, we

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding Temple's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of Temple's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the *City of Philadelphia Subrecipient Audit Guide*, but not for the purpose of expressing an opinion on the effectiveness of Temple's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a City of Philadelphia awards on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a City of Philadelphia awards will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a City of Philadelphia awards that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the *City of Philadelphia Subrecipient Audit Guide*. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of City of Philadelphia Awards and Schedule of City of Philadelphia Program Expenditures and Program Revenue required by the *City of Philadelphia Subrecipient Audit Guide*

We have audited the financial statements of Temple as of and for the year ended June 30, 2023, and have issued our report thereon dated October 27, 2023, which contained an unmodified opinion on those financial statements. Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of City of Philadelphia awards and Schedule of City of Philadelphia Program Expenditures and Program Revenue are presented for purposes of additional analysis as required by the *City of Philadelphia Subrecipient Audit Guide* and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of City of Philadelphia awards and Schedule of City of Philadelphia Program Expenditures and Program Revenue are fairly stated in all material respects in relation to the financial statements as a whole.

Deloitte & Touche LLP

March 29, 2024

**TEMPLE UNIVERSITY
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION**

**SCHEDULE OF EXPENDITURES OF CITY OF PHILADELPHIA AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Grantor/Pass-Through Grantor Program Title	Agency Number	AACO Number	ALN Number	2023 Subrecipient Federal	2023 Subrecipient State	2023 Subrecipient City	2023 Total Federal	2023 Total State	2023 Total City	2023 Subrecipient Expenditures	2023 Total Expenditures
City of Philadelphia Awards (City funds noted below may have been passed through federal agencies and may be included in the federal schedule):											
Direct Awards:											
Philadelphia Department of Human Services											
FY18 -Grandma's Kids (DHS)	17-20130			\$ -	\$ -	\$ -	\$ -	\$ 3,742	\$ 936	\$ -	\$ 4,678
Grandma's Kids Family Friends Program	21-20137			-	-	-	-	(17)	(17)	-	(33)
Grandma'S KidsFamily Friends Program FY22	21-20137			-	-	-	-	3,995	999	-	4,994
Grandma's KidsFamily Friends	21-20137-02			-	-	-	-	124,161	31,040	-	155,201
Temple Center City Classroom Space	21-20192-02			-	-	-	-	-	12,623	-	12,623
				\$ -	\$ -	\$ -	\$ -	\$ 131,881	\$ 45,581	\$ -	\$ 177,463
Philadelphia Department of Behavioral Health and Disability Services											
Philadelphia CeasefireCure Violence Hospital Responder Intervention Team (POCfCv)	18-020438		16.123	-	-	-	87	-	-	-	87
Philadelphia CeasefireCure Violence Hospital Responder Intervention Team FY22	22-20224		16.123	-	-	-	243,495	-	-	-	243,495
Support Services Navigation & Housing Services For Individuals With Opioid Use Disorder	18-20214-02		-	-	-	-	-	-	2,984	-	2,984
Intellectual Disability Service	21-020007		93.788	-	-	-	(21)	(28)	(3)	-	(52)
Intellectual Disability Service	21-20007		93.788	-	-	-	169,617	223,397	20,685	-	413,699
Philadelphia Recast Program	22-20321		93.243	-	-	-	87,523	-	-	-	87,523
Philadelphia Recast Program	22-20321		93.243	-	-	-	303,141	-	-	-	303,141
				\$ -	\$ -	\$ -	\$ 803,842	\$ 223,369	\$ 23,666	\$ -	\$ 1,050,877
Philadelphia Department of Public Health											
Health Centers 3 & 4n	22-0191		93.918	-	-	-	65,847	-	-	-	65,847
Hepatitis B Virus Infection Prevention, Vaccination, Navigation, Testing, And Treatment Elimination Program (Hbv Prevntt)	MPXX20000248		-	-	-	-	-	-	4,059	-	4,059
Detection Of Sars0Cov02 In Wastewater For Public Health Surveillance	20-020623		93.354	-	-	-	168	-	-	-	168
Merituz: COVID019 Community Vaccination Program	NUS0CK000521		97.036	(344,412)	-	-	(233,791)	-	-	(344,412)	(233,791)
Phi Airport Passenger Surveys	22-20081		-	-	-	-	-	-	111,948	-	111,948
Detection Of Sars-Cov-2 In Wastewater For Public Health Surveillance	22-20502		93.323	590,837	-	-	637,018	-	-	590,837	637,018
Ged Testing Center At Philadelphia	22 20554		-	-	-	-	-	-	2,954	-	2,954
Health Enterprise Zone (HEZ)	18-20598		-	-	-	-	-	(3,358)	-	-	(3,358)
				\$ 246,425	\$ -	\$ -	\$ 469,242	\$ (3,358)	\$ 118,961	\$ 246,425	\$ 584,845
Mayor's Fund For Philadelphia, Inc.											
Phlconnected Caregiver Digital	2022- CAREGIVERS-06		-	-	-	-	-	-	47,417	-	47,417
Igc - Phlconnected- School-Based	2022-SCHOOL-BASED-04		-	-	-	-	-	-	16,840	-	16,840
				\$ -	\$ -	\$ -	\$ -	\$ -	\$ 64,257	\$ -	\$ 64,257
City of Philadelphia Water Department											
Development Of Polymerase Chain Reaction (Per) Capabilities At The Philadelphia Water Department'S Central Laboratory	19-20233		-	-	-	48,048	-	-	51,608	48,048	51,608
				\$ -	\$ -	\$ 48,048	\$ -	\$ -	\$ 51,608	\$ 48,048	\$ 51,608
City of Philadelphia Professional Services Micro Purchase Provider Agreement											
Branching Up	UNKNOWN		-	-	-	-	-	-	10,511	-	10,511
Branching Up - Internship Component	UNKNOWN		-	-	-	-	-	-	6,606	-	6,606
2023 GED Testing in Philadelphia	UNKNOWN		-	-	-	-	-	-	250	-	250
				\$ -	\$ -	\$ -	\$ -	\$ -	\$ 17,367	\$ -	\$ 17,367
Office of Housing and Community Development											
Norris Afterschool Program (Ohed)	20-020057	0	14.889	-	-	-	(198)	-	-	-	(198)
				\$ -	\$ -	\$ -	\$ (198)	\$ -	\$ -	\$ -	\$ (198)
Philadelphia Housing Authority											
Pha Cares (Covid-19 Action) Phila Housing Authority	004970		14.xxx	185,668	-	-	566,402	-	-	185,668	566,402
Sharswood Choice Community Health	005166		14.889	-	-	-	26,077	-	12,272	-	38,349
				\$ 185,668	\$ -	\$ -	\$ 592,479	\$ -	\$ 12,272	\$ 185,668	\$ 604,751
Total City of Philadelphia Direct Awards											
				\$ 432,093	\$ -	\$ 48,048	\$ 1,865,365	\$ 351,892	\$ 333,712	\$ 480,141	\$ 2,550,970

**TEMPLE UNIVERSITY
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION**

**SCHEDULE OF EXPENDITURES OF CITY OF PHILADELPHIA AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

City of Philadelphia Financial Assistance Awards:

City of Philadelphia AIDS Activities Coordinating Office (AACO)

Grantor/Pass-Through Grantor Program Title	Agency Number	AACO Number	ALN Number	2023	2023	2023	2023	2023	2023	2023	2023
				Subrecipient Federal	Subrecipient State	Subrecipient City	Total Federal	Total State	Total City	Subrecipient Expenditures	Total Expenditures
OutpatientAmbulatory Medical Care	2020607-01	RW2700	93.914	\$ -	\$ -	\$ -	\$ 271,762	\$ -	\$ -	\$ -	\$ 271,762
Medical Case Management RW1701	2020607-01	RW2701	93.914	-	-	-	151,313	-	-	-	151,313
Care Services Case Management	2020607-01	RM3222	93.914	-	-	-	31,780	-	22,085	-	53,865
Substance Abuse Services	2020607-01	RW2419	93.914	-	-	-	21,476	-	-	-	21,476
Ending The Epidemic In Philadelphia	2120558	EC1002	93.940	-	-	-	(26,925)	-	-	-	(26,925)
Ending the Epidemic in Philadelphia	2120558-01	EC2002	93.940	-	-	-	71,730	-	-	-	71,730
Ending the Epidemic in Philadelphia	2120558-01	EC3002	93.940	-	-	-	87,291	-	-	-	87,291
Hiv Testing In Health Care Settings	1820421-04	CP0027	93.940	-	-	-	(49,918)	-	-	-	(49,918)
HIV Testing in Health Care Settings	2220529	CP2027	93.940	-	-	-	111,843	-	-	-	111,843
Ryan White HivAids Treatment Extension Act Of 2009 Services Fy 2019	1720663-03	RS0648	93.914	-	-	-	(40)	-	-	-	(40)
Ryan White HIV/AIDS Treatment	2120606	RS2648	93.914	-	-	-	84,316	-	-	-	84,316
Total City of Philadelphia AIDS Activities Coordinating Office (AACO)				\$ -	\$ -	\$ -	\$ 754,628	\$ -	\$ 22,085	\$ -	\$ 776,713
Grand Total of City of Philadelphia Awards				\$ 432,093	\$ -	\$ 48,048	\$ 2,619,993	\$ 351,892	\$ 355,797	\$ 480,141	\$ 3,327,683

See Notes to Schedule of Expenditures of City of Philadelphia Awards

TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF CITY OF PHILADELPHIA - PROGRAM EXPENDITURES AND PROGRAM REVENUE
 City of Philadelphia AIDS Activities Coordinating Office (AACO)

FOR THE YEAR ENDED JUNE 30, 2023

AACO#	RW2700	RW2701	RM2222	RW2419	EC1002	EC2002	EC3002	CP0027	CP1027	RS0648	RS2648
ALN#:	93.914	93.914	93.914	93.914	93.940	93.940	93.940	93.940	93.940	93.914	93.914
										Ryan White HIV AIDS Treatment Extension Act	Ryan White HIV AIDS Treatment Extension Act
Sponsor Name:	Outpatient Ambulatory Medical Care	Medical Case Management	Care Services Case Management	Substance Abuse Services	Ending The Epidemic In Philadelphia	Ending The Epidemic In Philadelphia	Ending The Epidemic In Philadelphia	HIV Testing In Health Care Settings	HIV Testing In Health Care Settings	Of 2009 Services FY 2019	Of 2009 Services FY 2022
Sponsor Number:	2020607-01	2020607-01	2020607-01	2020607-01	2120558	2120558-01	2120558-01	2220529	1820421-04	1720663-03	2120606
Project Start Date:	3/1/2022	3/1/2022	3/1/2022	3/1/2022	1/1/2021	1/1/2022	8/1/2022	6/1/2018	1/1/2021	6/1/2018	3/1/2022
Project End Date:	2/28/2023	2/28/2023	2/28/2023	2/28/2023	7/31/2021	7/31/2022	7/31/2023	5/31/2019	12/31/2021	5/31/2019	2/28/2023
Principal Investigator:	Tedaldi, Ellen M.	Tedaldi, Ellen M.	Tedaldi, Ellen M.	Tedaldi, Ellen M.	Tedaldi, Ellen M.	Tedaldi, Ellen M.	Tedaldi, Ellen M.	Varnum, Susan A.	Tedaldi, Ellen M.	Varnum, Susan A.	Macphail, Laurie A.
Temple Fund #:	430966	430965	430967	430968	430626	430961	401955	430972	430627	430592	430964

General Ledger Expenditures:

Personnel:

Salaries	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	60,701
Fringe Benefits	-	-	-	-	-	-	-	-	-	-	-	16,511
Total Personnel Expenditures	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	77,212

Operating Expenditures:

Patient Care	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	-
Supplies	-	-	-	-	-	-	-	-	-	-	-	-
Travel	-	-	-	-	-	-	-	-	-	-	-	-
Other	248,866	138,565	49,327	19,667	(24,657)	65,687	79,937	102,420	(45,712)	-	-	-
Total Operating Expenditures	\$ 248,866	\$ 138,565	\$ 49,327	\$ 19,667	\$ (24,657)	\$ 65,687	\$ 79,937	\$ 102,420	\$ (45,712)	\$ -	\$ -	-

Equipment Expenditures:

Purchase	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	-
Total Equipment Expenditures	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	-

Total Direct Expenditures

\$ 248,866	\$ 138,565	\$ 49,327	\$ 19,667	\$ (24,657)	\$ 65,687	\$ 79,937	\$ 102,420	\$ (45,712)	\$ -	\$ -	\$ 77,212
------------	------------	-----------	-----------	-------------	-----------	-----------	------------	-------------	------	------	-----------

Facilities & Administrative

\$ 22,896	\$ 12,748	\$ 4,538	\$ 1,809	\$ (2,268)	\$ 6,043	\$ 7,354	\$ 9,423	\$ (4,206)	\$ (40)	\$ 7,104
-----------	-----------	----------	----------	------------	----------	----------	----------	------------	---------	----------

Total Expenditures:

Program Revenue

\$ 271,762	\$ 151,313	\$ 53,865	\$ 21,476	\$ (26,925)	\$ 71,730	\$ 87,291	\$ 111,843	\$ (49,918)	\$ (40)	\$ 84,316
------------	------------	-----------	-----------	-------------	-----------	-----------	------------	-------------	---------	-----------

Net Funded Expenditures

**TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF
HIGHER EDUCATION**

**NOTES TO SCHEDULE OF EXPENDITURES – CITY OF PHILADELPHIA
AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

(1) DESCRIPTION OF BUSINESS AND OPERATIONS

Founded in 1884, Temple University – Of The Commonwealth System of Higher Education (“Temple”) is a comprehensive state-related research university with its headquarters and largest campus located in Philadelphia, Pennsylvania. With 17 schools and colleges, eight campuses, and approximately 35,700 undergraduate, graduate, and professional students.

**(2) BASIS OF PRESENTATION – SCHEDULE OF EXPENDITURES
OF CITY OF PHILADELPHIA AWARDS**

The accompanying Schedule of Expenditures of City of Philadelphia Awards and the Schedule of City of Philadelphia Program Expenditures and Program Revenue (the “Schedules”) summarizes the expenditures of Temple under programs of the City of Philadelphia for the year ended June 30, 2023. The information in the Schedules is presented in accordance with the requirements of *City of Philadelphia Subrecipients Audit Guide*. The Schedule does not include the City of Philadelphia funding awarded to Temple University Health System, Inc. and its subsidiaries.

(3) BASIS OF ACCOUNTING

The Schedule is presented using the accrual basis of accounting. For the purposes of the Schedule, City of Philadelphia awards include all grants, contracts, and similar agreements entered into directly between Temple and agencies or departments of the City of Philadelphia local government and all subawards to Temple by nonfederal organizations pursuant to City of Philadelphia grants, contracts, and similar agreements, except for Temple University Health System, Inc. and its subsidiaries as noted above.

**(4) BASIS OF PRESENTATION - AIDS ACTIVITIES COORDINATING
OFFICE – SCHEDULE OF CITY OF PHILADELPHIA PROGRAM
EXPENDITURES AND PROGRAM REVENUE**

The City of Philadelphia AIDS activities coordinating office requires Schedule of Program Expenditures and Program Revenue related to the City of Philadelphia which were included in federal awards Assistance Listing Numbers (ALN) 93.914 and 93.940.

TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

SCHEDULE OF FINDINGS AND QUESTIONED COSTS - CITY OF PHILADELPHIA AWARDS

FOR THE YEAR ENDED JUNE 30, 2023

SECTION I—SUMMARY OF AUDITOR’S RESULTS					
<i>Financial Statements</i>					
Type of report the auditor issued on whether the consolidated financial statements audited were prepared in accordance with GAAP: UNMODIFIED					
<i>City of Philadelphia Awards</i>					
Internal control over major City of Philadelphia Awards:					
• Material weakness (es) identified?		_____yes		_____X_____no	
• Significant deficiency (ies) identified?		_____yes		_____X_____none reported	
Type of auditor’s report issued on compliance for major City of Philadelphia Awards: UNMODIFIED					
Any audit findings disclosed that are required to be reported in accordance with <i>City of Philadelphia Subrecipient Audit Guide</i> ?		_____yes		_____X_____no	
<i>Identification of City of Philadelphia Major Programs</i>					
ALN #	Federal Program Name	Total	Federal	Pass-through from Pennsylvania Department of Health Total State Portion	Philadelphia Department of Behavioral Health and Disability Services Total City Portion
93.778	Intellectual Disability Service	\$413,647	\$169,596	\$223,369	\$20,682

Dollar threshold used to distinguish between: Major City of Philadelphia Award	\$ 750,000	
Auditee qualified as low-risk auditee?	<u> X </u> yes	<u> </u> no

**TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF HIGHER
EDUCATION**

**SCHEDULE OF FINDINGS AND QUESTIONED COSTS - CITY OF PHILADELPHIA
AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

SECTION II—CITY OF PHILADELPHIA AWARD FINDINGS AND QUESTIONED COSTS

The audit disclosed no items required to be disclosed in this section.

**TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF HIGHER
EDUCATION**

**SCHEDULE OF PRIOR YEAR FINDINGS – CITY OF PHILADELPHIA AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Prior year audit City of Philadelphia Schedule of Findings and Questioned Costs did not contain any findings; therefore, no items required to be reported in this section.

PENNSYLVANIA DEPARTMENT OF HEALTH SECTION:

REPORT ON SCHEDULE OF REVENUE FOR THE COMMONWEALTH OF PENNSYLVANIA DEPARTMENT OF HEALTH REQUIRED BY THE PENNSYLVANIA DEPARTMENT OF HEALTH AUDIT GUIDANCE

To the Board of Trustees
Temple University – Of The Commonwealth System of Higher Education
Philadelphia, Pennsylvania

We have audited the financial statements of Temple University – Of The Commonwealth System of Higher Education’s (“Temple”) as of and for the year ended June 30, 2023, and have issued our report thereon dated October 27, 2023, which contained unmodified opinions on those financial statements. Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying Schedule of Revenue for the Commonwealth of Pennsylvania Department of Health is presented for purposes of additional analysis as required by the *Pennsylvania Department of Health Audit Guide* and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the Schedule of Revenue for the Commonwealth of Pennsylvania Department of Health is fairly stated in all material respects in relation to the financial statements as a whole.

Deloitte & Touche LLP

March 29, 2024

**TEMPLE UNIVERSITY
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION**

**SCHEDULE OF EXPENDITURES OF STATE OF PENNSYLVANIA AWARDS
FOR THE YEAR ENDED JUNE 30, 2023**

Grantor/Pass-Through Grantor Program Title	Pass-Through Grantor	Agency Number	ALN Number	Beginning Balance Deferred Revenue (Accounts Receivable)	Recognized Revenue FY23	Cash Receipts FY23	Ending Balance Deferred Revenue (Accounts Receivable)
FY2006 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	Pennsylvania Department of Health	4100037827		\$ -	\$ 1,151	\$ -	\$ 1,151
FY2010 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	Pennsylvania Department of Health	4100054871		-	(1,653)	(19)	(1,672)
FY2014 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	Pennsylvania Department of Health	4100068727		(1,826)	(1,533)	-	(3,359)
FY2016 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	Pennsylvania Department of Health	4100077087		-	553	-	553
FY2017 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	Pennsylvania Department of Health	4100079747		(4,077)	4,077	-	-
FY2018 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	Pennsylvania Department of Health	4100083099		(1,116,124)	1,150,093	(35,406)	(1,437)
FY2019 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	Pennsylvania Department of Health	4100085728		(1,351,488)	925,344	(17,197)	(443,341)
FY2020 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	Pennsylvania Department of Health	4100088561		40,697	904,277	(2,279,725)	(1,334,751)
Healthy Youth PA	Pennsylvania Department of Health	4100069737	93.235	8,457	(8,457)	-	-
Emergency Preparedness Workshops	Pennsylvania Department of Health	4300468706	93.069	(233)	-	-	(233)
Mechanisms And Treatment Strategies To Counter Addiction Susceptibility Post Tbi	Pennsylvania Department of Health	4100077079		(443,108)	(13,410)	(13,627)	(470,145)
Teen Outreach Program (TOP)	Pennsylvania Department of Health	4100082233	93.235	178,113	469,702	(401,942)	245,873
Enhancing Healthy Reintegration And Recovery For High-Risk Opioid Users	Pennsylvania Department of Health	4100083339		(1,589,298)	547,986	(45,019)	(1,086,331)
Training And Investigative Services	Pennsylvania Department of Health	4100083406	93.778	-	327,786	(150,896)	176,890
Vascular Contributions To Mechanisms And Biomarkers Of Alzheimer""S Disease	Pennsylvania Department of Health	4100087336		(3,197,235)	792,592	(89,763)	(2,494,406)
Pa-Cccp Implementation Services And Workplan Development	Pennsylvania Department of Health	4400017651	93.898	119,022	(9,850)	(114,926)	(5,754)
Pennsylvania Inclusive Health Equity Collaborative	Pennsylvania Department of Health	4100090589	93.391	1,549,982	2,003,243	(2,391,276)	1,161,949
Colorectal Cancer Screening Program	Pennsylvania Department of Health	4100090593		-	3,855	-	3,855
Workforce Development Project at Temple University	Pennsylvania Department of Health	4300733186		-	213,056	(92,018)	121,038
				<u>\$ (5,807,118)</u>	<u>\$ 7,308,812</u>	<u>\$ (5,631,814)</u>	<u>\$ (4,130,120)</u>

TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

NOTES TO SCHEDULE OF REVENUE FOR THE COMMONWEALTH OF PENNSYLVANIA DEPARTMENT OF HEALTH FOR THE YEAR ENDED JUNE 30, 2023

(1) STATE OF PENNSYLVANIA DEPARTMENT OF HEALTH

State of Pennsylvania Department of Health provides Federal and state financial assistance to Temple University – Of the Commonwealth System of Higher Education (“Temple”). Temple is required to comply with all applicable Federal and state Grant requirements including *Pennsylvania Department of Health Audit Guidance*.

(2) BASIS OF PRESENTATION

The accompanying Schedule of Revenue for the Commonwealth of Pennsylvania Department of Health (the “Schedule”) summarizes the deferred revenue, revenue recognized and cash receipts by Pennsylvania Department of Health on an accrual basis of accounting.

The Schedule does not include the federal/State funding awarded to Temple University Health System, Inc. and its subsidiaries (“TUHS”). Separate audits in accordance with the U.S. Office of Management and Budget Compliance Supplement were performed for TUHS for the year ended June 30, 2023.
